Document:

EX-10.9

 Exhibit 10.9 

Execution Copy 03/28/2008 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

CONFIDENTIAL 

UNIVERSITY OF PENNSYLVANIA 

Amended and Restated Patent License Agreement 

This Amended and Restated Patent License Agreement (this “Agreement”) , effective March 28, 2008 (the “Restatement
Date”) is by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Potentia Pharmaceuticals Inc., a Delaware corporation (“Company”), and is an
amendment to and restatement of the original Patent License Agreement (the “Original Agreement”) which became effective on August 1, 2006 (the “Original Agreement Effective Date”). 

BACKGROUND 
 Penn owns certain
intellectual property developed by Dr. John Lambris of Penn’s School of Medicine relating to certain compounds that inhibit complement activation. Penn also owns (subject to the resolution of certain disputes among the University Parties
(as defined below), as described below) certain letters patent and/or applications for letters patent relating to the intellectual property. Company desires to obtain an exclusive license under the patent rights to exploit the intellectual property.
Penn has determined that the exploitation of the intellectual property by Company is in the best interest of Penn and is consistent with its educational and research missions and goals. 

Penn, Potentia, The Regents of the University of California (“California”) and Princeton University (“Princeton”) entered
into an Agreement for Resolution of Patent Inventorship Matters effective as of March 6, 2007, which agreement was amended as December 12, 2007 and March 13, 2008 (as it may be further amended from time to time, the “Patent
Inventorship Agreement”), pursuant to which the parties thereto have agreed on a process for resolving disputes among themselves concerning the inventorship of the subject matter claimed in the Patent Applications and Additional Patent
Applications (as defined in the Patent Inventorship Agreement), and ownership of any resulting patents, including without limitation certain of the Penn Patent Rights (as hereinafter defined). 

Pursuant to Section 3.3 of the Patent Inventorship Agreement, as amended, this Agreement is binding on each of California and Princeton, if such
institution is determined to have an ownership interest in the Penn Patent Rights, subject only to amendments to this Agreement that may be necessary to bring this Agreement into compliance with applicable institutional policies. 

The parties now desire to amend and restate the Original Agreement in its entirety with this Agreement to reflect various matters contemplated by the parties
as hereinafter set forth. 
 In consideration of the mutual obligations contained in this Agreement, the receipt and sufficiency of which are hereby
acknowledged, and intending to be legally bound, the parties agree as follows: 

 Execution Copy 03/28/2008 

 

	1.	LICENSE 

 1.1 License Grant. Penn grants to Company an exclusive, world-wide
license (the “License”) under the Penn Patent Rights to make, have made, use, import, offer for sale and sell Licensed Products and Other Licensed Products in the Field of Use during the Term (as such terms may be defined in
Sections 1.2 and 6.1). The License includes the right to sublicense as permitted by this Agreement. No other rights or licenses are granted by Penn. 

1.2 Related Definitions. The term “Licensed Products” means products that incorporate technology or use a process,
product, or machine claimed in a Valid Claim of the Penn Patent Rights and are made, made for, used, imported, offered for sale or sold in a country in which such Penn Patent Rights are pending or in force, whether such manufacture, use, or sale is
by Company or by its Affiliates or sublicensees. The term “Other Licensed Products” means products that incorporate technology or use a process, product or machine claimed in a Valid Claim of the Penn Patent Rights and are made,
made for, used or sold in a country in which such Penn Patent Rights are neither pending nor in force, whether such manufacture, use or sale is by Company or by its Affiliates or sublicensees. The term “Penn Patent Rights” means all
of Penn’s patent rights represented by or issuing from: (a) the United States patents and patent applications listed in Exhibit A; (b) any continuation, divisional, non-provisional, re-examination, and re-issue applications of (a);
and (c) any foreign counterparts and extensions of (a) or (b). The term “Valid Claim” means a claim of any pending patent application or issued, unexpired patent which has not been finally cancelled, withdrawn, abandoned,
rejected, permanently revoked or nullified, held invalid or declared unpatentable or unenforceable by any court or other body of competent jurisdiction in a decision that is unappealable or unappealed within the time allowed for appeal. The term
“Affiliate” means a legal entity that is controlling, controlled by or under common control with Company and that has executed either this Agreement or a written joinder agreement agreeing to be bound by all of the terms and
conditions of this Agreement. For purposes of this Section 1.2, the word “control” means (x) the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of a legal entity,
(y) the right to receive fifty percent (50%) or more of the profits or earnings of a legal entity, or (z) the right to determine the policy decisions of a legal entity. The term “Field of Use” means treatment of
ophthalmic indications. For avoidance of doubt, the Field of Use includes prophylactic treatment of ophthalmic indications. 
 1.3
Reservation of Rights by Penn. Penn reserves the right to use, and to permit other non-commercial entities to use, the Penn Patent Rights for educational and research purposes only. 

1.4 U.S. Government Rights. The parties acknowledge that the United States government retains rights in intellectual property funded
under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products, which result from such
intellectual property and are sold in the United States, must be substantially manufactured in the United States. 
 1.5 Sublicense
Conditions. The Company’s right to sublicense granted by Penn under the License is subject to each of the following conditions: 

  
 2 

 Execution Copy 03/28/2008 

 

 (a) In each sublicense agreement, Company will prohibit the sublicensee from further
sublicensing without the prior written consent of Penn (except for limited sublicenses granted by Company’s sublicensees to contractors or collaborators for the purpose of manufacturing, research, development or other such purpose not involving
commercial distribution of Licensed Products to third parties), and require the sublicensee to comply with the terms and conditions of this Agreement; provided that Penn shall not unreasonably withhold, delay or condition any such
consent. Notwithstanding the foregoing, if Company sublicenses to a Large Pharmaceutical Company (as defined below), Company may grant such Large Pharmaceutical Company a right to grant further sublicenses; provided that, in the case
of any such Large Pharmaceutical Company granting commercialization rights to a further sublicensee that is not an affiliate of the Large Pharmaceutical Company, the sublicense shall require that the Large Pharmaceutical Company notify Penn of the
identity of such non-affiliate further sublicensee within [**] days after the grant of such further sublicense. Further, in the event that such Company or sublicensee seeks Penn’s consent for a sublicensee to further sublicense its
commercialization rights to a downstream sublicensee or in the event a Large Pharmaceutical Company sublicensee grants such a further sublicense of commercialization rights (“sub-sublicensee”), any such downstream sublicense agreement
(“sub-sublicense”) must require the sub-sublicensee to comply with the terms of this Agreement and prohibit further sublicensing of commercialization rights. For clarity, the sub-sublicensee shall be prohibited from further sublicensing
commercialization rights, but such prohibition shall not apply to limited sublicenses granted by sub-sublicensees to contractors or collaborators for the purpose of manufacturing, research, development or other such purpose not involving commercial
distribution of Licensed Products to third parties. Finally, if Penn is requested to consent to such a sub-sublicense, the requesting party shall pay Penn’s legal expenses for review of such sublicense transaction. Except when used in this
Section 1.5a, the term sublicense includes any permitted sub-sublicense and the term sublicensee includes any permitted sub-sublicensee. “Large Pharmaceutical Company” means a company in the business of developing and commercializing
pharmaceuticals that has, together with its affiliates, a market value or, in the case of a publicly traded company, market capitalization, of at least $[**]. 

(b) Within [**] days after Company enters into a sublicense agreement, Company will deliver to Penn a complete and accurate copy of the entire
sublicense agreement written in the English language. Penn’s receipt of the sublicense agreement, however, will constitute neither an approval of the sublicense nor a waiver of any right of Penn or obligation of Company under this Agreement.

 (c) In the event that Company causes or experiences a Trigger Event (as defined in Section 6.4), all payments due to Company from
its Affiliates or sublicensees under the sublicense agreement will, upon notice from Penn to such Affiliate or sublicensee, become payable directly to Penn for the account of Company. Within [**] days after receipt of any such funds, Penn will remit
to Company the amount by which such payments exceed the amounts owed by Company to Penn. 
 (d) Company’s execution of a sublicense
agreement will not relieve Company of any of its obligations under this Agreement. Company is primarily liable to Penn for any act or omission of an Affiliate or sublicensee of Company that would be a breach of this Agreement

  
 3 

 Execution Copy 03/28/2008 

 

 
if performed or omitted by Company, and Company will be deemed to be in breach of this Agreement as a result of such act or omission. 

1.6 Necessary Amendments. Each party hereto shall use its reasonable efforts to enter into any such amendments to this Agreement that
may be necessary to bring this Agreement into compliance with certain institutional policies of University Parties other than Penn as may be determined, pursuant to the terms of the Patent Inventorship Agreement, to have an ownership interest in the
Penn Patent Rights. 
  

	2.	DILIGENCE 

 2.1 Development Plan. Company will deliver to Penn, within [**] days
after the Original Agreement Effective Date, a copy of an initial development plan for the Penn Patent Rights (as updated from time to time, the “Development Plan”). The purpose of the Development Plan is (a) to demonstrate
Company’s capability to bring the Penn Patent Rights to commercialization, (b) to project the timeline for completing the necessary tasks, and (c) to measure Company’s progress against the projections. Thereafter, Company will
deliver to Penn an annual updated Development Plan no later than [**] of each year during the Term. The Development Plan will include, at a minimum, the information listed in Exhibit B. It is understood that any timelines, projections, plans, or
predictions, contained in the Development Plan and updates thereto are non-binding and will give rise to no obligations on the part of Company other than as set forth in this Agreement. 

2.2 Company’s Efforts. Company will use commercially reasonable efforts (either itself or through its Affiliates or sublicensees)
to develop, commercialize, market and sell Licensed Products and Other Licensed Products in a manner consistent with the Development Plan. 

2.3 Diligence Events. The Company will use commercially reasonable efforts (either itself or through its Affiliates or sublicensees) to
achieve each of the diligence events set forth below by the applicable completion date listed in the table below for the first Licensed Product. For purposes of this Section 2.3 and Section 3.4 below, the diligence or milestone event, as
the case may be, associated with the initiation of a Phase II clinical trial for a Licensed Product shall be deemed achieved upon the initiation of any Phase II portion of a Phase I trial for such Licensed Product. 

 

			
	 DILIGENCE EVENT
	  	 COMPLETION DATE

	Filing of IND for the Licensed Product	  	July 1, 2007
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]

  
 4 

 Execution Copy 03/28/2008 

 

	3.	FEES AND ROYALTIES 

 3.1 License Initiation Fee. In partial consideration of the
License, Company will pay to Penn on the Original Agreement Effective Date a non-refundable, non-creditable license initiation fee of $[**], of which $[**] received in the Option Agreement between Potentia Pharmaceuticals, Inc. and the University of
Pennsylvania dated December 8, 2005 is fully creditable. 
 3.2 Equity Issuance. In partial consideration for the License,
Company will issue to Penn on or about the Original Agreement Effective Date, [**] shares of common stock of the Company. In connection with this Agreement, Penn will execute and accede to the provisions of a Stockholders Agreement between Company
and Penn (“Stockholders Agreement”), the terms of which shall be reasonably acceptable to Penn and substantially similar to and consistent with those applicable terms set forth in the Third Amended and Restated Stockholders Agreement,
dated as of April, 2008 and attached hereto as Exhibit C, by and between the Company and its stockholders, the terms of which shall apply to all shares of capital stock of the Company currently issued to or held by Penn. 

3.3 License Maintenance Fees. In partial consideration of the License, Company will pay to Penn, on or within [**] days of each
anniversary of the Original Agreement Effective Date, until the first Sale (as defined in Section 3.6) of the first Licensed Product, the applicable license maintenance fee listed in the table below. 

 

																					
	 ANNIVERSARY:
	  	First	 	 	Second	 	 	Third	 	 	Fourth	 	 	Fifth and
thereafter	 
	 LICENSE MAINTENANCE FEE:
	  	 	[**	] 	 	 	[**	] 	 	 	[**	] 	 	 	[**	] 	 	$	100,000	 

 3.4 Milestone Payments. 

(a) In partial consideration of the License, Company will pay to Penn the applicable milestone payment listed in the table below after the
first achievement of each milestone event for each Licensed Product. Company will provide Penn with written notice within [**] days after achieving each milestone. 
  

			
	 MILESTONE
	  	PAYMENT
	 Receipt of IND Approval for a Licensed Product
	  	$100,000 (Waived)
	 Initiation of Phase II clinical trial for a Licensed Product
	  	$100,000
	 [**]
	  	[**]
	 [**]
	  	[**]
	 [**]
	  	[**]
	 First calendar year in which Sales exceed $[**]
	  	[**]
	 First calendar year in which Net Sales exceed $[**]
	  	[**]

 “Initiation” of a clinical trial means dosing the first patient in such trial in accordance with the
trial protocol. For the sake of clarity, Milestone Events are cumulative. Achievement 

  
 5 

 Execution Copy 03/28/2008 

 

 
of a Milestone Event with respect to a Licensed Product triggers all prior milestones with respect to such Licensed Product unless previously triggered and paid. 

(b) Notwithstanding anything in Section 3.4(a) to the contrary, if development of a Licensed Product for a particular indication in the
Field of Use ceases (a “Failed Product”), and development of a next Licensed Product for the same indication (“Follow-On Product”) subsequently commences or continues, then any of the Milestone Payments previously made by Company
in connection with such Failed Product shall be fully creditable against the repeated achievement of such milestone event by such Follow-On Product to achieve such milestone event. In the event that Company files an IND before December 31,
2006, the Milestone Payment for Receipt of IND Approval will be waived by Penn. In the event that Company files an IND after December 31, 2006, but before July 1, 2007, the payment Milestone Payment for Receipt of IND Approval will be
reduced to $[**]. In addition, any License Maintenance Fee paid within the same year that one or more Milestone Payments are due will be creditable toward any applicable Milestone Payment payable with respect to any Licensed Product in the Field of
Use within a year after the date on which such License Maintenance Fee payment was due. 
 (c) The Milestone Payments set forth in this
Section 3.4 shall be payable upon achievement of the corresponding milestone event by Company or any of its Affiliates or sublicensees; provided that any such Milestone Payments payable based upon achievement of the corresponding milestone
event by a third party sublicensee shall be subtracted from Sublicense Income for purposes of determining the Sublicense Fees payable to Penn pursuant to Section 3.8. 

3.5 Earned Royalties. In partial consideration of the License, Company will pay to Penn a royalty of [**] percent ([**]%) of Net Sales
of Licensed Products during the Quarter. In partial consideration of the License, and in recognition of know-how conveyed by Penn to Company, Company will pay to Penn a royalty of [**] percent ([**]%) of Net Sales of Other Licensed Products during
the Quarter. The royalty percentage due on Net Sales of Licensed Products or Other Licensed Products is full pass-through and is not subject to reduction in any event, without the written consent of Penn. 

3.6 Related Definitions. The term “Sale” means any bona fide transaction for which consideration is received or
expected by Company or its Affiliate or sublicensee for the sale, use, lease, transfer or other disposition of a Licensed Product or Other Licensed Product, as the case may be, to a third party, but excluding any sales for test marketing,
pre-clinical or clinical studies, compassionate use, or disposition of samples in customary quantities. A Sale is deemed completed at the time that Company or its Affiliate or sublicensee receives payment for a Licensed Product or Other Licensed
Product. The term “Quarter” means each three-month period beginning on January 1, April 1, July 1 and October 1. The term “Net Sales” means the consideration received or expected from
or, in the case of consideration other than cash, the fair market value attributable to, such non-cash consideration, less Qualifying Costs that are directly attributable to a Sale, specifically identified on an invoice or other documentation and
actually borne by Company or its Affiliates or sublicensees. For purposes of determining Net Sales, the words “fair market value” means the cash consideration that Company or its Affiliates or sublicensees would realize from an
unrelated buyer in an arms length sale of an identical item sold in the same quantity and at the time and place of the transaction. The term “Qualifying Costs” means on a non-duplicative basis, actual costs and expenses incurred net
of any refunds 

  
 6 

 Execution Copy 03/28/2008 

 

 
or offsets specific to Licensed Products: (a) trade cash and quantity discounts (e.g. discounts, for prompt or timely payment), (b) inventory management fees paid to wholesalers and
distributors, not to exceed [**]% of Net Sales; (c) credits, chargebacks, retroactive price reductions, rebates, refunds or returns that do not exceed the original invoice amount; (d) outbound transportation and insurance expenses;
(e) sales and use taxes, tariffs, customs duties, excises and other taxes and fees imposed by, and indefeasibly paid to, a governmental agency on the sale, transportation or delivery of Licensed Product or Other Licensed Product (other than
taxes on income); (f) negotiated payments made to private sector and government third party payors (e.g., PBMs, HMOs and PPOs) and purchasers/providers (e.g., staff model HMOs, hospitals and clinics), regardless of the payment mechanism,
including without limitation rebate, chargeback and credit mechanisms; (g) discounts under discount prescription drug programs and reductions for coupon and voucher programs; and (h) Bad debts calculated in accordance with GAAP
consistently applied (any reductions to bad debts previously deducted from Net Sales will become an add back to Net Sales in the quarter when reduction in bad debt is recognized). In the event that the Licensed Product is Sold in combination with
one or more other active ingredients (as such, a “Combination Product”), Net Sales from such Combination Product, for the purpose of determining royalty payments hereunder, shall be determined by multiplying the Net Sales of the
Combination Product during the applicable royalty reporting period, by the fraction, A/A+B, where A is [**] the Licensed Product when sold separately in finished form, and B is [**] other active ingredients included in the Combination Product when
sold separately in finished form, in each case during the applicable royalty reporting period or, if sales of both the Licensed Product and the other active ingredients did not occur in such period, then in the most recent royalty reporting period
in which sales of both occurred. In the event that such [**] be determined for both the Licensed Product and the other active ingredients included in the Combination Product, Net Sales for purposes of determining royalty payments hereunder shall be
calculated by multiplying Net Sales of the Combination Product by the fraction of C/C+D, where C is [**] Licensed Product and D is [**] all other active ingredients included in the Combination Product. In such event, Company shall in good faith make
a determination of the [**] of the Licensed Product and the other active ingredients included in the Combination Product, and shall notify Penn in writing, of such determination and provide Penn with the data supporting such determination. Penn
shall have the right to review such determination and supporting data, and to notify Company if Penn disagrees with such determination within [**] days of Company’s notification to Penn in writing thereof (provided, that, if no notice is given
by Penn within such [**]day period, Penn shall be deemed to have accepted Company’s determination of such respective fair market values hereunder). If Penn notifies Company of its disagreement within such [**]day period, then such matter shall
be submitted for resolution pursuant to Section 13.10. 
 3.7 Minimum Royalties. In partial consideration of the License,
Company will pay to Penn the amount, if any, that the applicable minimum royalty listed in the table below exceeds Company’s actual earned royalties under Section 3.5 for each Quarter after the first Sale of a Licensed Product. 

  
 7 

 Execution Copy 03/28/2008 

 

																	
	 QUARTER:
	  	First 4
Quarters	 	  	Next 4
Quarters	 	  	Next 4
Quarters	 	  	All Quarters
thereafter	 
	 MINIMUM:
	  	 	[**	] 	  	 	[**	] 	  	 	[**	] 	  	 	[**	] 

 3.8 Sublicense Fees. Subject to Section 3.3(c), in partial consideration of the License,
Company will pay to Penn, within [**] days after the end of each Quarter following the Original Agreement Effective Date, a sublicense fee of [**] percent ([**]%) of all Sublicense Income (as hereinafter defined) received by Company and its
Affiliates during such Quarter from any non-Affiliate sublicensee for a sublicense under the Penn Patent Rights. “Sublicense Income” means all cash payments plus the fair market value of all other consideration of any kind, received
by Company and its Affiliates from non-Affiliate sublicensees for sublicenses granted under the License by Company and its Affiliates, other than (i) royalties paid to Company or any Affiliate by such a sublicensee based upon Sales or Net Sales
by such sublicensee (and, in sublicensing arrangements in which a profit-sharing structure is used to compensate Company or Affiliate, other than profit-sharing amounts paid to Company or Affiliate), (ii) payments made to Company or any
Affiliate in consideration for the issuance of equity or debt securities of Company or such Affiliate, provided, that if an equity or debt investment is made in Company or such Affiliate in connection with such a sublicense agreement, any premium
paid over the fair market value for such equity or debt securities will be treated as Sublicense Income hereunder; (iii) amounts paid to Company or any Affiliate to fund the research and/or development of Licensed Products and/or Other Licensed
Products; (iv) reimbursement of expenses relating to prosecution, maintenance and/or defense of Penn Patent Rights under which such sublicenses are granted; and (v) amounts paid to Company or any Affiliate, on a per detail fee, full-time
equivalent funding or other fee-for-service basis that reasonably represents the value of such services, for conducting detailing activities with respect to Licensed Products and/or Other Licensed Products under a co-promotion or similar arrangement
with such sublicensee.  
  

	4.	REPORTS AND PAYMENTS 

 4.1 Royalty Reports. Within [**] days after the end of each
Quarter following the first Sale, Company will deliver to Penn a report, certified by the chief financial officer of Company, detailing the calculation of all royalties, fees and other payments due to Penn for such Quarter. The report will include,
at a minimum, the following information for the Quarter, each listed by product, by country: (a) the number of units of Licensed Products or Other Licensed Products, as the case may be, constituting Sales; (b) the gross consideration
received for Sales; (c) Qualifying Costs, listed by category of cost; (d) Net Sales; (e) the gross amount of any payments and other consideration received by Company from sublicensees and the amounts of any deductions permitted by
Section 3.6; (f) the royalties, fees and other payments owed to Penn, listed by category; and (g) the computations for any applicable currency conversions. Each royalty report will be substantially in the form of the sample report
attached as Exhibit D. 
 4.2 Payments. Company will pay all royalties, fees and other payments due to Penn under Sections 3.4, 3.5,
3.7, and 3.8 within [**] days after the end of the Quarter in which the royalties, fees or other payments accrued. 
 4.3 Records.
Company will maintain, and will cause its Affiliates and sublicensees to maintain, complete and accurate books, records and related background information to verify 

  
 8 

 Execution Copy 03/28/2008 

 

 
Sales, Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement, as well as the various computations reported under Section 4.1. The records for each
Quarter will be maintained for at least [**] years after submission of the applicable report required under Section 4.1. 
 4.4
Audit Rights. Upon reasonable prior written notice to Company, Company and its Affiliates and sublicensees will provide independent certified public accountants reasonably acceptable to Company with access to all of the books, records and
related background information required by Section 4.3 to conduct a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. Access will be made available: (a) during normal
business hours; (b) in a manner reasonably designed to facilitate Penn’s review or audit without unreasonable disruption to Company’s business; and (c) no more than [**] during the Term (as defined below) and for a period of
[**]years thereafter. Company will promptly pay to Penn the amount of any underpayment determined by the review or audit, plus accrued interest. If the review or audit determines that Company has underpaid any payment by [**] percent ([**]%) or
more, then Company will also promptly pay the costs and expenses of Penn and its accountants in connection with the review or audit. 
 4.5
Information Rights. Until the closing of the Company’s initial public offering, Company will provide to Penn, at least as frequently as the following reports are distributed to the Board of Directors of Company, copies of: (a) all
reports to the board that relate to the Penn Patent Rights or the Licensed Products or the Other Licensed Products, as the case may be; and (b) such portions of all business plans, projections and financial statements for Company that are
distributed to the Board of Directors of Company that relate to the Penn Patent Rights or the Licensed Products or the Other Licensed Products, as the case may be; provided that Penn’s right to receive such reports, business plans, projections
and financial statements shall not include the right to attend Board meetings or to receive materials with respect to which Company reasonably determines must be excluded to preserve attorney-client privilege or with respect to which Penn has a
conflict of interest related to the parties’ respective rights and obligations under this Agreement. It is understood that as an owner of equity in Company, Penn shall also receive all reports and other information provided by Company to other
owners of a like amount of equity in Company. After the closing of the Company’s initial public offering, Company will provide to Penn, promptly after filing, a copy of each annual report, proxy statement, 10-K, 10-Q and other material report
filed with the U.S. Securities and Exchange Commission. 
 4.6 Currency. All dollar amounts referred to in this Agreement are
expressed in United States dollars. All payments will be made in United States dollars. If Company receives payment from a third party in a currency other than United States dollars for which a royalty or fee is owed under this Agreement, then
(a) the payment will be converted into United States dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal as of the last business day of the Quarter in which the payment was
received by Company, and (b) the conversion computation will be documented by Company in the applicable report delivered to Penn under Section 4.1. 

4.7 Place of Payment. All payments by Company are payable to “The Trustees of the University of Pennsylvania” and will be
made to the following addresses: 

  
 9 

 Execution Copy 03/28/2008 

 

			
	By Electronic Transfer:	  	By Check:
	By Electronic Transfer:	  	 By Check:

	[**]	  	 The Trustees of the University of Pennsylvania

		  	 c/o Center for Technology Transfer

		  	 P.O. Box 785546

		  	 Philadelphia, PA 19178-5546

 4.8 Interest. All amounts that are not paid by Company when due will accrue interest from the date due
until paid at a rate equal to [**] percent ([**]%) per month (or the maximum allowed by law, if less). 
  

	5.	CONFIDENTIALITY AND USE OF PENN’S NAME 

 5.1 Confidentiality Agreement. If
Company and Penn entered into one or more Confidential Disclosure Agreements prior to the Restatement Date, then such agreements will continue to govern the protection of confidential information under this Agreement, and each Affiliate and
sublicensee of Company will be bound to Company’s obligations under such agreements. If, however, no Confidential Disclosure Agreement has been entered into between Company and Penn prior to the Restatement Date, then in connection with the
execution of this Agreement, the parties will enter into a Confidential Disclosure Agreement substantially similar to Penn’s standard form. The term “Confidentiality Agreement” means all Confidential Disclosure Agreements
between the parties that remain in effect after the Restatement Date. 
 5.2 Other Confidential Matters. Penn is not obligated to
accept any confidential information from Company, except for the delivery of information and/or reports required by Sections 1.5, 2.1, 4.1, 4.4, 4.5 and 6.6. Penn, acting through its Center for Technology Transfer and finance offices, will use
reasonable efforts not to disclose to any third party outside of Penn any confidential information of Company contained in those reports, for so long as such information remains confidential. Without limiting the parties’ respective rights and
obligations under any separate Confidentiality Agreement between the parties, Penn bears no institutional responsibility for maintaining the confidentiality of any other information of Company. Company may elect to enter into confidentiality
agreements with individual investigators at Penn that comply with Penn’s internal policies. 
 5.3 Use of Penn’s Name.
Company and its Affiliates, sublicensees, employees, and agents may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, organization, employee, student or representative, without
the prior written consent of Penn. Company and its Affiliates, sublicensees, vendors, and manufacturers shall have the right to mark the Licensed Products and/or packaging thereof with relevant patent numbers. 

 

	6.	TERM AND TERMINATION 

 6.1 Term. This Agreement will commence on the Original
Agreement Effective Date and terminate, on a product-by-product and country-by-country basis upon the later of: (a) the expiration of the last Valid Claim to expire of the Penn Patent Rights; or (b) ten (10) years after the first Sale
of the first Licensed Product or Other Licensed Product, as the case may be, in a 

  
 10 

 Execution Copy 03/28/2008 

 

 
country if no Valid Claim of Penn Patent Rights covering the applicable Licensed Product or Other Licensed Product is pending or remains in force in such country (as the case may be, the
“Term”). 
 6.2 Early Termination by Company. Company may terminate this Agreement at any time effective upon
completion of each of the following conditions: (a) providing at least sixty (60) days prior written notice to Penn of such intention to terminate; (b) ceasing to make, have made, use, import, offer for sale and sell all Licensed
Products and Other Licensed Products except to the extent permitted under Section 6.6; (c) causing all Affiliates to cease making, having made, using, importing, offering for sale and selling all Licensed Products and Other Licensed
Products, except to the extent permitted under Section 6.6; and (d) paying all amounts owed to Penn under this Agreement through the effective date of termination. 

6.3 Early Termination by Penn. Penn may terminate this Agreement if: (a) Company is more than [**] days late in paying to Penn any
amounts owed under this Agreement and does not pay Penn in full, including accrued interest, within [**] days after written demand from Penn therefor (a “Payment Default”), provided that (i) if Company in good faith disputes
any payment amount allegedly due under a provision of this Agreement other than Section 3.5, Company may pay the disputed amount to Penn under protest and, upon final resolution of the dispute, Penn shall refund any amounts so paid that are
determined not to have been payable to Company, with interest at the rate set forth in Section 4.8 and (ii) if Company or a sublicensee of Company in good faith disputes any payment amount allegedly due under Section 3.5 or the amount
of Net Sales made by Company or a sublicensee of Company upon which such royalty obligation is based, Penn may not terminate this Agreement unless Company fails to pay any such disputed amount finally determined to have been payable to Penn, with
interest at the rate set forth in Section 4.8, within [**] days after final resolution of the dispute; provided further that, in the event that a good faith dispute regarding a payment amount allegedly due under
Section 3.5 arises because a sublicensee of Company disputes Net Sales amounts that Company contends were made by the sublicensee, Company shall use good faith efforts to resolve such dispute and shall keep Penn reasonably informed regarding
the status of such dispute; (b) except for a Payment Default, Company or its Affiliate or sublicensee materially breaches this Agreement and does not cure the breach within [**] days after written notice of the breach; or (c) Company or
its sublicensee experiences a Trigger Event and, in the case of a sublicensee Company has not terminated the license to such sublicensee prior to or automatically upon the occurrence of the Trigger Event. For purposes of Sections 6.3 and 6.4, the
terms “sublicensee” excludes (i) manufacturers not authorized to sell or commercially distribute Licensed Products or Other Licensed Products to third parties and (ii) contractors, service providers, and collaborators whose
rights are limited to making, having made, and/or using Licensed Products or Other Licensed Products for research and/or development purposes. 

6.4 Trigger Event. The term “Trigger Event” means any of the following: (a) a material default by Company under the
Stockholders Agreement, other than a material breach of a representation or warranty, that is not cured during any specified cure periods; (b) if Company or its Affiliate or sublicensee (i) becomes insolvent, bankrupt or generally fails to
pay its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in writing its inability to pay its debts, (iv) suffers the appointment of a custodian, receiver or trustee for it or its property and, if
appointed without its consent, not discharged within [**] days, (v) makes an 

  
 11 

 Execution Copy 03/28/2008 

 

 
assignment for the benefit of creditors, or (vi) suffers proceedings being instituted against it under any law related to bankruptcy, insolvency, liquidation or the reorganization,
readjustment or release of debtors and, if contested by it, not dismissed or stayed within [**] days; (c) the institution or commencement by Company or its Affiliate or sublicensee of any proceeding under any law related to bankruptcy,
insolvency, liquidation or the reorganization, readjustment or release of debtors; (d) the entering of any order for relief relating to any of the proceedings described in Section 6.4 (b) or (c) above; (e) the calling by
Company or its Affiliate or sublicensee of a meeting of its creditors with a view to arranging a composition or adjustment of its debts; (f) the act or failure to act by Company or its Affiliate or sublicensee indicating its consent to,
approval of or acquiescence in any of the proceedings described in Section 6.4(b) – (e) above; (g) failure by Company to pay patent counsel pursuant to the terms of a Client and Billing Agreement or Patent Management Agreement,
if any, after an opportunity of at least [**] days to cure such failure after written notice thereof, or (h) the commencement by Company of any action against Penn, including an action for declaratory judgment, to declare or render invalid or
unenforceable the Patent Rights, or any claim thereof; provided that the foregoing clauses (a) , (b), (c), (d), (e), and (f) shall not apply with respect to Company or its Affiliates if Company has sublicensed all or substantially all of
its rights hereunder to one or more Large Pharmaceutical Company(-ies) and such Large Pharmaceutical Company(-ies) remain in material compliance with the terms and conditions of its or their sublicense(s) relating to this Agreement and the foregoing
clauses (a) , (b), (c), (d), (e), and (f) shall not apply with respect to a sublicensee or acquirer of Company that is a Large Pharmaceutical Company that seeks protection under applicable bankruptcy laws for the purpose of reorganizing
and continuing to operate if such sublicensee or acquirer of Company remains in material compliance with the terms and conditions of its sublicense relating to this Agreement. 

6.5 Effect of Termination. Upon the termination of this Agreement for any reason except as a result of the expiration of the Term:
(a) the License terminates; (b) Company and all its Affiliates will cease all making, having made, using, importing, offering for sale and selling all Licensed Products or Other Licensed Products, as the case may be, except to extent
permitted by Section 6.6; (c) Company will pay to Penn all amounts, including accrued interest, owed to Penn under this Agreement through the date of termination; (d) Company will, at Penn’s request, return to Penn all
confidential information of Penn and provide to Penn one complete copy of all data with respect to Licensed Products and Other Licensed Products as the case may be generated by Company during the Term in the course of its performance of this
Agreement that will facilitate the further development of the technology licensed under this Agreement; and (e) except as otherwise provided in this Agreement in the case of termination under Section 6.3, all duties of Penn and all rights
(but not duties) of Company under this Agreement immediately terminate without further action required by either Penn or Company. Notwithstanding the foregoing, in the event of any termination of this Agreement by Penn under Section 6.3 (Early
Termination by Penn), each sublicense of the Penn Patent Rights shall survive such termination and remain in full force and effect in accordance with its terms and shall be assigned to and assumed by Penn, provided, that (x) the sublicensee is
not then in material breach of the terms and conditions of its sublicense or the applicable terms of this Agreement, (y) the sublicensee agrees in writing to remain in material compliance with all terms and conditions of the sublicense, and
(z) Penn shall not be required to assume the obligations of the Company under such sublicense other than the grant of the sublicense itself and other obligations under this Agreement which are passed-through to such sublicensee under such
sublicense. At Company’s 

  
 12 

 Execution Copy 03/28/2008 

 

 
request, Penn shall enter into a “stand-by” license agreement directly with the applicable sublicensee on terms reasonably acceptable to Penn, to confirm the rights of the sublicensee
set forth in this Section 6.5. 
 6.6 Inventory & Sell Off. Upon the termination of this Agreement for any reason,
Company will cause physical inventories to be taken immediately of: all completed Licensed Products or Other Licensed Products as the case may be, including Licensed Products and Other Licensed Products that have been formulated into final finished
form (“Pre-Termination Formulated Product”), and are under the control of Company or its Affiliates or sublicensees (except for sublicensees whose sublicense agreements remain in effect following such termination pursuant to
Section 6.5 (“Surviving Sublicensees”). Company will deliver promptly to Penn a copy of the written inventory, certified by an officer of the Company. Upon termination of this Agreement for any reason, Company will promptly
remove, efface or destroy all references to Penn from any advertising, labels, web sites or other materials used in the promotion of the business of Company or its Affiliates or sublicensees (except Surviving Sublicensees), and Company and its
Affiliates and sublicensees (except Surviving Sublicensees) will not represent in any manner that it has rights in or to the Penn Patent Rights or the Licensed Products or Other Licensed Products as the case may be, provided however, that inventory
on hand may be marked with appropriate patent numbers. Upon the termination of this Agreement as a result of expiration of the Term, Company and its Affiliates and sublicensees may continue to sell Licensed Products and Other Licensed Products;
provided that royalties on Net Sales of Pre-Termination Formulated Product sold after such termination shall continue to be payable notwithstanding such termination. Upon any termination of this Agreement other than as a result of expiration of the
Term and other than pursuant to Section 6.3(a) or (c), Company and its Affiliates and sublicensees (except Surviving Sublicensees) may sell off its inventory of Licensed Products, and/or Other Licensed Products as the case may be, existing on
the date of termination for a period of [**] months and pay Penn royalties on Net Sales of such inventory within [**] days following the expiration of such [**] month period. 

6.7 Survival. Company’s obligation to pay all amounts, including accrued interest, owed to Penn under this Agreement will survive
the termination of this Agreement for any reason. Sections 1.5(c), 6.1, 6.5, 6.6, 6.7, 13.9, 13.10 and 13.11 and Articles 4, 5, 9, 10, and 11 will survive the termination of this Agreement for any reason in accordance with their respective terms.
Company’s right to continue to prosecute and/or participate in litigation instituted pursuant to Section 8, and Company’s right to recover the proceeds of patent litigation instituted pursuant to Section 8 shall also survive
termination of this Agreement for any reason, provided that such infringement actions are instituted by Company while the License is in effect. It is understood that Company’s right to continue to prosecute and/or participate in patent
litigation and to recover the proceeds thereof following termination of this Agreement are based on infringement occurring while the License is in effect and do not entitle Company to share in financial recoveries based on acts of infringement that
may occur following termination of this Agreement. 
  

	7.	PATENT MAINTENANCE AND REIMBURSEMENT 

 7.1 Patent Maintenance. Penn controls the
preparation, prosecution and maintenance of the Penn Patent Rights and the selection of patent counsel, with input from Company. If, 

  
 13 

 Execution Copy 03/28/2008 

 

 
however, Company desires to manage the preparation, prosecution and maintenance of the Patent Rights with input from Penn, and with agreement from Penn, which will not be unreasonably withheld,
and Company is the sole licensee to the Penn Patent Rights, then Company and Penn will enter into with patent counsel a Patent Management Agreement in the form attached as Exhibit E. Penn will consider Company’s reasonable request to select
alternate patent counsel. For clarity, for so long as there is more than one licensee to Penn Patent Rights, Penn does not typically agree to a Patent Management Agreement but may consider doing so if all licensees to the Penn Patent Rights agree
thereto. 
 7.2 Patent Reimbursement. Within [**] days after the Original Agreement Effective Date, Company will reimburse Penn for
all historically accrued attorneys fees, expenses, official fees and all other charges accumulated prior to the Original Agreement Effective Date incident to the preparation, filing, prosecution and maintenance of the Penn Patent Rights, including
any interference negotiations, claims or proceedings. Hereafter, subject to section 7.3, Company will either pay directly under the Patent Management Agreement or reimburse Penn for the following percentage of all documented attorneys fees,
expenses, official fees and all other charges accumulated on or after the Restatement Date incident to the preparation, filing, prosecution, and maintenance of the Penn Patent Rights, including any interference negotiations, claims or proceedings,
within [**] days after Company’s receipt of invoices for such fees, expenses and charges, provided however, that for so long as there is more than one licensee to the Penn Patent Rights, Company’s reimbursement of ongoing patent expenses
will be reduced by the percentage of such expenses assumed by such other licensee(s). At the time of the Restatement Date, the parties expect that there will be another licensee and that Company’s reimbursement obligation will be reduced to
[**] percent ([**]%) of such expense. Penn will provide Company with prompt written notice of any reduction and will negotiate in good faith to apportion the reimbursement obligation equitably among licensees. 

7.3 Other Matters. Except during the pendency of a Patent Management Agreement: (1) Penn will use reasonable efforts to copy, and
will instruct patent counsel to copy, Company on all patent prosecution and patent maintenance matters related to the Penn Patent Rights including all correspondence from and to patent offices and all drafts of proposed filings with patent offices;
(2) Penn will use reasonable efforts to and will instruct patent counsel to notify Company in writing at least [**] days prior to the due date or deadline for any action which could adversely affect the pending status of any patent application
within the Penn Patent Rights, the maintenance of any granted patent within the Penn Patent Rights, Penn’s right to file any continuing application or foreign counterpart application based on the Penn Patent Rights, or the breadth of any claim
within the Penn Patent Rights; (3) Company has the right to consult with Penn, and Penn will give due consideration to Company’s comments; and (4) Penn will request Company’s written consent prior to taking any of the following
actions: (i) provoking or participating in interference or opposition proceedings; (ii) filing national stage applications or continuation applications in any country other than the United States. Should Company refuse to consent to such
actions, Penn may proceed with any such actions at Penn’s expense and thereafter, the patents, patent rights or patent applications obtained, maintained or secured through such actions will be excluded from the Penn Patent Rights, provided that
patents, patent rights or patent applications will not be excluded from Penn Patent Rights to the extent they are obtained through the filing of national stage applications without Company’s consent, in countries other than Australia, Canada,
Europe, Japan and the United States. For clarity, 

  
 14 

 Execution Copy 03/28/2008 

 

 
Company shall not be required to pay attorney’s fees, expenses, official fees or other charges, or reimburse Penn therefor, in connection with any of the actions listed in (4)(i) or
(ii), including in connection with subsequent prosecution and maintenance of national stage applications listed in 4(ii), if such action(s) was/were undertaken without Company’s prior written consent. 

 

	8.	INFRINGEMENT 

 8.1 Notice. Company and Penn will notify each other promptly of any
infringement of the Penn Patent Rights by a product in the Field of Use (“Field Infringement”) that may come to their attention. Company and Penn will consult each other in a timely manner concerning any appropriate response to the Field
Infringement. 
 8.2 Enforcement. Company may enforce the Penn Patent Rights against any Field Infringement at Company’s
expense. Company shall not, and shall require its Affiliates and sublicensees not to, settle or compromise any such litigation in a manner that imposes any obligations or restrictions on Penn without Penn’s prior written permission. Financial
recoveries from any such litigation will be: (a) first, applied to reimburse Company and/or its Affiliates and/or sublicensees and to reimburse Penn for its or their Litigation Expenditures; and (b) second, as to any remainder, (i) if
such litigation is brought by Company and/or its Affiliates, [**] percent ([**]%) shall be paid to Company and/or its Affiliates and [**] percent ([**]%) shall be paid to Penn or (ii) if such litigation is brought by a non-Affiliate
sublicensee, [**] of any amount paid to Company and/or its Affiliates under the applicable sublicense agreement shall be retained by Company and or its Affiliates and [**] of any amount paid to Company and/or its Affiliates under the applicable
sublicense agreement shall be paid to Penn. For purposes of this Agreement, “Litigation Expenditures” shall be defined as: any attorneys’ fees or costs, whether incurred directly or indirectly, in reference to a pertinent litigation
or investigation, including but not limited to, court costs, local counsel fees, deposition costs, subpoena costs, court reporter costs, expert fees, and other reasonable expenses directly incurred for investigation or litigation of claims. 

8.3 Intervention and Involuntary Participation. 

(a) Voluntary Intervention. Penn reserves the right to voluntarily intervene and join Company in any litigation under Section 8.2. 

(b) Involuntary Participation. If Penn is required to participate involuntarily in any litigation referred to under Section 8.2, (such
as, for example, but not limited to, being joined or named as a defendant, necessary party, involuntary plaintiff, or indispensable party), then: (i) Company may seek to join Penn involuntarily and (ii) if Penn cannot be joined
involuntarily, then Company may join Penn in any litigation referred to under Section 8.2 if Penn’s participation is required for standing to bring or maintain the lawsuit in which Company seeks to join Penn, and Penn will not object to
being joined in said litigation; provided however, that in any instance described in this Section 8.3(b), Company will reimburse Penn’s Litigation Expenditures on an ongoing basis, within [**] days of submission of actual invoices.

 8.4 Penn Prosecution. If Company does not prosecute any infringement of the Patent Rights, then Penn may elect to prosecute such
infringement at Penn’s expense. If Penn elects to 

  
 15 

 Execution Copy 03/28/2008 

 

 
prosecute such infringement, then any financial recoveries will retained by Penn in their entirety; provided, however, that if Company, its Affiliates, or sublicensees is/are involuntarily joined
in any litigation referred to in this Section 8.4, any financial recoveries will first be applied to reimburse any Litigation Expenditures incurred by Company, its Affiliates and sublicensees. If Company, its Affiliates, or sublicensees
participates in any litigation referred to in this Section 8.4 at Penn’s request, Penn will reimburse any Litigation Expenditures incurred by Company, its Affiliates and sublicensees on an ongoing basis, within [**] days of submission of
actual invoices. 
 8.5 Cooperation. In any litigation under this Article 8, either party, at the request and expense of the other
party, will cooperate to the extent reasonable and reasonably possible. This Section 8.5 will not be construed to require either party to undertake any activities, including legal discovery, at the request of any third party, except as may be
required by lawful process of a court of competent jurisdiction. Notwithstanding anything else herein, if Company or its Affiliates sublicenses any or all rights under the License to, or is acquired by, a Large Pharmaceutical Company, such Large
Pharmaceutical Company shall not be required to cooperate under this section 8.5 if such Large Pharmaceutical Company reasonably deems that doing so would present unacceptable business or legal risks. 

 

	9.	DISCLAIMER OF WARRANTIES 

 9.1 Disclaimer. THE PENN PATENT RIGHTS, LICENSED
PRODUCTS, OTHER LICENSED PRODUCTS AND ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS. PENN MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF
ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE. 
  

	10.	LIMITATION OF LIABILITY 

 10.1 Limitation of Liability. PENN WILL NOT BE LIABLE TO
COMPANY, ITS AFFILIATES, SUBLICENSEES, SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM: ARISING FROM COMPANY’S USE OF THE PENN PATENT RIGHTS, LICENSED PRODUCTS, OTHER LICENSED PRODUCTS OR ANY OTHER TECHNOLOGY LICENSED UNDER
THIS AGREEMENT; ARISING FROM THE DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS OR OTHER LICENSED PRODUCTS BY COMPANY, ITS AFFILIATES, SUBLICENSEES, SUCCESSORS OR ASSIGNS; OR FOR LOST PROFITS, BUSINESS INTERRUPTION, OR INDIRECT,
SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND. 
  

	11.	INDEMNIFICATION 

 11.1 Indemnification. Except to the extent that Penn is grossly
negligent or engaged in willful misconduct with respect to Penn’s use of the Penn Patent Rights, Company will defend, indemnify, and hold harmless each Indemnified Party from and against any and all Liabilities

  
 16 

 Execution Copy 03/28/2008 

 

 
with respect to an Indemnification Event. The term “Indemnified Party” means each of Penn and its trustees, officers, faculty, agents, contractors, employees and students. The
term “Liabilities” means all damages, awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses (including, but
not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) that are incurred by an Indemnified Party or awarded or otherwise required to be paid to third parties by an Indemnified Party. The term
“Indemnification Event” means any Claim against one or more Indemnified Parties arising out of or resulting from: (a) the development, testing, use, manufacture, promotion, sale or other disposition of any Penn Patent Rights or
Licensed Products or Other Licensed Products as the case may be by Company, its Affiliates, its sublicensees, its assignees or its vendors, including, but not limited to, (x) a product liability or other Claim of any kind related to use by a
third party of a Licensed Product, (y) a Claim by a third party that the practice of any of the Penn Patent Rights or the design, composition, manufacture, use, sale or other disposition of any Licensed Product infringes or violates any patent,
copyright, trade secret, trademark or other intellectual property right of such third party, and (z) a Claim by a third party relating to clinical trials or studies for Licensed Products or Other Licensed Products as the case may be;
(b) any material breach of this Agreement by Company or its Affiliates or sublicensees; and (c) the enforcement of this Article 11 by any Indemnified Party. The term “Claim” means any charges, complaints, actions, suits,
proceedings, hearings, investigations, claims or demands. 
 11.2 Other Provisions. Company will not settle or compromise any Claim
giving rise to Liabilities in any manner that imposes any restrictions or obligations on Penn without Penn’s prior written consent, which will not be unreasonably withheld. Penn will promptly notify Company of any Claim of which it becomes
aware and will cooperate with Company’s reasonable requests in connection with defense of such Claim, at Company’s expense. If Company fails or declines to assume the defense of any Claim within [**] days after notice of the Claim, then
Penn may assume the defense of such Claim for the account and at the risk of Company, and any Liabilities related to such Claim will be conclusively deemed a liability of Company. The indemnification rights of the Indemnified Parties under this
Article 11 are in addition to all other rights that an Indemnified Party may have at law, in equity or otherwise. 
  

	12.	INSURANCE 

 12.1 Coverages. Company (either itself or through its Affiliates or
sublicensees) will procure and maintain insurance policies for the following coverages with respect to personal injury, bodily injury and property damage arising out of Company’s performance under this Agreement or under the applicable
sublicense agreement; provided that, if insurance coverage obligations are met through Affiliates or sublicensees, then any such Affiliate or sublicense must directly indemnify Penn to the full extent of Company’s indemnification hereunder and,
further provided that any such insurance, whether procured and maintained by Company or through an Affiliate or sublicensee, must name Penn as an additional insured and Company, its Affiliate and/or sublicensee, as applicable, shall provide Penn
with evidence of such insurance: (a) during the Term, comprehensive general liability, including broad form and contractual liability, in a minimum amount of $[**] combined single limit per occurrence and in the aggregate; (b) prior to the
commencement of clinical trials involving Licensed Products or Other Licensed Products as the case may be, clinical trials coverage in a minimum amount of $[**] combined single limit 

  
 17 

 Execution Copy 03/28/2008 

 

 
per occurrence and in the aggregate; and (c) prior to the Sale of the first Licensed Product, product liability coverage, in a minimum amount of $[**] combined single limit per occurrence
and in the aggregate. Penn may review periodically the adequacy of the minimum amounts of insurance for each coverage required by this Section 12.1, and Penn reserves the right to require Company to adjust the limits accordingly, consistent
with industry standards for comparable products, markets, insured parties and indemnified claims. The required minimum amounts of insurance do not constitute a limitation on Company’s liability or indemnification obligations to Penn under this
Agreement. Notwithstanding the foregoing, if Company and/or any Affiliate sublicenses the Penn Patent Rights to a Large Pharmaceutical Company or Company is acquired by a Large Pharmaceutical Company, such sublicensee or acquirer may satisfy the
insurance criteria set forth under Section 12.1 (a), (b) and (c) through reasonable self-insurance. 
 12.2 Other
Requirements. The policies of insurance required by Section 12.1 will be issued by an insurance carrier with an A.M. Best rating of “A” or better and will name Penn as an additional insured with respect to Company’s
performance under this Agreement. Company will provide Penn with insurance certificates evidencing the required coverage within [**] days after the Original Agreement Effective Date and the commencement of each policy period and any renewal periods.
Each certificate will provide that the insurance carrier will notify Penn in writing at least [**] days prior to the cancellation or material change in coverage. 
  

	13.	ADDITIONAL PROVISIONS 

 13.1 Independent Contractors. The parties are independent
contractors. Nothing contained in this Agreement is intended to create an agency, partnership or joint venture between the parties. At no time will either party make commitments or incur any charges or expenses for or on behalf of the other party.

 13.2 No Discrimination. Neither Penn nor Company will discriminate against any employee or applicant for employment because of
race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status. 
 13.3
Compliance with Laws. Company must comply with all prevailing laws, rules and regulations that apply to its activities or obligations under this Agreement. For example, Company will comply with applicable United States export laws and
regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United States government and/or written assurances by Company that Company will not export data or commodities to certain
foreign countries without prior approval of the agency. Penn does not represent that no license is required, or that, if required, the license will issue. 

13.4 Modification, Waiver & Remedies. This Agreement may only be modified by a written amendment that is executed by an
authorized representative of each party. Any waiver must be express and in writing. No waiver by either party of a breach by the other party will constitute a waiver of any different or succeeding breach. Unless otherwise specified, all remedies are
cumulative. 
 13.5 Assignment & Hypothecation. Company may not assign this Agreement or any part of it, either directly or
by merger or operation of law, without the prior written consent of 

  
 18 

 Execution Copy 03/28/2008 

 

 
Penn. Penn will not unreasonably withhold, condition or delay its consent, provided that: (a) at least [**] days before the proposed transaction effecting or conveying such assignment,
Company gives Penn written notice and such background information as may be reasonably necessary to enable Penn to give an informed consent; (b) the assignee agrees in writing to be legally bound by this Agreement and to deliver to Penn an
updated Development Plan within [**] days after the closing of the proposed transaction; and (c) Company provides Penn with a copy of assignee’s undertaking. Notwithstanding the foregoing, Penn’s consent shall not be required for any
assignment of this Agreement to a Large Pharmaceutical Company or acquirer of Company that has, together with its affiliates, a market value or, in the case of a publicly traded company, market capitalization, of at least $[**], provided that:
(A) the assignee agrees in writing to be legally bound by this Agreement and to deliver to Penn an updated Development Plan within [**] days after the closing of the proposed transaction; and (B) Company provides Penn with a copy of
assignee’s undertaking. Any permitted assignment will not relieve Company of responsibility for performance of any obligation of Company that has accrued at the time of the assignment. Company will not grant a security interest in the License
or this Agreement during the Term. Any prohibited assignment or security interest will be null and void. 
 13.6 Notices. Any notice
or other required communication (each, a “Notice”) must be in writing, addressed to the party’s respective Notice Address listed on the signature page, and delivered: (a) personally; (b) by certified mail, postage
prepaid, return receipt requested; (c) by recognized overnight courier service, charges prepaid; or (d) by facsimile. A Notice will be deemed received: if delivered personally, on the date of delivery; if mailed, five (5) days after
deposit in the United States mail; if sent via courier, one (1) business day after deposit with the courier service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a confirming copy of such Notice is sent
by certified mail, postage prepaid, return receipt requested. 
 13.7 Severability & Reformation. If any provision of this
Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be automatically revised to be
a valid or enforceable provision that comes as close as permitted by law to the parties’ original intent. 
 13.8
Headings & Counterparts. The headings of the articles and sections included in this Agreement are inserted for convenience only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be
executed in several counterparts, all of which taken together will constitute the same instrument. 
 13.9 Governing Law. This
Agreement will be governed in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to the conflict of law provisions of any jurisdiction. 

13.10 Dispute Resolution. If a dispute arises between the parties concerning any right or duty under this Agreement, then the parties
will confer, as soon as practicable, in an attempt to resolve the dispute. If the parties are unable to resolve the dispute amicably, then the parties will 

  
 19 

 Execution Copy 03/28/2008 

 

 
submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania with respect to all disputes arising under this Agreement. 

[Remainder of the Page Left Intentionally Blank] 

  
 20 

 Execution Copy 03/28/2008 

 

 13.11 Integration. This Agreement with its Exhibits, the Stockholders Agreement, the
Patent Inventorship Agreement, and the Confidentiality Agreements contain the entire agreement between the parties with respect to the Penn Patent Rights and the License and supersede all other oral or written representations, statements, or
agreements with respect to such subject matter, including but not limited to the Original Agreement. 
 Each party has caused this Agreement to be executed
by its duly authorized representative. 
  

									
	THE TRUSTEES OF THE	 		 	POTENTIA PHARMACEUTICALS, INC.
				
	UNIVERSITY OF PENNSYLVANIA	 		 		 	
					
	By:	 	 /s/ Michael Cleare
	 		 	By:	 	 /s/ Cedric Francois

	Name:	 	Michael J. Cleare	 		 	Name:	 	Cedric Francois, M.D. Ph.D.
	Title:	 	Executive Director, Technology Transfer	 		 	Title:	 	CEO and President

  

							
	Address:	 	Center for Technology Transfer	 	Address:	 	201 E. Jefferson St.
		 	University of Pennsylvania	 		 	Suite 301
		 	3160 Chestnut Street, Suite 200	 		 	Louisville, KY 40202
		 	Philadelphia, PA 19104-6283	 		 	
		 	Attention: Executive Director	 		 	

  

					
	Required copy to:	 	University of Pennsylvania	 	Potentia Pharmaceuticals, Inc.
		 	Office of General Counsel	 	201 E. Jefferson St.
		 	133 South 36th Street, Suite 300	 	Suite 301
		 	Philadelphia, PA 19104-3246	 	Louisville, KY 40202
		 	Attention: General Counsel	 	Attn: General Counsel

  
 21 

 Execution Copy 03/28/2008 

 

 EXHIBIT INDEX 

 

			
	Exhibit A	  	Patents and Patent Applications in Patent Rights
		
	Exhibit B	  	Minimum Contents of Development Plan
		
	Exhibit C	  	Form of Stockholders Agreement
		
	Exhibit D	  	Format of Royalty Report
		
	Exhibit E	  	Form of Patent Management Agreement

  
 22 

 EXHIBIT A 

Patent Rights 
  

											
	 Penn Docket
	  	 Docket Title
	  	 Inventors
	  	 Applicants
	  	 US Patents
	  	 Foreign Patents

	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]

  
 A-1 

 EXHIBIT B 

Development Plan Contents 
 The
Development Plan and each update to the Development Plan will include, at a minimum, the following information: 
 [**] 

  
 B-1 

 EXHIBIT C 

[Form of Potentia Stockholders Agreement] 

 THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

by and among 
 POTENTIA
PHARMACEUTICALS, INC. 
 and 

THE PARTIES LISTED ON 

EXHIBIT A HERETO 
 Dated
as of 
 March     , 2008 

 POTENTIA PHARMACEUTICALS, INC. 

THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

March     , 2008 
  

 
 TABLE OF CONTENTS 

 

							
	 ARTICLE 1
	  	 DEFINITIONS
	  	 	1	 
			
	 ARTICLE 2
	  	 PREEMPTIVE RIGHTS
	  	 	4	 
			
	 2.1
	  	 Generally
	  	 	4	 
			
	 2.2
	  	 Acceptance
	  	 	4	 
			
	 2.3
	  	 Sale by Company
	  	 	4	 
			
	 2.4
	  	 Decrease in Shares Sold
	  	 	5	 
			
	 2.5
	  	 Purchase of Shares
	  	 	5	 
			
	 2.6
	  	 Shares Not Sold
	  	 	5	 
			
	 2.7
	  	 Exclusions from First Refusal Right
	  	 	5	 
			
	 2.8
	  	 Applicability of this Agreement to Offered Securities
	  	 	6	 
			
	 ARTICLE 3
	  	 RESTRICTIONS ON TRANSFER
	  	 	6	 
			
	 3.1
	  	 Generally
	  	 	6	 
			
	 3.2
	  	 Permitted Transfers
	  	 	6	 
			
	 3.3
	  	 Offer for Sale; Notice of Proposed Sale
	  	 	7	 
			
	 3.4
	  	 Option to Purchase
	  	 	7	 
			
	 3.5
	  	 Sale to Offeror; Closing
	  	 	8	 
			
	 ARTICLE 4
	  	 CO-SALE
	  	 	8	 
			
	 4.1
	  	 Co-Sale Rights
	  	 	8	 
			
	 4.2
	  	 Treatment of Sale Proceeds
	  	 	8	 
			
	 ARTICLE 5
	  	 DRAG-ALONG OBLIGATIONS
	  	 	9	 
			
	 5.1
	  	 Generally
	  	 	9	 
			
	 5.2
	  	 Notice
	  	 	10	 
			
	 5.3
	  	 Closing
	  	 	10	 
			
	 ARTICLE 6
	  	 BOARD ELECTIONS
	  	 	12	 
			
	 ARTICLE 7
	  	 GENERAL PROVISIONS
	  	 	12	 
			
	 7.1
	  	 Legends
	  	 	12	 
			
	 7.2
	  	 Amendments
	  	 	13	 

  
 i 

							
			
	 7.3
	  	 Effect of Agreement
	  	 	13	 
			
	 7.4
	  	 Governing Law
	  	 	14	 
			
	 7.5
	  	 Counterparts
	  	 	14	 
			
	 7.6
	  	 Notices
	  	 	14	 
			
	 7.7
	  	 Entire Agreement
	  	 	14	 
			
	 7.8
	  	 Severability
	  	 	14	 
			
	 7.9
	  	 Construction
	  	 	14	 
			
	 7.10
	  	 Limited Proxy
	  	 	14	 

  
 ii 

 POTENTIA PHARMACEUTICALS, INC. 

THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT 

THIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”) is entered into as of March
    , 2008, by and among Potentia Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and those individuals identified on Exhibit A hereto (individually, each a “Stockholder” and
collectively, the “Stockholders”). 
 RECITALS 

WHEREAS, the Stockholders believe that it is in the best interest of the Company and the Stockholders to (i) provide preemptive rights
with respect to future sales of Preferred Stock to the Preferred Stockholders; (ii) provide limitations on certain transfers of Shares; (iii) provide for certain drag-along and co-sale rights and obligations of the Stockholders;
(iv) provide for the election of certain persons as directors of the Company; and (v) set forth their agreements on certain other matters; 

WHEREAS, the Company and the Stockholders entered into that certain Shareholders Agreement dated March 31, 2005, amended and restated by
that certain First Amended and Restated Stockholders Agreement dated October 27, 2006, and further amended and restated by that certain Second Amended and Restated Stockholders Agreement dated October 18, 2007; 

WHEREAS, the Second Amended and Restated Stockholders Agreement by and among the Company and the Stockholders dated October 18, 2007, is
amended and restated by this Agreement, effective upon the execution and delivery of written consents by the holders of a majority of the outstanding shares of Common Stock, $0.0001 par value, and Series 2006 Preferred Stock, $0.0001 par value, of
the Company. 
 NOW, THEREFORE, the parties hereto agree as follows: 

 
 ARTICLE 1 

DEFINITIONS 
 1.1
“Affiliate” means, with respect to any Person, any other Person who controls, is controlled by, or is under common control with, such Person. 

1.2 “Available Amount” has that meaning set forth in Section 2.1 of this Agreement. 

1.3 “Board of Directors” means the board of directors of the Company. 

1.4 “Certificate” has that meaning set forth in Section 4.1 of this Agreement. 

1.5 “Company” means Potentia Pharmaceuticals, Inc., a Delaware corporation, and its successors and assigns. 

  
 C-1 

 1.6 “Co-Sale” has that meaning set forth in Section 4.1 of this Agreement.

 1.7 “Co-Sale Purchaser” has that meaning set forth in Section 4.1 of this Agreement. 

1.8 “Co-Sale Transaction” means a transaction whereby a majority of the Shares become beneficially owned by a single Person
(including Affiliates of such Person). 
 1.9 “Drag-Along Notice” has that meaning set forth in Section 5.2 of this
Agreement. 
 1.10 Drag-Along Stockholders” has that meaning set forth in Section 5.1 of this Agreement. 

1.11 “Drag-Along Transaction” has that meaning set forth in Section 5.1 of this Agreement. 

1.12 “Electing Co-Sale Purchaser” has that meaning set forth in Article 4.1 of this Agreement. 

1.13 “Excluded Securities” has that meaning set forth in Section 2.7 of this Agreement. 

1.14 “Notice” has that meaning set forth in Section 3.3 of this Agreement. 

1.15 “Notice of Acceptance” has that meaning set forth in Section 2.2 of this Agreement. 

1.16 “Offer” has that meaning set forth in Section 2.1 of this Agreement. 

1.17 “Offeree” has that meaning set forth in Section 2.1 of this Agreement. 

1.18 “Offered Securities” has that meaning set forth in Section 2.1 of this Agreement. 

1.19 “Offeror” has that meaning set forth in Section 3.3 of this Agreement. 

1.20 “Option” has that meaning set forth in Section 3.4 of this Agreement. 

1.21 “Option Period” has that meaning set forth in Section 3.4 of this Agreement. 

1.22 “Participating Sellers” has that meaning set forth in Section 5.1 of this Agreement. 

1.23 “Permitted Transferee” has that meaning set forth in Section 3.2 of this Agreement. 

1.24 “Person” means any individual, limited liability company, partnership (general or limited), corporation, trust, estate,
association, or other entity. 
 1.25 “Preferred Stockholder” means any holder of shares of Series 2006 Preferred Stock or
Series 2007 Preferred Stock. 

  
 C-2 

 1.26 “Proposed Buyer” has that meaning set forth in Section 5.1 of this
Agreement. 
 1.27 “Qualifying Financing” has that meaning set forth in the Certificate of Incorporation of the Company, as
in effect immediately prior to the date of any such financing. 
 1.28 “Refused Securities” has that meaning set forth in
Section 2.3 of this Agreement. 
 1.29 “Requisite Majority” shall mean the holders of a majority of the outstanding
shares of Series 2006 Preferred Stock and Series 2007 Preferred Stock voting together as a single class. 
 1.30 “Securities
Act” means the Securities Act of 1933, as amended, or any similar Federal statute, and the rules and regulations of the Securities and Exchange Commission issued under such Act, as they each may, from time to time, be in effect. 

1.31 “Selling Parties” has that meaning set forth in Section 7.1 of this Agreement. 

1.32 “Stockholders” has that meaning set forth in the introductory paragraph of this Agreement. 

1.33 “Shares” means shares of the Common Stock, $0.0001 par value, the Series 2006 Preferred Stock, $0.0001 par value, and/or
the Series 2007 Preferred Stock, $0.0001 par value, of the Company, and, for the purpose of determining a majority or other percentage of the outstanding shares of Common Stock and Preferred Stock held by Stockholders hereunder, the Common Stock,
the Series 2006 Preferred Stock and the Series 2007 Preferred Stock, considered together as a single class on an as-converted basis. 

1.34 “Shares Proposed for Transfer” has that meaning set forth in Section 3.3 of this Agreement. 

1.35 “Subsidiary” means any entity 50% or more of whose securities are owned by the Company or as to which the Company has
the right to elect a majority of the members of the board of directors or similar governing body. 
 1.36 “Transfer” means
any sale, transfer or other disposition of any Shares, or of any interest in such Shares, whether voluntary or by operation of law. 

1.37 “Transferring Co-Sale Stockholders” has that meaning set forth in Section 4.1 of this Agreement. 

1.38 “Transferring Party” has that meaning set forth in Section 3.3 of this Agreement. 

  
 C-3 

 ARTICLE 2 

PREEMPTIVE RIGHTS 
 2.1
Generally. Subject to Sections 2.7 and 2.8 below, the Company shall not issue, sell or exchange, agree to issue, sell or exchange, or reserve or set aside for issuance, sale or exchange, any Preferred Stock or any other equity securities of the
Company having rights, preferences and privileges senior to those of the Common Stock, (collectively, unless excluded by Section 2.7 below, the “Offered Securities”), unless in each such case the Company shall have first
complied with this Agreement. The Company shall deliver to each Preferred Stockholder a written notice of any proposed or intended issuance, sale or exchange of Offered Securities (the “Offer”), which Offer shall (i) identify
and describe the Offered Securities, (ii) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or amount of the Offered Securities to be issued, sold or exchanged, (iii) identify the
persons or entities to which or with which the Offered Securities are to be offered, issued, sold or exchanged (the “Offerees”), and (iv) offer to issue and sell to or exchange with each Preferred Stockholder (A) such
portion of the Offered Securities as the aggregate number of shares of Common Stock into which all shares of Preferred Stock held by such Preferred Stockholder are convertible bears to the total number of shares of Common Stock into which all shares
of Preferred Stock held by the Preferred Stockholders are then convertible (the “Available Amount”). Each Preferred Stockholder shall have the right, for a period of fifteen (15) days following delivery of the Offer, to
purchase or acquire, at the price and upon the other terms specified in the Offer, the number of Offered Securities described above. The Offer by its terms shall remain open and irrevocable for such 15-day period. 

2.2 Acceptance. To accept an Offer, in whole or in part, a Preferred Stockholder must deliver a written notice (the “Notice of
Acceptance”) to the Company prior to the end of the 15-day period of the Offer, setting forth with respect to such Preferred Stockholder, the portion of such Preferred Stockholder’s Available Amount that the Preferred Stockholder
elects to purchase. A Preferred Stockholder may designate, at any time prior to actual purchase, any Affiliate of such Preferred Stockholder as the entity entitled to purchase all or a portion of such Preferred Stockholder’s Available Amount,
provided that (i) such designee agrees to be bound by the terms of this Agreement in the same capacity as the Preferred Stockholder hereunder and (ii) the purchase of such Offered Securities by such designee does not violate the
registration requirements of or require registration under the Securities Act or any applicable state securities laws. 
 2.3 Sale by
Company. In the event that Notices of Acceptance are not given by Preferred Stockholders in respect of all the Offered Securities, the Company shall have up to 120 days from the expiration of the period set forth in Section 2.1 above to
issue, sell or exchange all or any part of such Offered Securities as to which Notices of Acceptance have not been given by the Preferred Stockholders (the “Refused Securities”), but only to one or more of the Offerees and only upon
terms and conditions (including, without limitation, unit prices and interest rates) which are not more favorable, in the aggregate, to the acquiring person or persons or less favorable to the Company than those set forth in the Offer. 

  
 C-4 

 2.4 Decrease in Shares Sold. In the event the Company shall propose to sell less than all
the Refused Securities (any such sale to be in the manner and on the terms specified in Section 2.3 above), then each Preferred Stockholder may, at its sole option and in its sole discretion by delivery of notice to the Company within ten
(10) days of receipt of notice of such reduction, reduce the number or amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be not less than the number or amount of the Offered Securities that the
Preferred Stockholder elected to purchase pursuant to Section 2.2 above multiplied by a fraction, (i) the numerator of which shall be the reduced number or amount of Offered Securities the Company proposes to issue, sell or exchange
(including Offered Securities to be issued or sold to Preferred Stockholders pursuant to Section 2.2 above prior to such reduction) and (ii) the denominator of which shall be the amount of all Offered Securities. In the event that any
Preferred Stockholder so elects to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may not issue, sell or exchange more than the reduced number or amount of the Offered Securities unless and until
such securities have again been offered to the Preferred Stockholders in accordance with Section 2.1 above. 
 2.5 Purchase
of Shares. Upon the closing of the issuance, sale or exchange of all or less than all of the Refused Securities, or if there are no Refused Securities, on a date mutually agreeable to the Company and the Preferred Stockholders who have delivered
Notices of Acceptances with respect to at least a majority of the Offered Securities. Section 2.2 above, the Preferred Stockholders shall acquire from the Company, and the Company shall issue to the Preferred Stockholders, the number or amount
of Offered Securities specified in the Notices of Acceptance, as reduced pursuant to Section 2.4 above if the Preferred Stockholders have so elected, upon the terms and conditions specified in the Offer. The purchase by the Preferred
Stockholders of any Offered Securities is subject in all cases to the preparation, execution and delivery by the Company and each Preferred Stockholder of a purchase agreement relating to such Offered Securities reasonably satisfactory in form and
substance to the Offerees and Preferred Stockholders who will purchase at least a majority of such Offered Securities. 
 2.6
Shares Not Sold. Any Offered Securities not acquired by the Preferred Stockholders or the Offerees in accordance with Section 2.3 above may not be issued, sold or exchanged until they are again offered to the Preferred Stockholders in
accordance with Section 2.1 above.  
 2.7 Exclusions from First Refusal Right. The rights of the Preferred Stockholders
under Sections 2.1 through 2.6, inclusive, shall not apply to the following securities and such securities (“Excluded Securities”), shall not be deemed “Offered Securities”: 

(a) Common Stock issued as a stock dividend to holders of Common Stock or upon any subdivision of shares of Common Stock; 

(b) Preferred Stock issued as a stock dividend to holders of Preferred Stock or upon any subdivision of shares of Preferred Stock; 

  
 C-5 

 (c) the issuance of shares of Common Stock, or options exercisable therefor, including
options outstanding on the date of this Agreement, issued or issuable to current or former employees, officers or directors of, or consultants or advisers to, the Company pursuant to stock purchase or stock option plans or similar arrangements
approved by the Board of Directors; 
 (d) securities issued or issuable in connection with a bona fide non-equity financing
transaction (e.g. equipment financing arrangements and bank lines of credit) that is approved by the Board of Directors; 
 (e)
securities issued solely in consideration for the acquisition (whether by merger or otherwise) by the Company or any of its Subsidiaries of all or substantially all of the stock or assets of any other entity in a transaction that is approved by the
Board of Directors; 
 (f) shares of Common Stock issued in a Qualifying Financing; 

(g) securities issued to a strategic partner in connection with a development, collaboration or other similar agreement that is approved
by the Board of Directors; or 
 (h) securities issued, sold or exchanged by the Company as to which the Requisite Majority has
elected to designate as Excluded Securities. 
 2.8 Applicability of this Agreement to Offered Securities. All Offered Securities
issued, sold or exchanged pursuant to this Agreement as applicable, shall be subject to the terms of this Agreement unless otherwise determined by the Requisite Majority. 

ARTICLE 3 
 RESTRICTIONS
ON TRANSFER 
 3.1 Generally. Any Transfer of any of the Shares by a Stockholder, other than according to the terms of this
Agreement, shall be void and transfer no right, title or interest in or to any such Shares to the purported transferee. Moreover, unless approved by the Board of Directors, no Transfers shall be valid unless and until the transferee shall have
executed and delivered a counterpart of this Agreement. 
 3.2 Permitted Transfers. A Stockholder may Transfer without
compliance with Sections 3.3 through 3.5 of this Agreement, any or all of his Shares to an Affiliate of such Stockholder, to his spouse or children or to a trust established for the benefit of his spouse, children or himself, or dispose of them
under his will or pursuant to a judicial decree or order (provided that, in each such case, the Company receives written notice of such Transfer and, prior to the completion of such Transfer, each such transferee (a “Permitted
Transferee”) or his or her legal representative shall have executed documents assuming the obligations of the transferring Stockholder under this Agreement with respect to the transferred Shares). Notwithstanding the foregoing, in the event
of any Transfer pursuant to this Section 3.2 the 

  
 C-6 

 
transferor and the Permitted Transferee(s) shall be jointly and severally liable as one Stockholder pursuant to this Agreement. The pledge of any Shares by a Stockholder shall be permitted only
with the approval of the Board of Directors, in its sole discretion. 
 3.3 Offer for Sale; Notice of Proposed Sale. If any
Stockholder (the “Transferring Party”) desires to Transfer any of his Shares in any transaction other than pursuant to Section 3.2 of this Agreement, such Transferring Party shall first deliver written notice of such desire to
do so (the “Notice”) to the Company. The Notice shall specify: (i) the name and address of the party to which the Transferring Party proposes to Transfer the Shares (the “Offeror”), (ii) the number of
Shares the Transferring Party proposes to Transfer (the “Shares Proposed for Transfer”), (iii) the consideration per Share offered by the Offeror to the Transferring Party for the proposed Transfer, and (iv) all other
material terms and conditions of the proposed transaction. The Notice shall be accompanied by a copy of the offer from the Offeror to the Transferring Party or such other evidence of the offer that is reasonably satisfactory to the Company.

 3.4 Option to Purchase. 

(a) The Company shall have the option (the “Option”) to purchase all but not less than all of the Shares Proposed for
Transfer for the consideration per Share and on the terms and conditions specified in the Notice. The Option must be exercised no later than thirty (30) days after such Notice has been delivered (the “Option Period”). Such
option shall be exercised by delivery of written notice to the Secretary of the Company. 
 (b) In the event the Company duly
exercises its option to purchase the Shares Proposed for Transfer, the closing of such purchase shall take place at the offices of the Company on a single date agreed to between the Transferring Party and the Company, which date shall be not later
than sixty (60) days after the expiration of the Option Period. 
 (c) To the extent that the consideration proposed to be paid
by the Offeror for the Shares Proposed for Transfer consists of property other than cash or a promissory note, the consideration required to be paid by the Company upon exercise of the Option may consist of cash equal to the value of such property,
as determined in good faith by agreement of the Transferring Party and the Company. In the event that the parties are not able to determine the value of such property, the value of such property shall be determined by a panel of three appraisers
whose decision shall be final and binding on the parties hereto. The Transferring Party shall choose one appraiser; the Company shall choose the second appraiser; and the two so selected shall select and designate a third appraiser. The value of the
property shall be equal to the average of the values determined by the three appraisers. The fees and expenses of all such appraisers shall be borne equally by the Transferring Party and by the Company. 

  
 C-7 

 3.5 Sale to Offeror; Closing. If the Company does not exercise the Option within the
Option Period, then the option of the Company to purchase such Shares Proposed for Transfer, whether exercised or not, shall terminate and, subject to the provisions in Section 3.1, the Transferring Party may sell, on the terms and conditions
set forth in the Notice, the Shares Proposed for Transfer to the Offeror, provided that (a) the transaction contemplated by the Notice shall be consummated not later than ninety (90) days after the expiration of the Option Period and
(b) the Offeror agrees to be bound by the terms of this Agreement in the same capacity as the Transferring Party. 
 ARTICLE 4

 CO-SALE 
 4.1
Co-Sale Rights. Upon the proposed occurrence of a Co-Sale Transaction, any one or more of the Stockholders may demand that the effectiveness of the Co-Sale Transaction be conditioned upon the right of each such Stockholder to sell to the Person
acquiring Shares in the Co-Sale Transaction (the “Co-Sale Purchaser”) all or any part of such Stockholder’s Shares (a “Co-Sale”), provided that such Stockholder (an “Electing Co-Sale
Stockholder”) delivers written notice to the Stockholders transferring Shares in the Co-Sale Transaction (the “Transferring Co-Sale Stockholders”) to the Co-Sale Purchaser of such demand stating the number of Shares he so
wishes to sell within forty-five (45) days after having received notice from the Transferring Co-Sale Stockholders that a proposed sale of Shares would constitute a Co-Sale Transaction. The price for such Stockholders’ Shares shall be
equal to the per Share price to be paid in the Co-Sale Transaction; provided, however, that the proceeds from the Co-Sale Transaction shall be reallocated among such Electing Co-Sale Stockholders and the Transferring Co-Sale Stockholders such that
such Electing Co-Sale Stockholders and the Transferring Stockholders shall be entitled to receive such portion of the proceeds as if the proceeds had been distributed by the Company in complete liquidation pursuant to the rights and preferences set
forth in the Certificate of Incorporation (the “Certificate”) of the Company as in effect immediately prior to the entry into the first agreement entered into in connection with, and prior to, such Co-Sale Transaction (giving effect
to applicable orders of priority). The closing of the Co-Sale shall take place concurrently with the sale by the Transferring Co-Sale Stockholders to the Co-Sale Purchaser. If the Co-Sale Purchaser is unwilling or unable to purchase all of the
Shares such Stockholders desire to sell, neither the Company nor any Stockholders shall enter into the Co-Sale Transaction. 
 4.2
Treatment of Sale Proceeds. The proceeds of any sale made by any Transferring Co-Sale Stockholders without compliance with the provisions of Section 4.1 shall be deemed to be held in constructive trust in such amount as would have been due
to the Stockholders desiring to sell Shares if the Transferring Co-Sale Stockholders had complied with this Agreement. 

  
 C-8 

 ARTICLE 5 

DRAG-ALONG OBLIGATIONS 

5.1 Generally. 

(a) If requested by the holders of a majority of the outstanding Shares (the Stockholders constituting such majority are hereinafter
referred to as the “Drag-Along Stockholders”), each of the other Stockholders (the “Participating Sellers”) hereby agrees to sell all of his Shares to any other Person (the “Proposed Buyer”) in the
manner and on the terms set forth in this Article 5 in connection with the sale by the Drag-Along Stockholders to the Proposed Buyer of all of the Shares held by the Drag-Along Stockholders (a “Drag-Along Transaction”). 

(b) The obligations of the Stockholders pursuant to this Section 5.1 are subject to the satisfaction of the following conditions:

 (i) upon the consummation of a Drag-Along Transaction, each of the Stockholders shall receive the same proportion of the aggregate
consideration from such Drag-Along Transaction that such Stockholder would have received if such aggregate consideration had been distributed by the Company in complete liquidation pursuant to the rights and preferences set forth in the Certificate
as in effect immediately prior to the entry into the first agreement entered into in connection with, and prior to, such Drag-Along Transaction (giving effect to applicable orders of priority); 

(ii) subject to Section 5.3(b), if any Stockholders are given an option as to the form of consideration to be received, each other
Stockholder shall be given the same option; 
 (iii) the Drag-Along Transaction must be a bona fide, arms’ length transaction;

 (iv) the Proposed Buyer must not be affiliated with any of the Drag-Along Stockholders, including without limitation, that the
Proposed Buyer must not, directly or indirectly, be a shareholder, officer, director, partner, member or manager of any of the Drag-Along Stockholders, and the Proposed Buyer must not, directly or indirectly, control, be controlled by, or be under
common control with, any of the Drag-Along Stockholders; 
 (v) if any Drag-Along Stockholder obtains in connection with the
Drag-Along Transaction any contractual rights, such as registration rights, rights of co-sale, preemptive rights, and the like, each Participating Seller shall receive substantially commensurate contractual rights in connection with such Drag-Along
Transaction; 

  
 C-9 

 (vi) no options, warrants or similar rights to acquire equity in the Proposed Buyer (or
its parent) in the Drag-Along Transaction may be granted, issued or sold to any Drag-Along Stockholder unless granted, or issued to each Participating Seller on a pro rata basis (except for options granted to Drag-Along Stockholders who are
employees of the Company), based on the proportion of outstanding Shares held by each Stockholder as of immediately prior to the consummation of the Drag-Along Transaction; 

(vii) no Participating Seller shall be obligated to make any out-of-pocket expenditure prior to the consummation of the Drag-Along
Transaction and no Participating Seller shall be obliged to pay more than such Participating Seller’s pro rata share (based upon the amount of consideration received) of reasonable expenses incurred in connection with a consummated Drag-Along
Transaction to the extent such costs are incurred for the benefit of all Stockholders and are not otherwise paid by the Company or the Proposed Buyer (costs incurred by or on behalf of a Stockholder for such Stockholder’s sole benefit will not
be considered costs of the transaction hereunder), provided that a Stockholder’s liability for such expenses shall be limited to the total purchase price received by such Stockholder in such Drag-Along Transaction for such Stockholder’s
Shares; 
 (viii) in the event that the Stockholders are required to provide indemnification of the Proposed Buyer in connection with
the Drag-Along Transaction, each Stockholder shall not be liable for more than such Stockholder’s pro rata share (based upon the amount of consideration received) of any indemnification liability and such liability shall not exceed the total
purchase price or consideration received by such Stockholder for such Stockholder’s Shares in such Drag-Along Transaction; and 

(ix) each Stockholder shall only be obligated to make representations or warranties in any such Drag-Along Transaction as to such
Stockholder’s (A) title and ownership of the Shares to be sold by such Stockholder, (B) authorization, execution and delivery of relevant documents by such Stockholder, and (C) the enforceability of relevant documents against
such Stockholder. 
 5.2 Notice. A “Drag-Along Notice” shall be delivered by a Stockholder who is a part of the
Drag-Along Stockholders on behalf of all such Stockholders to the Participating Sellers. The Drag-Along Notice shall set forth the principal terms of the proposed Drag-Along Transaction insofar as it relates to the Shares, the purchase price, the
name and address of the Proposed Buyer and the other principal terms of the proposed Drag-Along Transaction. 
 5.3
Closing. 

  
 C-10 

 (a) If the Drag-Along Stockholders consummate the Drag-Along Transaction, the
Participating Sellers shall be bound and obligated to sell all of their Shares in the Drag-Along Transaction on the same terms and conditions (except as otherwise contemplated by Section 5.1(b)(i) and Section 5.3(b)) as the Drag-Along
Stockholders sell their Shares. Subject to Section 5.1, the Stockholders agree that they will also take such actions and execute such documents and instruments as shall be necessary or desirable in order to consummate the Drag-Along Transaction
expeditiously. If at the end of the one hundred eightieth (180th) day following the date of the Drag-Along Notice the Drag-Along Transaction has not been completed other than by reason of any failure of a Participating Seller to comply with its
obligations under this Article 5, the Participating Sellers shall be released from their obligations under the Drag-Along Notice, the Drag-Along Notice shall be null and void, and it shall be necessary for a separate Drag-Along Notice to have been
furnished and the terms and provisions of this Article 5 separately complied with, in order to consummate a Drag-Along Transaction pursuant to this Article 5. 

(b) Notwithstanding any other provision of this Agreement, in the event the consideration to be paid in exchange for Shares in the
proposed Drag-Along Transaction includes any securities and the receipt thereof by a Participating Seller which would require under applicable law (i) the registration or qualification of such securities or of any person as a broker or dealer
or agent with respect to such securities or (ii) the provision to any participant in the Drag-Along Transaction of any information other than such information as would be required under Regulation D promulgated under the Securities Act in an
offering made pursuant to said Regulation D solely to “accredited investors” as defined in Regulation D, the Stockholders constituting the Drag-Along Stockholders shall have no obligation to cause such Participating Seller to receive as to
the Shares the same amount and kind of securities as the Drag-Along Stockholders to the extent of such receipt of securities, unless the Drag-Along Stockholders shall have elected to cause such requirements to have been complied with to the extent
necessary to permit such Participating Seller to receive such securities. The Participating Seller shall be entitled to receive, in lieu thereof, against surrender of the Shares (in accordance with Section 5.3(c)) which would have otherwise
been transferred by such Participating Seller to the Proposed Buyer in the Drag-Along Transaction, an amount in cash equal to the fair market value of the securities which such Participating Seller would otherwise have received (as determined in
good faith by the Board of Directors in its sole discretion). In the event such requirements have been complied with to the extent necessary to permit such Participating Seller to receive such securities, the Participating Seller shall execute such
documents and instruments, and take such other actions (including without limitation, if required by the Drag-Along Stockholders, agreeing to be represented, without cost to the Participating Seller, during the course of such Drag-Along Transaction
by a “purchaser representative” (as defined in Regulation D) in connection with evaluating the merits and risks of the prospective investment and acknowledging that he was so represented), as the Proposed Buyer

  
 C-11 

 
or the Company shall reasonably request in order to permit such requirements to have been complied with; provided, however, that such actions shall not include any expenditure of funds by the
Participating Seller, it being understood that payment by the Participating Seller of the fees and disbursements of any counsel the Participating Seller may elect to retain shall be deemed not to constitute a required expenditure of funds for
purposes of this provision. 
 (c) At the closing of any Drag-Along Transaction under this Article 5, the Participating Sellers shall
deliver the Shares to be sold by them, duly endorsed for transfer with signature guaranteed, free and clear of any liens, against delivery of the applicable purchase price. 

ARTICLE 6 
 BOARD
ELECTIONS 
 6.1 Until such time as Cédric François is no longer the owner of at least 5% of the outstanding
Shares, the Stockholders agree to vote or act with respect to their Shares so as to elect him as a member of the Board of Directors. 

6.2 Until such time as Alec Machiels is no longer the owner of at least 5% of the outstanding Shares, the Stockholders agree to vote or
act with respect to their Shares so as to elect him as a member of the Board of Directors. 
 6.3 Until such time as
HealthCare Ventures LLC is no longer the owner of at least 1,000,000 shares of Series 2007 Preferred Stock or of Common Stock issuable upon conversion of Series 2007 Preferred Stock, the Stockholders agree to vote or act with respect to their Shares
so as to elect one representative of HealthCare Ventures LLC as a member of the Board of Directors. 
 ARTICLE 7 

GENERAL PROVISIONS 

7.1 Legends. 
 (a)
The following legends shall appear on the back of any certificate for Shares issued by the Company to the Stockholders: 
 THE SHARES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS (A) SUCH SHARES MAY BE OFFERED,
SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED PURSUANT TO RULE 144 OR RULE 144A UNDER THE ACT OR (B) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT COVERING SUCH OFFER, SALE, TRANSFER, ASSIGNMENT, PLEDGE OR HYPOTHECATION OR
(C) THE 

  
 C-12 

 
COMPANY RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER OF THESE SHARES, OR OTHER EVIDENCE SATISFACTORY TO THE COMPANY, STATING THAT SUCH OFFER, SALE, TRANSFER, ASSIGNMENT, PLEDGE OR HYPOTHECATION
IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
THE TERMS OF A STOCKHOLDERS AGREEMENT AMONG THE COMPANY AND CERTAIN OF ITS STOCKHOLDERS, AS THE SAME MAY BE AMENDED FROM TIME TO TIME. ANY PURCHASER, ASSIGNEE, TRANSFEREE, PLEDGEE OR OTHER SUCCESSOR TO ANY HOLDER HEREOF IS BOUND BY THE TERMS OF SUCH
AGREEMENT, A COPY OF WHICH WILL BE MAILED, WITHOUT CHARGE, WITHIN FIVE (5) DAYS AFTER RECEIPT OF A WRITTEN REQUEST THEREFOR DIRECTED TO THE SECRETARY OF THE COMPANY. 

(b) A legend substantially as set forth below shall appear on the back of any certificate for Shares issued to any person not a party to
this Agreement: 
 THE COMPANY AND CERTAIN OF ITS STOCKHOLDERS HAVE ENTERED INTO A STOCKHOLDERS AGREEMENT THE TERMS OF WHICH MAY AFFECT THE
RIGHTS OF STOCKHOLDERS NOT A PARTY THERETO. THE COMPANY WILL MAIL A COPY OF SUCH STOCKHOLDERS AGREEMENT TO ANY REGISTERED HOLDER OF ANY OF ITS CAPITAL STOCK, WITHOUT CHARGE, WITHIN FIVE (5) DAYS AFTER A WRITTEN REQUEST THEREFOR IS RECEIVED BY
THE SECRETARY OF THE COMPANY. 
 7.2 Amendments. This Agreement may be amended (including amendments adding additional parties to
this Agreement, which shall not be deemed to impose a new, or increase an existing, obligation of any party) only by an appropriate action of the Board of Directors and the written consent of a majority of the outstanding Shares, or, with respect to
any amendment of either Section 4.1 or Section 5.1(b)(i), the holders of a majority of the outstanding shares of Common Stock and the holders of a majority of the outstanding shares of Series 2006 and Series 2007 Preferred Stock voting
together. Any amendment effected in accordance with this Section shall be binding upon each holder of any Shares on the date hereof, each future holder of Shares and the Company. 

7.3 Effect of Agreement. This Agreement shall be binding upon and shall inure to the benefit of the Company and shall be binding upon
and inure to the benefit of the other parties hereto and any person who acquires Shares from the Company or from a party hereto in accordance with the terms of this Agreement (including, without limitation, pursuant to the provisions of Article 3 of
this Agreement). Unless approved by the Board, the Company shall not issue any certificate for Shares to any person until such person shall have first executed and delivered a copy of this Agreement. No party to this Agreement may assign any of its
rights or delegate any of its duties under this Agreement except in connection with a transfer of its Shares which complies in all respects with the terms of this Agreement. 

  
 C-13 

 7.4 Governing Law. This Agreement shall in all respects be interpreted, construed and
governed by and in accordance with the internal substantive law of the State of Delaware.  
 7.5 Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute the same Agreement. 

7.6 Notices. All notices, elections and other communications pursuant to this Agreement shall be made in writing and sent to
(a) the Company at its principal business address or (b) to any Stockholder at the address as shown on the books and records of the Company and shall be deemed to be received the second business day following deposit with an overnight mail
or courier service, the date of receipt of electronic confirmation of receipt of an electronic facsimile message or one week after being sent by regular or certified mail, postage prepaid. 

7.7 Entire Agreement. Except as expressly set forth herein or in an instrument in writing signed by the party to be bound thereby which
makes reference to this Agreement, this Agreement embodies the entire agreement in relation to its subject matter, and supersedes all prior agreements and negotiations.  

7.8 Severability. Each Section, Article and lesser section of this Agreement constitutes a separate and distinct undertaking, covenant
and/or provision hereof. In the event that any provision of this Agreement shall finally be determined to be unlawful, all of such provision shall be deemed severed from this Agreement, but every other provision of this Agreement shall remain in
full force and effect, and in substitution for any such provision held unlawful, there shall be substituted a provision of similar import reflecting the original intent of the parties hereto to the extent permissible under law. 

7.9 Construction. The headings of the Articles and Sections of this Agreement are inserted for convenience only and shall not be deemed
to constitute a part hereof. Unless otherwise specifically indicated, references in is Agreement to Articles, Sections, paragraphs and clauses refer to the Articles, Sections, paragraphs and clauses of this Agreement. All personal pronouns used in
this Agreement, whether used in the masculine, feminine or neuter gender, shall include all other genders, and the singular shall include the plural and vice versa. 

7.10 Limited Proxy. Each Stockholder hereby grants to the Chief Executive Officer of the Company an irrevocable proxy, coupled with an
interest, to vote all Shares owned by such Stockholder and to take such other actions to the extent necessary to carry out any of the provisions of this Agreement in the event of any breach by such Stockholder of his or her obligations thereunder.
 
 [THIS SPACE INTENTIONALLY LEFT BLANK] 

  
 C-14 

 IN WITNESS WHEREOF, the parties to this Agreement have executed this Agreement as of the
date and year first above written.  
  

			
	COMPANY:
	
	POTENTIA PHARMACEUTICALS, INC.,
	
	a Delaware corporation

 
			
		
	By:	 	  

 
			
	
	Cédric François, as President and
	Chief Executive Officer
	Address: 201 E. Jefferson Street
	Suite 302
	Louisville, KY 40202

  
 C-15 

 SIGNATURE PAGE TO 

STOCKHOLDERS AGREEMENT 
  

					
	STOCKHOLDERS:

 
			
		
	By:	 	  

 
			
	Cédric François, pursuant to the limited power of attorney granted by the persons listed on Exhibit A hereto

  
 C-16 

 SIGNATURE PAGE TO 

STOCKHOLDERS AGREEMENT 
  

					
	STOCKHOLDERS:
	
	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
		
		 	  

		 	By:	 	  

		 	Title:	 	  

  
 C-17 

 SIGNATURE PAGE TO 

STOCKHOLDERS AGREEMENT 
  

					
	STOCKHOLDERS:
	
	HEALTH CARE VENTURES LLC
		
		 	  

		 	By:	 	  

		 	Title:	 	  

  
 C-18 

 EXHIBIT A 

Stockholders 
  

	
	Name
	HealthCare Ventures LLC
	Cedric Francois
	Pascal Deschatelets
	Paul Olson
	Bernard Darty
	Alec Machiels
	Robert Rothschild
	MASA Life Science Ventures
	Robert Scherer
	David Darst Jr.
	Frederick Whittemore
	The Trustees of the University of Pennsylvania
	Michael Gellert
	Potentia Investors LLC
	Ed Hajim
	David Darst Sr.
	Christophe Dubois
	Reahard Investments LLC
	Kia Joorabchian
	Harold Snyder
	KSTC
	Michael Parekh
	Barwald Overseas Limited
	Marie-Claude Bernal
	Annette & John Carroll
	Robert Burch
	Gabriel Coscas
	Averell Mortimer
	Jean-Luc Halconruy
	Jean Machiels & Olga Machiels-Osterrieth
	[Affiliates of EMBL]

  
 C-19 

 EXHIBIT D 

Format of Royalty Report 
  

			
	

	  	 Center for Technology Transfer

University of Pennsylvania
 Royalty Report

	  
	  

  

													
	Licensee:
                                         
                                     	 	Agreement:
                                         
                         	  		  	
	Inventor:                                  
                                         
     	 	Patent #:
                                         
                              	  		  	
	Period Covered: From:                 /            
    /                              	 	 Through:
                /                 /     
                         
	  		  	
	Prepared By:                                 
                                         
               	 	 Date:
                                         
                           
	  		  	
	Approved By:                                 
                                         
             	 	 Date:
                                         
                           
	  		  	
			
	 If License covers several major product lines, please prepare a separate for each line. Then combine all
product lines into a summary report.
	  		  	
						
	Report Type:	 	☐	  	Single Product Line Report:	  		  		  	
		 	☐	  	Multi-product Summary Report: Page 1 of      Pages	  		  	
		 	☐	  	Product Line Detail: Line:             
Trade name:              Page:            	  		  	

															
	Report Currency:	 	☐	  	U.S. Dollars                    ☐  Other	  	  
	  		  	

  

																									
	Country  	  	Gross            
Sales          
  	 	  	*Less:            
Allowances         
   	 	  	Net Sales            	 	  	Royalty            
Rate          
  	 	  	Period Royalty Amount	 
	  	  	  	  	  	This Year            	 	  	Last Year            
	 
	U.S.A.	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	Canada	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	Europe	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	Japan	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	Other	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 
	Total:	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 

 Total Royalty:
                     Conversion Rate:
                     Royalty in U.S. Dollars $
                     
 The following royalty
forecast is non-binding and for CTT internal planning purposes only: Royalty Forecast Under this agreement: Next Quarter:              Q2:
             Q3:              Q4:             

  
 D-1 

 Exhibit E 

Form of Patent Management Agreement 

 PATENT MANAGEMENT AGREEMENT 

The Trustees of the University of Pennsylvania (“Penn”), a Pennsylvania non-profit corporation doing business at 3160 Chestnut Street, Suite 200,
Philadelphia, PA 19104-6283; and                      (“Company”), a corporation doing business at
                                        , have
entered into a License Agreement with respect to certain inventions which are the subject of the patent applications and patents listed in Appendix A hereto, including any continuations, divisions, extensions thereof, and any foreign counterpart
patents, applications, or registrations (“Patent Rights”). 
 Penn has retained the services of
                     (“Law Firm”) with offices at
                     to prepare, file and prosecute the pending patent applications constituting the Patent Rights and to maintain the patents that
issue thereon. 
 Penn, Company and Law Firm, intending to formalize their business relationships, agree as follows: 

 

	1.	Penn is the owner of the Patent Rights. 

  

	2.	Company is the licensee of Penn’s interest in the Patent Rights. 

  

	3.	Penn shall maintain an attorney-client relationship with Law Firm in furtherance of efforts to secure and maintain the Patent Rights. 

 

	4.	Law Firm will interact directly Company on all patent prosecution and patent maintenance matters related to the Patent Rights and will copy Penn on all correspondence related thereto. Company and Law Firm
agree to use all reasonable efforts to notify Penn in writing at least thirty (30) days prior to the due date or deadline for any action which could adversely affect the pending status of any patent application within the Patent Rights, the
maintenance of any granted patent within the Patent Rights. Penn’s right to file any continuing application or foreign counterpart application based on the Patent Rights, or the breadth of any claim within the Patent Rights, In any case,
Company shall give Penn written notice of any final decision regarding the action to be taken on such matters prior to instructing Law Firm to implement the decision. Penn reserves the right to countermand any instruction given by Company to Law
Firm. 

  

	5.	Law Finn’s legal services relating to the Patent Rights will be performed on behalf of Penn. Law Firm will invoice Penn for all such services. Company will reimburse Penn for all such services within thirty
(30) days of Company’s receipt of Penn’s invoice for such services. 

  

	6.	To clarify each party’s position with regard to prosecution and maintenance of the Patent Rights, Company will notify Law Firm in writing of all decisions to authorize the performance of any desired
service(s), which shall be subject to Penn’s right to countermand, as provided in paragraph 4, above. In the event Penn countermands any decision or instruction of Company, such countermand shall be promptly communicated in writing to Law Firm.

  
 - 2 - 

	7.	This agreement represents the complete understanding of each of the undersigned parties as to the arrangements defined herein. Additions or deletions of dockets identified m Appendix A will become effective only
by written addendum to Appendix A. All such additions or deletions of individual patents or applications filed in the US, or as foreign counterparts thereof are considered to be within the terms of this Patent Management Agreement.

  

	8.	Notices and copies of all correspondence relating to the Patent Rights should be sent to the following: 

  

			
	To PENN:	  	To COMPANY:
		
	 Center for Technology Transfer
 University of
Pennsylvania
 3160 Chestnut Street, Suite 200
 Philadelphia, PA
19104-6283
 Attn: Director, Intellectual Property
	  	

 To Law Firm: 
  

									
	ACCEPTED AND AGREED TO:	 		 	
			
	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	 		 	COMPANY
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title	 	  

					
	Date	 	  
	 		 	Date:	 	  

				
	LAW FIRM	 		 		 	
					
	By:	 	  
	 		 		 	
					
	Name:	 	  
	 		 		 	
					
	Title:	 	  
	 		 		 	

  
 - 2 - 

 Appendix A 

COMPANY LICENSED TECHNOLOGIES 
  

							
	PENN	  	 	  	 	 
	Docket	  	 	  	 	 
	 Number
	  	 Title
	  	Patent Numbers	 
		  		  			
		  		  			
		  		  			

  
 - 3 - 

 FIRST AMENDMENT TO 

AMENDED AND RESTATED PATENT LICENSE AGREEMENT 

This First Amendment to the Amended and Restated Patent License Agreement (this “Amendment”) is dated as of October 14, 2009,
by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Potentia Pharmaceuticals, Inc., a Delaware corporation (“Company”). Capitalized terms used but not otherwise
defined herein shall have the meanings ascribed to such terms in the Amended and Restated Patent License Agreement (the “Agreement”) entered into as of March 28, 2008 (the “Agreement Effective Date”), by and between Penn and
Company, and references herein to Sections shall refer to Sections of the Agreement. 
 WHEREAS, under the Agreement, Penn has licensed to
Company rights to develop and commercialize Licensed Products and Other Licensed Products in the Ophthalmic Field; 
 WHEREAS, Company and
Alcon Research Ltd. (“Alcon”) intend to enter into a license agreement in which rights to develop and commercialize Licensed Products and Other Licensed Products in the Ophthalmic Field are granted to Alcon (the “Alcon License”);

 WHEREAS, Penn has determined that, pursuant to the terms set forth in this Amendment, providing Company and Alcon with additional
flexibility regarding the development and commercialization of Licensed Products and Other Licensed Products in the Ophthalmic Field is in the best interest of Penn and is consistent with its educational and research missions and goals; 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the parties hereto,
intending to be legally bound, hereby agree as follows: 
 1. Company acknowledges and agrees that the Technology Access Fee that Company expects to receive
from Alcon as a result of the execution of the Alcon License will be Sublicense Income under the Agreement. 
 2. Penn agrees that Alcon shall be deemed a
Large Pharmaceutical Company for purposes of the Agreement. 
 3. The table set forth in Section 2.3 is hereby amended and restated in its entirety to
read as follows: 
  

			
	 DILIGENCE EVENT
	  	COMPLETION DATE
	Filing of IND for the Licensed Product	  	July 1, 2007
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]

  
 - 2 - 

 4. Penn agrees that the study described in Exhibit A hereto shall qualify as a Phase II clinical trial for
purposes of the tables set forth in Sections 2.3 and 3.4. 
 5. Penn agrees that, in the event that no Valid Claim for Development Purposes (as defined
below) exists on January 1, 2014 in an issued United States patent that covers the manufacture, use, offer for sale, sale or importation of a Licensed Product then under development, the completion date for the Initiation of a Phase III
Clinical Trial for the Licensed Product diligence event set forth in Section 2.3 shall be extended until the earlier of (a) the date that is three (3) months after the issuance of such a Valid Claim of a United States patent or
(b) January 1, 2015, and any delay in initiating Phase III Clinical Trials that is wholly or partially attributable to the non-existence of such Valid Claim shall not constitute a breach of Company’s obligations under Sections 2.2 or
2.3. For purposes of the preceding sentence, “Valid Claim for Development Purposes” shall mean a claim: (i) in any issued, unexpired Penn Patent Right which has not been donated to the public, revoked nor held unenforceable or invalid
by a governmental agency or court of competent jurisdiction by a decision from which there is no appeal or (if there is a right to appeal) from which the period for appeal has expired without such appeal, and that has not been disclaimed or admitted
to be invalid, or unenforceable through reissue, disclaimer or otherwise, or (ii) in any United States or foreign patent application among the Penn Patent Rights, which shall not have been finally cancelled, withdrawn or abandoned by any
administrative agency or other body of competent jurisdiction; provided that, on a Licensed Product-by-Licensed Product and country-by-country basis, a pending patent application shall be deemed to have been abandoned if, as of the date that is [**]
years subsequent to the earliest filing date from which such application claims priority, no other Valid Claim that covers the manufacture, use, offer for sale, sale or importation of such Licensed Product has issued as a patent in such country (the
“Constructive Abandonment Date”), and the claims of such application shall no longer constitute Valid Claims with respect to such Licensed Product in such country as of such Constructive Abandonment Date. 

6. In lieu of the definitions of “Net Sales”, “Qualifying Costs” and “Combination Product” set forth in Section 3.6, solely
for purposes of calculating royalties payable by Company to Penn pursuant to Section 3.5 as a consequence of sales by Alcon, its affiliates and permitted licensees of Licensed Products and Other Licensed Products pursuant to the Alcon License,
“Net Sales” shall mean the gross invoiced price for Licensed Products and Other Licensed Products sold by Alcon, its affiliates or permitted sublicensees (the “Selling Party”) to third parties, less Qualifying Costs.
“Qualifying Costs” shall mean the following deductions from such gross amounts: (i) normal and customary trade, cash and other quantity discounts, rebates and allowances actually allowed and taken; (ii) credits or allowances
actually granted to the customer for damaged goods, returns, recalls, rebates or rejections of Licensed Products and Other Licensed Products; (iii) sales, use, excise, ad valorem or any other sales-related taxes (to the extent borne by Selling
Party and separately stated on the invoice and included in the computation of gross sales); (iv) chargebacks related to sales of Licensed Products and Other Licensed Products, to the extent actually allowed and taken by a third party;
(v) freight, insurance and other transportation and handling fees to the extent included in the invoice price; and (vi) compulsory payments and rebates directly related to the sale of Licensed Products and Other Licensed Products, accrued,
paid, or deducted pursuant to federal or state government regulations. Generally, only items that are deducted from Selling Party’s gross sales of Licensed Product(s) and Other Licensed Product(s), as included in Selling Party’s published
financial 

  
 - 3 - 

 
statements and that are in accordance with GAAP, applied on a consistent basis, shall be considered Qualifying Costs and shall be deducted from such gross sales for purposes of the calculation of
Net Sales. However, compulsory payments required by federal or state governments based upon sales volume or market share of Licensed Products (but for clarity excluding taxes on the Selling Party’s net income), to the extent borne by the
Selling Party, shall be deducted from “Net Sales” regardless of its classification in the Selling Party’s published financial statements; provided that any such deduction shall be limited to that share of such compulsory payment
proportional to the share of the total sales volume or market share of the Selling Party used to compute the compulsory payment represented by applicable Net Sales of Licensed Products; and provided further that, Company shall include in each report
provided to Penn pursuant to Section 4.1 for any Quarter in which such deduction is taken an explanation of how the share of such compulsory payment allocated to applicable Net Sales of Licensed Products was calculated. A Qualifying Cost may be
deducted only once regardless of the number of categories that describe such amount. In the event that a Selling Party makes any adjustment to such deductions after the associated Net Sales have been reported pursuant to Section 4.1, the
adjustments and payment of any royalties due shall be reported with the next quarterly report. Sales between or among Alcon, its affiliates and sublicensees shall be excluded from the computation of Net Sales if such sales are not intended for end
use, but Net Sales shall include the subsequent final sales to third parties by Alcon or any such affiliates or sublicensees. A Licensed Product or Other Licensed Product shall not be deemed to be sold if it is provided free of charge to a third
party in reasonable quantities as a sample consistent with industry standard promotional and sample practices. 
 If Alcon or its affiliates or any
permitted sublicensee sells a Licensed Product or Other Licensed Product in combination with one or more other therapeutically or prophylactically active ingredients (whether combined in a single formulation or package, as applicable, or formulated
separately but packaged under a single label approved by a regulatory authority and sold together for a single price in a manner consistent with the terms of this Agreement) (a “Combination Product”), Net Sales of such Combination Product
for the purpose of determining the payments due to Penn pursuant to the Agreement will be calculated by multiplying actual Net Sales of such Combination Product as determined pursuant to the preceding paragraph by the fraction A/(A+B) where A is
[**] such Licensed Product or Other Licensed Product on a worldwide basis, if sold separately, and B is [**] the other active ingredient(s) in the combination on a worldwide basis, if sold separately. In the event it is not possible to determine the
fraction A/(A+B) based on the criteria specified in the preceding sentence (e.g., if the Licensed Product or Other Licensed Product component is not sold separately), Net Sales for the purpose of determining royalties due to Penn pursuant to the
Agreement for the Combination Product shall be D/(D+E) where D is [**] the portion of the Combination Product that contains the Licensed Product or Other Licensed Product and E is [**] the portion of the Combination Product containing the other
active ingredient(s) included in such Combination Product, with such fair market values determined by mutual agreement of Penn, Alcon and Company, provided that after any acquisition of Company by Alcon, the Company shall be represented by a
representative of the Company’s stockholders immediately prior to such acquisition. 
 In the event that Alcon or its affiliates or any of its
permitted sublicensees bundle the Licensed Product(s) or Other Licensed Product(s) with other products or services being purchased from the Selling Party and the Selling Party discounts the sales price of the Licensed Product(s) or

  
 - 4 - 

 
Other Licensed Product(s) to customers as a loss leader, or Licensed Product(s) or Other Licensed Product(s) are otherwise provided to customers without a specific sale price, then, in such case,
the Net Sales for such Licensed Product(s) or Other Licensed Product(s) to such customers shall be deemed to equal the average sales price for which such Licensed Product(s) or Other Licensed Product(s) themselves have been sold over the immediately
preceding [**] months, and if no such sales have occurred, the arm’s length price that third parties would generally pay for the Licensed Product(s) or Other Licensed Product(s) alone when not purchasing any other product or service from the
Selling Party. 
 7. Penn agrees that the [**] day period for Company to provide the report set forth in Section 4.1 shall be extended to [**] days
with respect to sales of Licensed Products and Other Licensed Products by Alcon, its affiliates and permitted sublicensees pursuant to the Alcon License. 

8. Penn agrees that the [**] day periods for payments set forth in Sections 3.4(a) and 4.2 shall be extended to [**] days with respect to any obligations for
Company to make payments to Penn under the Agreement that arise from the development and commercialization of Licensed Products and Other Licensed Products by Alcon, its affiliates or permitted sublicensees under the Alcon License. 

9. Effectiveness of Amendment. This Amendment will take effect upon the execution of the Alcon License by both Alcon and Company (the “Amendment
Effective Date”), written notice of which Company shall promptly provide to Penn. 
 10. Miscellaneous. The parties hereby confirm and agree
that, as amended hereby, the Agreement remains in full force and effect and is a binding obligation of the parties hereto. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly
authorized representatives. 
  

									
	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	 		 	POTENTIA PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Michael J. Cleare
	 		 	By:	 	 /s/ Cedric Francois

					
	Name:	 	Michael J. Cleare, Ph.D.	 		 	Name:	 	Cedric Francois, M.D., Ph.D.
	Title:	 	 Associate Vice Provost for Research
 And
Executive Director for the
 Center for Technology Transfer
	 		 	Title:	 	CEO and President

  
 - 5 - 

 EXHIBIT A 

POE Study 
 Study Design/Primary
Endpoint 
 The purpose of the POE Study is to determine if there is [**] 

The primary endpoint will be [**]. 
 POE Criteria –
[**] 
 [**] 

 Penn
Draft:      /    /     
 UNIVERSITY OF
PENNSYLVANIA 
 ASSIGNMENT AND ASSUMPTION AGREEMENT 

Signature Page 
  

					
	COMPANY CONTACT INFORMATION
	 Company full legal name and notice
address:
  
 Potentia Pharmaceuticals, Inc.

6400 Westwind Way, Suite A
 Crestwood, KY 40014

 
	 	
Company primary phone

number:

(502)241-4114

	 	
Company primary fax number:

(502)241-4116
  

	 Company contact name:

Cedric Francois
	 	 Contact title:

CEO
	 	 Contact phone
number:
 [**]

		 		 	
	ASSIGNEE CONTACT INFORMATION
	 Company full legal name and notice
address:
  
 Apellis Pharmaceuticals, Inc.

6400 Westwind Way, Suite A
 Crestwood, KY 40014

 
	 	 Company primary
phone
 number:

(502) 241-4114

	 	 Company primary fax
number:
 (502) 241-4116
  

	 Company contact name:

David Watson
	 	 Contact title:

Vice President
	 	 Contact phone
number:
 (615) 430-1983

		 		 	
	PENN CONTACT INFORMATION
	 Penn notice address:

 
	 	
Penn primary phone number:

215-573-4500

	 University of Pennsylvania

Penn Center for Innovation
 3160 Chestnut Street, Suite 200

Philadelphia, PA 19104-6283
 Attention: Executive Director

 
	 	
Penn primary fax number:

215-898-9519

	Penn Investigator name:	 	Penn department:	 	Investigator phone number:
		 		 	
	PATENT LICENSE AGREEMENT
	 Patent/Docket Numbers:

Penn Docket: [**]
	 	
Effective Date of License:

3/28/2008

	 Field of Use:

TREATMENT OF OPHTHALMIC INDICATIONS
	 	
Amendments/Effective Dates:

10/14/2009

		 		 	
	EFFECTIVE DATE OF ASSIGNMENT
	 Background: Assignee is purchasing all or substantially all of the
assets of Company related to the License, pursuant to an Asset Purchase Agreement dated September 24, 2014. The assignment will become effective immediately upon the closing of the Asset Purchase Agreement.

 
	 	 Effective Date of
Assignment:
  

                          
      , 201    
  

		 		 	

	
	SIGNATURES
	 This
Agreement includes this Signature Page and all of the attached Terms and Conditions. By signing below, Company, Assignee and Penn agree to all of the provisions of this Agreement and intend to be bound hereby.

 

																					
	COMPANY	 	ASSIGNEE	 	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

  

					
	Assignment and Assumption Agreement	 	 Page 1
	  	Penn =
                                

 Penn
Draft:      /    /     
  

																					
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	 /s/ Cedric Francois
	 	 	 	By:	 	 /s/ David Watson
	 	 	 	By:	 	 /s/ John S. Swartley

	(please sign)	 		 	 	 	(please sign)	 	(please sign)
	Name:	 	 Cedric Francois
	 	 	 	Name:	 	 David Watson
	 	 	 	Name:	 	 John S. Swartley, Ph.D.

	(please sign)	 	(please sign)	 	(please sign)
	Title:	 	 President
	 	 	 	Title:	 	 Vice President
	 	 	 	Title:	 	 Associate Vice Provost for Research
Executive Director PCI

	(please print)	 	(please print)	 	(please print)
	Date:	 	 1/19/15
	 	, 2015	 	 	 	Date:	 	 1/19
	 	, 2015	 	 	 	Date:	 	 May 13
	 	, 2015
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  

					
	Assignment and Assumption Agreement	 	 Page 2
	  	Penn =
                                

 Penn
Draft:      /    /     
  

 Assignment and Assumption Agreement 

Terms and Conditions 
 This Assignment
and Assumption Agreement (“Assignment Agreement”) is entered into by and between Company, Assignee and Penn to be effective as of the Effective Date (as defined in Section 3 below). 

1. Defined Terms. Capitalized terms used but not defined in this Assignment Agreement are defined in the License Agreement between Penn and Company
identified in the signature page. 
 2. Assignment and Assumption. As of the Effective Date (as defined in Section 3 below): 

(a) Company conveys, assigns, transfers and delivers to Assignee all of Company’s right, title and interest in, to and under the License
Agreement, 
 (b) Assignee accepts all of Company’s right, title and interest in, to and under the License Agreement, 

(c) Assignee will become a party to the License Agreement and will succeed to all of the rights and assume all of the obligations of Company
thereunder, and 
 (d) all references to “Company” in the License Agreement will refer to Assignee; provided that Assignee and
Company will be jointly and severally liable (as between each of them and Penn) for any liabilities or obligations of Company, whether actual or contingent, or known or unknown, arising under the License Agreement and related to events or
circumstances that occurred prior to the Effective Date. 
 3. Conditions to Effectiveness. This Assignment Agreement takes effect on the date on
which the last of the following occurs (the “Effective Date”): 
 (a) Penn receives counterparts of this Assignment
Agreement duly executed by each of Company and Assignee; 
 (b) Company is in full compliance with all of the terms and conditions of the
License Agreement; and 
 (c) the Effective Date listed on the Signature Page. 

4. Representations and Warranties. Each party represents and warrants to each other that the person executing this Assignment Agreement on its behalf
has all necessary power and authority to do so, and that upon such execution, this Assignment Agreement is a legal, valid and binding obligation enforceable against such party. 

5. Miscellaneous. Any notice must be in writing and sent to the address of the party listed on the Signature Page. The parties do not intend that any
agency or partnership relationship be created by this Assignment Agreement. This Agreement may only be modified by a written amendment that is executed by an authorized representative of each party. Any waiver must be express and in writing. No
waiver by a party of a breach by another party will constitute a waiver of any different or succeeding breach. This Assignment Agreement will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania without regard
to conflicts of law principles of any jurisdiction. This Assignment Agreement and the License Agreement contain the entire agreement between the parties with respect to subject matter of this Assignment Agreement and supersede all other oral or
written 

  

					
	Assignment and Assumption Agreement	 	Page 3	  	Penn =
                                

 Penn
Draft:      /    /     
  

 
representations, statements, or agreements with respect to such subject matter. This Assignment Agreement is binding upon the parties and their respective heirs, successors, assigns, and personal
representatives. No party may assign this Assignment Agreement without the prior written consent of the other parties. This Assignment Agreement may be signed in counterparts which, taken as a whole will constitute one agreement. 

  

					
	Assignment and Assumption Agreement	 	Page 4	  	Penn =EX-10.10

 Exhibit 10.10 

BLUEGRASS EYE BUILDING 

OFFICE LEASE AGREEMENT 

BY AND BETWEEN 
 DHB
PROPERTIES. LLC, 
 A KENTUCKY PROFESSIONAL SERVICE CORPORATION 

(“LANDLORD”) 

AND 
 APELLIS
PHARMACUTICALS, INC. 
 A DELAWARE CORPORATION 

(“TENANT”) 

DATED OCTOBER 21, 2010 

 TABLE OF CONTENTS 

LEASE AGREEMENT 
  

					
	 	  	PAGE	 
	 ARTICLE I - BASIC LEASE PROVISIONS AND LEASE OF PREMISES
	  	 	1	 
		
	 ARTICLE II - TERM AND POSSESSION
	  	 	3	 
		
	 ARTICLE III - RENT
	  	 	5	 
		
	 ARTICLE IV - SECURITY DEPOSIT
	  	 	8	 
		
	 ARTICLE V - OCCUPANCY AND USE
	  	 	8	 
		
	 ARTICLE VI - UTILITIES AND OTHER BUILDING SERVICES
	  	 	10	 
		
	 ARTICLE VII - REPAIRS, MAINTENANCE, ALTERATIONS, IMPROVEMENTS AND FIXTURES
	  	 	11	 
		
	 ARTICLE VIII - FIRE OR OTHER CASUALTY INSURANCE
	  	 	12	 
		
	 ARTICLE IX - EMINENT DOMAIN
	  	 	15	 
		
	 ARTICLE X - LIENS
	  	 	15	 
		
	 ARTICLE XI - RENTAL, PERSONAL PROPERTY AND OTHER TAXES
	  	 	16	 
		
	 ARTICLE XII - ASSIGNMENT AND SUBLETTING
	  	 	16	 
		
	 ARTICLE XIII - SUBORDINATION
	  	 	17	 
		
	 ARTICLE XIV - ABANDONMENT
	  	 	17	 
		
	 ARTICLE XV - DEFAULTS AND REMEDIES
	  	 	17	 
		
	 ARTICLE XVI - LANDLORD’S RIGHT TO RELOCATE TENANT
	  	 	19	 
		
	 ARTICLE XVII - HAZARDOUS MATERIAL, GOVERNMENTAL, INSURANCE AND ADA REQUIREMENTS
	  	 	19	 
		
	 ARTICLE XVIII - NOTICE AND PLACE OF PAYMENT
	  	 	21	 
		
	 ARTICLE XIX - MISCELLANEOUS GENERAL PROVISIONS
	  	 	21	 

 OFFICE LEASE AGREEMENT 

THIS OFFICE LEASE AGREEMENT (“Lease”) is entered into and made this     day of October, 2010, by and
between (i) DHB PROPERTIES, LLC, a Kentucky professional services corporation (“Landlord”), and (ii) APELLIS PHARMACEUTICALS, INC, a
Delaware corporation (“Tenant”). 
 WITNESSETH: 

WHEREAS, Landlord desires to lease to Tenant, and Tenant desires to lease from Landlord, the Premises (as hereinafter defined), on the
terms and conditions set forth in this Lease; 
 NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby
acknowledged, the parties hereto agree as follows: 
 ARTICLE I - BASIC LEASE PROVISIONS AND LEASE OF PREMISES 

1.01 Basic Lease Provisions. The basic terms and definitions of this Lease are set forth below: 

 

											
	A.	  	Building:	 	 The Bluegrass Eye Building
 6400
Westwind Way
 Crestwood, Kentucky 40014
	  		  	
					
		  	Premises:	 	Suite A	  		  	
					
	B.	  	Total Leasable Area in the Building:	 	2,107 Square Feet	  		  	
				
		  	Total Leasable Area of the Premises:	 	20,000 Leasable Square Feet	  	
					
		  	Tenant’s “Pro Rata Share”:	 	10.54%	  		  	
					
	C.	  	Term (see Paragraph 2.01):	 	Five (5) Years	  		  	
					
		  	Scheduled Commencement Date:	 	January 31, 2011	  		  	
					
		  	Expiration Date:	 	December 31, 2015	  		  	
					
	D.	  	Base Rent (see Paragraph 3.01):	 	 Year(s):
  

1 and 2
	 	$60,000 total paid in full by Tenant	  	
						
		  		 	3-5	 	 per month:
 $2,984.92
	  	 per annum:
 $35,819.00
	  	
						
		  	Prepaid Rent:	 	$60,000	 		  		  	
						
		  	Tenant Paid Utilities:	 	N/A	 		  		  	

  
 1 

					
	E.	  	 Security Deposit
 (see Paragraph 4.01):
	  	None
			
	F.	  	Base Year for Operating Expense Adjustment	  	2009
			
	G.	  	Guarantor(s) (see Paragraph 20.17):	  	Dr. Pascal Deschatelets and Dr. Cedric Francois
			
	H.	  	Addresses for Notices and Payments:	  	
			
		  	 Notices to Tenant:
  

6400 Westwind Way,
 Suite A

Crestwood, KY 40014
 Attn: Dr. Pascal Deschatelets
	  	 Notices to Landlord:
  

6400 Westwind Way
 Crestwood, Kentucky 40014

Attn: Dr. Matt Blair

			
		  	 Billing to Tenant:
  

Apellis Pharmaceuticals Inc.
 6400 Westwind Way, Suite A

Crestwood, Kentucky 40014
	  	 Payments to Landlord:
  

DHB Properties, LLC
 6400 Westwind Way

Crestwood, Kentucky 40014

			
	I.	  	Real Estate Broker (Paragraph 19.04):	  	Horizon Commercial Realty
			
	J.	  	Option to renew:	  	Tenant shall have the option to renew the Lease for one (1) additional period of five (5) years at 95% of the then prevailing market rate for comparable space.
			
	K.	  	Termination Right:	  	Tenant shall have the one-time right to terminate the Lease at the end of year two (2) with 120 days prior written notice to Landlord.
			
	L.	  	Right of First Refusal:	  	Tenant shall have a continuing right of first refusal to lease any contiguous vacant space available in the Building. Tenant shall five (5) business days from notice of perceived interest from a third party in such vacant space as
evidenced by a written letter of intent or offer to lease, a copy of which will be furnished to Tenant, to lease of such available space on the same terms and conditions offered to the third party terms pursuant to an amendment of this Lease
otherwise reasonably acceptable to Landlord.

  
 2 

 1.02 Lease of Premises. Landlord hereby leases to Tenant, and Tenant hereby takes and leases from
Landlord, the Premises on the terms and conditions set forth in this Lease, to have and to hold the same, with all appurtenances, unto Tenant for the term hereinafter specified. 

1.03 Description of Building, Premises and Common Areas. The following terms used in this Lease shall have the meanings hereinafter set forth: 

A. The Building. “Building” is the office building and the Common Areas (as hereinafter defined) located on the land
described in the Legal Description attached as “Exhibit A”. The number of leasable square feet in the Building is specified in Paragraph 1.01B above. 

B. The Premises. “Premises” is the office space located in an area of the Building which is shown as outlined and labeled as
the Premises on the floor plan attached hereto as “Exhibit B”. The Premises are known or are to be known by the suite number(s) specified in Paragraph 1.01 A above. 

C. The Common Areas. “Common Areas” are the areas of the Building which are designated by Landlord for use in common by all
tenants of the Building and their respective employees, agents, customers, invitees and others, and includes, without limitation, entrances and exits, hallways and stairwells, elevators, rest rooms, sidewalks, driveways, parking areas, landscaped
areas, plaza and any other areas as may be designated at any time by Landlord as part of the Common Areas of the Building. 
 ARTICLE II -
TERM AND POSSESSION 
 2.01 Commencement and Expiration. The “Term” of this Lease shall be the period of time specified in Paragraph
1.01C, commencing on the Scheduled Commencement Date shown in Paragraph 1.01C or such date as the Premises shall be tendered to Tenant as set forth below, or such earlier date as Tenant takes possession or commences use of the Premises for any
purpose, including construction. The Lease shall expire without notice to Tenant on the Expiration Date shown in Paragraph 1.01C, or in the event the Premises are not ready for occupancy on the Scheduled Commencement Date, this Lease shall remain in
effect, and the Term shall begin on the first day the Premises are ready for occupancy and run for the full Term of the Lease from that date. If the Lease commences on any day other than the first day of a calendar month, the Term shall be extended
by that part of one month necessary to cause the Expiration Date to be on the last day of a calendar month. The dates of commencement (“Commencement Date”) and expiration (“Expiration Date”) of the Term shall be
confirmed by Landlord and Tenant by execution of a “Acceptance of Premises Amendment” in the form attached hereto as “Exhibit C”. In the event of Landlord’s inability to deliver possession of the Premises upon the
Commencement Date due to Acts of God, force majeure or other matters or occurrences beyond the reasonable control of Landlord (e.g. strike, riot, shortage of labor or materials, delays in governmental approvals, or unseasonable inclement weather),
Landlord shall not be liable for any damage caused thereby nor shall this Lease become void or voidable, nor shall the Term be extended, but in such event, Tenant shall not be liable for any rent until such time as Landlord delivers possession;
provided, that if delays in delivery of the Premises are due to Tenant’s actions or delays or inaction when required or requested, then Base Rent shall begin to accrue as of the Scheduled Commencement Date. If Landlord permits Tenant to enter
into possession of the Premises prior to the Commencement 

  
 3 

 
Date, all of the terms and conditions of this Lease shall apply to such prior period. Landlord shall endeavor to notify Tenant at least fourteen (14) days prior to the Scheduled Commencement
Date in the event that Landlord believes that it will be unable to deliver possession of the Premises by the Scheduled Commencement Date, regardless of the cause of such delay. 

2.02 Construction of Tenant Finish Improvements and Possession. Landlord will perform or cause to be performed the work, if any, set forth on
“Exhibit D” attached hereto (“Landlord’s Work”). Landlord shall perform Landlord’s Work in accordance with the terms of “Exhibit D” and otherwise in compliance with all applicable laws, rules,
regulations, codes and ordinances, subject to events and delays due to Acts of God, force majeure or other matters or occurrences beyond the reasonable control of Landlord and for which Landlord will not be liable to Tenant in any way. Upon delivery
of possession of the Premises to Tenant, Landlord covenants that the Premises shall be habitable in accordance with and required by applicable law, and Landlord and Tenant shall execute the Acceptance of Premises Amendment, which, besides fixing the
Commencement Date and Expiration Date, will contain acknowledgments that Tenant has accepted the Premises in the then present condition thereof, and that the Premises and the Building are satisfactory in all respects except for minor “punch
list” items agreed to in writing by Landlord and Tenant, which Landlord will promptly remedy. If Tenant takes possession of the Premises, Tenant shall be deemed to have accepted the Premises even though the Acceptance of Premises Amendment may
not have yet been executed. Other than Landlord’s Work, Tenant shall make all other necessary improvements to the Premises to operate Tenant’s business (“Tenant’s Work”). Tenant’s Work shall comply with all
applicable statutes, ordinances, regulations and codes and shall strictly comply with the requirements of Paragraph 7.03 hereof. In the event that Landlord is unable to deliver possession of the Premises upon the Scheduled Commencement Date due to
matters or occurrences within Landlord’s reasonable control, then Tenant shall, as its sole remedy, be entitled (a) to recover from Landlord, and Landlord shall pay to Tenant upon the actual Commencement Date and delivery of the Premises
to Tenant, the aggregate holdover rent paid by Tenant for its currently occupied premises with respect to the period from and after the Scheduled Commencement date to the actual Commencement Date at a rate not to exceed $3,440 per month, and
(b) to rent-free dry storage of Tenant’s boxed and secured laboratory equipment, which Landlord shall at its expense move to and store in the Building pending completion and delivery of possession of the Premises to Tenant. 

2.03 Surrender of the Premises. Upon the expiration or earlier termination of this Lease or upon default or breach of this Lease by Tenant, Tenant
shall immediately surrender the Premises and all keys to the Premises to Landlord, together with all alterations, improvements and other property as provided elsewhere herein, in broom-clean condition and in good order, condition and repair, except
for ordinary wear and tear and such damage as Tenant is not obligated to repair; failing this, Landlord may restore the Premises to such condition at Tenant’s expense, and for which Tenant shall immediately reimburse Landlord upon demand. Prior
to such expiration or termination, Tenant shall have the right to remove its property (as described in Paragraph 7.04). Tenant shall promptly repair any damage caused by any such removal, and shall restore the Premises to the condition existing
prior to the installation of the items so removed. 
 2.04 Holding Over. If Tenant shall hold over after the expiration of the Term, it shall be
deemed to be occupying the Premises as a Tenant from month to month, which tenancy may be terminated as provided by law. Tenant agrees that holding over beyond the Term shall cause 

  
 4 

 
irreparable damage to Landlord and that it will be impossible to estimate or determine the damage that will be suffered by Landlord in such an event. Therefore during such tenancy, unless
Landlord has otherwise agreed in writing, Tenant agrees to pay to Landlord monthly Base Rent at a rate equal to 125% of the monthly Base Rent which was payable in the month immediately preceding the month in which the expiration or
termination occurs and to be otherwise bound by all of the terms, covenants and conditions contained in this Lease. If Tenant fails to surrender the Premises upon the termination of this Lease, in addition to any other liabilities to Landlord
arising therefrom Tenant shall indemnify and hold Landlord harmless from loss or liability resulting from such failure from whatever source. In the event that this Lease is extended by Landlord and Tenant in writing after any prior termination, the
parties agree that the Base Rent negotiated for the extension term shall control over and apply to the tenancy of Tenant in the Premises without regard to the holdover rent provided for herein. 

ARTICLE III - RENT 
 3.01 Base
Rent. Tenant shall pay to Landlord as base rent (“Base Rent”) for the Premises the annual sum specified in Paragraph 1.01D, payable as also specified in Paragraph 1.01D, in advance, on or before the first day of each and every
calendar month during the Term without demand, notice or offset; provided, however, that if the Commencement Date shall be a day other than the first day of a calendar month, the Base Rent installment for such first fractional month shall be
prorated on the basis of the number of days during the month this Lease was in effect in relation to the total number of days in such month. 
 3.02
Additional Rent. All other payments due under this Lease from Tenant shall be considered additional rent (“Additional Rent”) and shall include the following: 

A. Increases in Operating Expenses and Taxes: 

1. Definitions: 
 (a)
“Operating Expenses” shall mean the amount of any and all of Landlord’s direct costs, expenses and disbursements of any kind and nature, incurred in connection with the management, operation, maintenance and repair of the
Building (including the Common Areas and the land described in “Exhibit A”) or any improvements situated on the land for a particular calendar year or portion thereof, as determined by Landlord, together with all additional direct costs,
expenses and disbursements with respect to the management, operation and maintenance of the Building. If less than 100% of the rentable square feet in the Building is occupied, Operating Expenses shall be adjusted to the amount which Landlord
determines that it would have paid during such year (including the Base Year) if the Building had been 100% occupied. Operating Expenses include by way of illustration but not limitation: water, sewer, electrical and other utility charges for the
Common Areas and utility charges for the Premises which is not separately metered; service and other charges paid in connection with the operation and maintenance of the heating, ventilation and air-conditioning system; tools and supplies; repair
costs; landscape maintenance costs; snow and ice removal; security services; license, permit and inspection fees; management fees; auditing fees; wages and related employee benefits payable for the maintenance and operation of the Building; and, in
general, all other costs and expenses which would generally be regarded as operating and maintenance costs and expenses, including those 

  
 5 

 
which would normally be amortized over a period not to exceed five (5) years. There shall also be included in the Operating Expenses the cost or portion thereof reasonably allocable to any
capital improvement made to the Building by Landlord after the date of this Lease which (i) improves the operating efficiency of any system within the Building and thereby reduces Operating Expenses, or (ii) is required under any
governmental law or regulation that was not applicable to the Building at the time it was constructed, or (iii) is installed pursuant to Paragraph 3.02C, with such cost being amortized over such period of time and in such manner as Landlord
shall reasonably determine over the life of the improvement in accordance with GAAP, together with interest on such cost or the unamortized balance thereof. Operating Expenses shall not include (i) expenses for painting, redecorating or other
work which Landlord performs for any tenant in the Building; (ii) expenses for repairs or other work reimbursed by insurance proceeds; (iii) expenses incurred in leasing or procuring new tenants: (iv) legal expenses incurred in
enforcing the terms of any lease; (v) interest or amortization payments on any mortgage or mortgages; (vi) Taxes: and (vii) Insurance. 

(b) “Taxes” shall mean any form of real estate tax or assessment, general, special, ordinary or extraordinary, improvement bond or
bonds imposed on the Building or a portion thereof by any authority having a direct or indirect power to tax, including any city, county, state or federal government, or any school, agricultural, sanitary, fire, street, drainage or other improvement
district thereof against any legal or equitable interest of Landlord in the Building or any portion thereof. 
 (c) “Insurance
Expenses” shall mean insurance premiums on insurance coverage which is required to be carried by Landlord or which Landlord may elect to carry at Landlord’s discretion 

(d) Tenant’s “Pro Rata Share” shall mean the percentage specified in Paragraph 1.01B. 

(e) “Base Year” shall mean the calendar year defined in Paragraph 1.01F. 

(f) “Adjustment Year” shall mean any calendar year or portion thereof during the term of the Lease commencing with the year after
the Base Year. In the event the last Adjustment Year is not a full calendar year, the Additional Rent payable under Paragraph 3.02A.2 with respect to such partial year shall be prorated. 

2. Payment Obligations, If in any Adjustment Year during the Term: 

(a) the Operating Expenses exceed the Operating Expenses for the Base Year, then Tenant shall pay as Additional Rent for such Adjustment Year
a Pro Rata Share of the Operating Expenses in excess of the Operating Expenses for the Base Year; 
 (b) the Taxes exceed the Taxes for the
Base Year, then Tenant shall pay as Additional Rent for such Adjustment Year a Pro Rata Share of the Taxes in excess of the Taxes for the Base Year; and 

  
 6 

 (c) the Insurance Expenses exceed the Insurance Expenses for the Base Year, then Tenant shall
pay as Additional Rent for such Adjustment Year a Pro Rata Share of the Insurance Expenses in excess of the Insurance Expenses for the Base Year. 

Statements showing the actual Operating Expenses, Taxes and Insurance Expenses and Tenant’s Pro Rata Share thereof shall be delivered by
Landlord to Tenant within a reasonable period of time after the end of any calendar year. Within thirty (30) days after delivery by Landlord to Tenant of such statement, Tenant shall pay to Landlord its Pro Rata Share of the excess Operating
Expenses, Taxes and/or Insurance Expenses which shall be deemed Additional Rent under this Lease. Unless Tenant objects in writing within fifteen (15) days to Landlord’s statements related to Operating Expenses, Taxes and Insurance
Expenses, Tenant shall be deemed to have accepted such statements and shall thereafter be estopped from challenging same. 
 In no event
shall the provisions of this Paragraph 3.02 reduce the Base Rent payable to Landlord. 
 3. Succeeding Year Expenses. Prior to the
beginning of each Adjustment Year, Landlord shall advise Tenant of the estimated amount, if any, of the increase in Operating Expenses, Taxes and Insurance Expenses over the Base Year, for the upcoming calendar year, and Tenant shall pay to Landlord
Tenant’s Pro Rata Share of such estimated increase in equal monthly installments on the first day of each month during that Adjustment Year together with the Base Rent. At the end of each Adjustment Year, Landlord shall ascertain and advise
Tenant of Tenant’s Pro Rata Share of the actual amount of any increase in Operating Expenses, Taxes and Insurance Expenses for the preceding year and any additional sum owed by Tenant to Landlord shall be paid to Landlord within thirty
(30) days following the receipt of Landlord’s notice thereof. Should any excess have been paid by Tenant to Landlord for the preceding year, Landlord shall apply the excess toward sums due for the next following calendar year. 

B. Improved Operating Efficiency. If Landlord shall, at any time after the Commencement Date, install a labor-saving device or other
equipment, which improves the operating efficiency of any system within the Building (such as an energy management computer system) designed or intended to limit Operating Expenses or the cost of electricity or other utility service to operate the
Building, or to limit future increases in Operating Expenses or electrical or other utility costs, then Landlord may add to Operating Expenses an annual amortization allowance based upon the costs of such device or equipment, plus interest on the
unamortized balance thereof, amortized in equal installments over such period as determined by generally accepted accounting principals; provided, however, that the amount of such annual amortization allowance and interest shall not exceed the
annual cost or expense limitation attributed by Landlord to such installed device or equipment, and in no event shall such amortization allowance increase the sum of Operating Expenses over what it would have been if such labor-saving device or
other equipment had not been installed. 
 C. Audit. Tenant may at its expense and upon 30 days’ prior written notice to
Landlord elect to audit Landlord’s records relating to Operating Expenses; provided, that if any such audit reveals unequivocally that the Operating Expenses charged to Tenant are in excess of the actual Operating Expenses incurred, then
Landlord shall refund the excess amount to Tenant. 

  
 7 

 3.03 Definition of Rent. The Base Rent, Additional Rent and any other amounts of money to be paid by
Tenant to Landlord pursuant to the provisions of this Lease, including any sums due under any and all Exhibits attached hereto, whether or not such payments are denominated Base Rent or Additional Rent and whether or not they are to be periodic or
recurring, shall be deemed Base Rent or Additional Rent for purposes of this Lease; and any failure to pay any of the same as provided in this Lease shall entitle Landlord to exercise all of the rights and remedies afforded hereby or by law for the
collection and enforcement of Tenant’s obligation to pay rent. Tenant’s obligation to pay any such Base Rent or Additional Rent pursuant to the provisions of this Lease shall survive the expiration or other termination of this Lease and
the surrender of possession of the Premises after any hold-over period. 
 3.04 Late Charge. If any payment due Landlord under this lease has not
been received by Landlord within ten (10) days after the same has become due, a late charge of five percent (5%) of the amount of the payment so overdue may be charged, and an additional five percent (5%) late charge may be charged on
the first day of each calendar month thereafter until the delinquent payment has been paid in full. 
 ARTICLE IV - SECURITY DEPOSIT

 4.01 As security for the performance and observance by Tenant of all of its obligations under this Lease, Tenant has deposited with Landlord
the sum specified in Paragraph 1.01E, which sum shall be held by Landlord as a security deposit during the Term. If Tenant performs and observes all of it obligations under this Lease, Landlord shall return the security deposit, or balance thereof
then held by Landlord, without interest, to Tenant within thirty (30) days after the Expiration Date or after Tenant surrenders possession of the Premises, whichever is later. In the event of a default by Tenant under this Lease, whether in
payment of rent or otherwise, then Landlord may, at its option and without notice, apply all or any part of the security deposit in payment of such rent or to cure any other such default; and if Landlord does so, Tenant shall, upon request, deposit
with Landlord the amount so applied so that Landlord will have on hand at all times during the Term the full amount of the security deposit. Landlord may commingle the security deposit with Landlord’s other funds. 

4.02 In the event of a sale or lease of the Building, Landlord shall have the right to transfer the security deposit to its purchaser or Tenant, and
Landlord shall thereupon be released by Tenant from all responsibility for the return of such deposit; and Tenant agrees to look solely to the new purchaser or Tenant for the return of such deposit. In the event of a permitted assignment of this
Lease by Tenant, the security deposit shall be deemed to be held by Landlord as a deposit made by the assignee, and Landlord shall have no further responsibility of such deposit to the assignor. 

ARTICLE V - OCCUPANCY AND USE 
 5.01
Use of Premises. The Premises shall be occupied and used exclusively as office space and for the purposes incidental thereto, and shall not be used for any other purpose. Tenant will not use or occupy or permit the use or occupancy of the
Premises for any purpose which is forbidden by law, ordinance or governmental or municipal regulation or order or which may be dangerous to life, limb or property; or permit the maintenance of any public or private nuisance; or do or permit any
other thing which may disturb the quiet enjoyment of any other tenant of the Building; or keep 

  
 8 

 
any substance or carry on or permit any operation which might emit offensive odors or conditions into other portions of the Building or the environment, or use any apparatus which might make
undue noise or set up vibrations in the Building; or permit anything to be done by Tenant, its employees, agents, contractors or Invitees which would Increase the fire and extended coverage insurance rate on the Building or contents, provided that
if there is any increase in such rate by reason of acts of Tenant, then Tenant agrees to pay such increase promptly upon demand therefore by Landlord. Payment by Tenant of any such rate increase shall not be a waiver of Tenant’s duty to comply
herewith. 
 5.02 Compliance with Building Rules and Regulations. Rules and regulations governing the use and occupancy of the Premises and all other
leased space in the Building have been adopted by Landlord for the mutual benefit and protection of all the tenants in the Building (as existing and modified from time to time, the “Rules and Regulations”). Tenant shall comply with
and conform to the Rules and Regulations currently in effect, which are set forth on “Exhibit E” attached hereto. Landlord shall have the right to amend the Rules and Regulations or to make new Rules and Regulations from time to time in
any reasonable manner upon at least ten (10) days prior written notice to the Tenant. Any such amendments or additions to the Rules and Regulations shall be set forth in writing and shall be given to Tenant, who shall thereafter comply with and
conform to the same. The Landlord shall use its good faith and commercially reasonable efforts to apply the Rules and Regulations in an even-handed non-discriminatory manner to all tenants of the Building. 

5.03 Floor Loads. Tenant shall not overload the floors of the Premises beyond their designed weight-bearing capacity as determined by Landlord.
Landlord reserves the right to direct the positioning of all heavy equipment, furniture and fixtures which Tenant desires to place in the Premises so as to distribute properly the weight thereof. Landlord may require the removal of any equipment or
furniture which exceeds the weight limits of the Building. 
 5.04 Signs. Tenant shall not inscribe, paint, affix or display any signs,
advertisements or notices on, in or around the Building, or in the windows thereof, except for such Tenant identification information as Landlord permits to be included or shown on or adjacent to the Tenant access door(s) to the Premises or on the
Building directory. 
 5.05 Access to and Inspection of the Premises. Landlord, its employees and agents and any mortgagee of the Building shall have
the right to enter any part of the Premises upon at least 48 hours advance written notice for the purpose of examining or inspecting the same, showing the same to prospective purchasers, mortgagees or tenants and for making such repairs, alterations
or improvements to the Premises or the Building as Landlord may deem necessary or desirable; provided, that no advance notice shall be required in the event of an emergency. Such right of entry shall also include, but not be limited to, access to
the Premises for purposes of environmental inspections and sampling during regular business hours upon such advance notice, or during other hours either by agreement of the parties or in the event of any environmental or Building emergency. If
representatives of Tenant shall elect not to be present to open and permit such entry into the Premises at any time when such entry is necessary or permitted hereunder, or otherwise in the event of an emergency, Landlord and its employees and agents
may enter the Premises by means of a master key or otherwise. Landlord shall incur no liability to Tenant for such entry 

  
 9 

 
permitted hereunder, nor shall such permitted entry constitute an eviction of Tenant or a termination of this Lease or entitle Tenant to any abatement of rent therefore. 

5.06 Quiet Enjoyment. Except as provided in Article XV hereof to the extent that it may be applicable, if and so long as Tenant pays the prescribed
rent and performs and observes all of the terms, conditions, covenants and obligations of this Lease required to be performed or observed by it hereunder, Tenant shall at all times during the term hereof have the peaceful and quiet enjoyment,
possession, occupancy and use of the Premises without any interference from Landlord or any person or persons claiming the Premises by, through or under Landlord, subject to any mortgages, underlying leases or other matters of record to which this
Lease is or may become subject. 
 ARTICLE VI - UTILITIES AND OTHER BUILDING SERVICES 

6.01 Services to be Provided. Landlord shall furnish Tenant, without cost to Tenant except as otherwise specifically provided in this Lease, during
standard hours of operation, with utilities and other building services, as provided in the Rules and Regulations, to the extent considered by Landlord to be reasonably necessary for Tenant’s comfortable use and occupancy of the Premises for
general office use or as may be required by law or directed by governmental authority. Tenant shall pay for replacement of all lamps, starters and ballasts required as a result of normal usage, at the cost established from time to time by Landlord.

 6.02 Services not provided. Any provision of this Lease to the contrary notwithstanding, Tenant shall be responsible at Tenant’s sole cost
and expense to obtain janitorial service to the Premises sufficient to keep the same in first class condition during the Term of this Lease. The cost of such janitorial services shall not be included by Landlord in the Operating Expenses. 

6.03 Additional Services. If Tenant requests any other utilities or building services not customarily provided by Landlord for the Building and
Landlord desires and is in a reasonable position to attempt to furnish Tenant with such additional utilities or building services’, then Landlord may impose a reasonable charge for such additional utilities or building services, which shall be
paid monthly by Tenant at the same time the monthly installment of Base Rent is due. 
 6.04 Special Equipment. Tenant shall obtain Landlord’s
written consent prior to installing or connecting any lights, machines or equipment (including but not limited to computers) which would materially affect the normal operation, or exceed the designed capacity of the Building’s electrical or
heating and air-conditioning systems. If Landlord determines that any such equipment is in any way incompatible with the Building’s electrical or heating and air-conditioning systems, then Landlord shall have the right, as a condition to
granting its consent, to install any machinery or equipment, or to make any modifications to the Building’s electrical or heating and air-conditioning systems, or to require Tenant to make such modifications to the equipment to be installed or
connected, as Landlord considers to be reasonably necessary. All costs expended by Landlord to install any such machinery or equipment or to make any such modifications, and any such additional costs of operation and maintenance occasioned thereby,
shall be borne by Tenant, who shall, upon demand, reimburse Landlord for the same as Additional Rent. 

  
 10 

 6.05 Interruption of Services. Tenant understands, acknowledges and agrees that any one or more of the
utilities or other building services identified in this Article VI may be interrupted by reason of accident, emergency or other causes beyond Landlord’s control or may be discontinued or diminished temporarily by Landlord or other persons until
certain repairs, alterations or improvements can be made; that Landlord does not represent or warrant the uninterrupted availability of such utilities or building services’ and that any such interruption shall not be deemed an eviction or
disturbance of Tenant’s right to possession, occupancy or use of the Premises or any part thereof or render Landlord liable to Tenant for damages by abatement of rent or otherwise or relieve Tenant from the obligation to perform its covenants
under this Lease; provided, that in the event that any such utility services are interrupted due to an act or omission of Landlord thereby rendering the Premises untenantable, and if such interruption is not cured or corrected within ten
(10) business days thereafter, then any provision of this Lease to the contrary notwithstanding, Tenant may as its sole remedy hereunder elect to terminate this Lease upon written notice to Landlord given prior to restoration of such
interrupted service, and to receive a pro-rata refund of any prepaid Base Rent paid to Landlord prior thereto, and neither Landlord nor Tenant shall have any further obligations hereunder. 

ARTICLE VII - REPAIRS, MAINTENANCE, ALTERATIONS, IMPROVEMENTS AND FIXTURES 

7.01 Repair and Maintenance of Building. Landlord shall keep and maintain the Building in good order, condition and repair, including the roof,
exterior walls and windows, foundations, the Common Areas and the electrical, elevator, plumbing, heating, ventilation and air-conditioning systems serving the Premises and other parts of the Building. The cost of all such repairs shall be included
by Landlord as part of the Operating Expenses, except for those made to any electrical, plumbing, heating, ventilation and air-conditioning components which have been installed in the Premises pursuant to Paragraph 6.03, and except for those made
necessary by the negligence, misuse or default of Tenant, its employees, agents, customers, or invitees, in which event they shall be borne by Tenant, who shall be separately billed and shall, upon demand, reimburse Landlord for the same as
Additional Rent. 
 7.02 Repair and Maintenance of Premises. Tenant shall keep and maintain the interior of the Premises and all improvements thereto
(including, but not limited to Tenant Finish Improvements) in good order, condition, and repair, reasonable wear and tear excepted. Such requirement notwithstanding, Landlord shall repair and maintain the Premises and the Building, including
building standard plumbing, heating, ventilating, air conditioning and electrical systems installed or furnished by Landlord, and the cost of all such repairs shall be included by Landlord as part of the Operating Expenses, unless such maintenance
and repairs are caused in part or in whole by the act, neglect, fault of or omission of any duty by Tenant, its agents, servants, employees or invitees, in which case Tenant shall pay to Landlord, as Additional Rent, the reasonable cost of such
maintenance and repairs. Tenant shall immediately notify Landlord in writing of any needed repairs and in the event of any damage or casualty to the Premises. If Landlord provides any nonstandard services and/or supplies to Tenant or the Leased
Premises (including, without limitation, photocopies, carpet cleaning, repairs, locks, additional keys, additional directory strips and replacement specialty light bulbs) at Tenant’s request, all charges for these services imposed by Landlord
together with all applicable sales tax or other taxes thereon shall be billed to Tenant and payable by Tenant as Additional Rent. 

  
 11 

 7.03 Alterations or Improvements. Tenant may make, or permit to be made, alterations or improvements to
the Premises, but only if Tenant obtains the prior written consent of Landlord. If Landlord allows Tenant to make any such alterations or improvements, Tenant shall make the same in accordance with all applicable laws and building codes, in a good
and workmanlike manner and in quality equal to or better than the original construction of the Building and shall comply with such requirements as Landlord considers necessary or desirable, including without limitation requirements as to the manner
in which and the times at which such work shall be done and the contractor or subcontractors to be selected to perform such work. Tenant may not puncture the roof or interfere with the sprinkler system without specific written permission from
Landlord. Upon completion of any such work, Tenant shall provide Landlord with “as built” plans, copies of all construction contracts, and proof of payment for all labor and materials. Tenant shall promptly pay all costs attributable to
such alterations and improvements and shall indemnify Landlord against any mechanics’ liens or other liens or claims filed or asserted as a result thereof, as provided in Article X; and shall also indemnify Landlord against any costs or
expenses which may be incurred as a result thereof, as provided in Article X; and shall also indemnify Landlord against any costs or expenses which may be incurred as a result of building code violations attributable to such work. Tenant shall
promptly repair any damage to the Premises or the Building caused by any such alterations or improvements. Any alterations or improvements to the Premises, except movable furniture and equipment and trade fixtures, shall become a part of the realty
and the property of Landlord and shall not be removed by Tenant unless Landlord specifies otherwise at the time of approval thereof by Landlord. 
 7.04
Trade Fixtures. Any trade fixtures installed on the Premises by Tenant at its own expense, such as movable partitions, counters, shelving, showcases, mirrors and the like, may (and at the request of Landlord shall) be removed on the Expiration
Date or earlier termination of the Lease provided that Tenant is not then in default, that Tenant bears the cost of such removal and further that Tenant repairs at its own expense any and all damage to the Premises resulting from such removal. If
Tenant fails to remove any and all such trade fixtures from the Premises on the Expiration Date or earlier termination of this Lease, all such trade fixtures shall become the property of Landlord unless Landlord elects to require their removal, in
which case Tenant shall promptly remove same and restore the Premises to their prior condition, except for ordinary wear and tear. 

ARTICLE VIII - FIRE OR OTHER CASUALTY INSURANCE 

8.01 Destruction of Premises. If the Premises are damaged or destroyed, in whole or in part, at any time during the Term by fire or other casualty and
the Lease is not terminated pursuant to Paragraph 8.02, Landlord with due diligence will repair and rebuild the Premises so that after such work of repairing and rebuilding has been completed, the Premises shall be substantially the same as that
prior to such damage. Any provisions contained in this Lease requiring repairs, rebuilding, restoration or reconstruction or providing for the use of insurance proceeds for any purpose shall be subject to the rights of the mortgagee of Landlord. In
the event more than fifty percent (50%) of the Premises are damaged or destroyed and less than one (1) year is left in the term of the Lease, Landlord, at its election, may terminate this Lease rather than repair the Premises. 

8.02 Irreparable Destruction of Building. If the Building shall be damaged or destroyed to such an extent that Landlord in its discretion determines
the Building to be irreparably destroyed, 

  
 12 

 
Landlord shall give Tenant notice of such determination within sixty (60) days after the date of such damage or destruction, and, in such event, this Lease shall terminate on the date
specified in such notice, and Landlord shall not be obligated to repair or rebuild. 
 8.03 Rental Abatement during Reconstruction. In the event of
any damage or destruction of the Premises or Building to the extent that the Premises shall have been rendered unfit for use for Tenant’s business purposes, Landlord shall, in Landlord’s sole discretion, either (1) relocate Tenant in
another comparable building within a three (3) mile radius with comparable office space and Landlord shall pay all reasonable uninsured moving expenses of said relocation and rent shall remain as specified within this Lease; or (2) provide
an abatement of rent which shall be made corresponding to the time during which, and the extent to which, the Premises may not be used by Tenant for its business purposes. The abatement of rent will terminate on the day that Landlord has completed
its repair of the Premises and tenders possession of the Premises to Tenant. 
 8.04 Landlord’s Damage Obligations. No damages, compensations,
setoffs or claims shall be payable by Landlord for inconvenience, loss of business or annoyance arising from any repair or restoration of any portion of the Premises or of the Building required to be made by Landlord under the provisions of this
Article VIII, but this paragraph shall not be construed to limit the abatement of Tenant’s rent in accordance with Paragraph 8.03 above. Landlord covenants with Tenant that it shall use its best commercially reasonable efforts to effect all
such repairs promptly and in such manner as to not unreasonably interfere with Tenant’s occupancy. 
 8.05 Indemnification. Except as provided
in Paragraph 8.09, Tenant shall assume the risk of, be responsible for, have the obligation to insure against, and indemnify Landlord and hold it harmless from, any and all liability for any loss, damage, injury or death to person or property
occurring in the Premises, regardless of cause, except for that caused by the sole negligence of Landlord and its employees, agents, customers and invitees; and Tenant hereby releases Landlord from any and all liability for the same. Tenant’s
obligation to indemnify Landlord hereunder shall include the duty to defend against any claims asserted by reason of such loss, damage or injury and to pay any judgments, settlements, costs, fees and expenses, including court costs and reasonable
attorney’s fees, incurred in connection therewith. Notwithstanding Landlord’s obligations hereunder, Tenant shall bear the sole risk of any loss of or damage to any personal property (including but not limited to, any furniture, machinery,
equipment, goods or supplies) of Tenant or which Tenant may have on the Premises or any trade fixtures installed by or paid for by Tenant on the Premises or any additional improvements which Tenant may construct on the Premises. Landlord shall not
be liable for any injury to or death of any person or any loss of or damage to property sustained by Tenant, or by any other person(s) whatsoever, which may be caused by the Building or the Premises or any appurtenances thereto or thereof being out
of repair, or by the bursting or leakage of any water, gas, sewer, or steam pipes, or by theft or by any act or neglect of any tenant or occupant of the Building, or of any other person, or by any other cause of whatsoever nature, unless, subject to
Paragraph 8.09, caused by the negligence of Landlord or its officers, agents or employees. 
 8.06 Tenant’s Insurance. Tenant, in order to
enable it to meet its obligation to insure against the liabilities specified in this Lease, shall at all times during the Term carry, at its own expense, one or more policies of general public liability and property damage insurance, issued by one
or 

  
 13 

 
more insurance companies acceptable to Landlord, with the following minimum coverage on an occurrence basis: 
  

			
	 A. Worker’s Compensation:
	  	 -   As provided by Law.

	  
 B. Commercial General Liability Insurance,
Including Blanket Contractual Liability, Broad Form Property Damage, Personal Injury, Completed Operations, Products Liability and Fire Damage, or if any such coverages are not in effect when needed, such other similar coverage as is then in
effect:
	  	 -   Not less than $3,000,000 Combined Single Limit for both Bodily Injury and
Property Damage

	  
 C. Fire and Extended Coverage, Vandalism and
Malicious Mischief, and Sprinkler Leakage Insurance for the full cost of replacement of Tenant’s property and fixtures located in the Premises.
	  	

 Commercial General Liability Insurance policies shall name Landlord as an additional insured. All insurance
carried by Tenant shall be in a form approved by Landlord and in an insurance company approved by Landlord, authorized to do business in the State and have a policy holder’s rating of no less than “A” and with a financial class size
of IX or better in the most current edition of Best’s Insurance Reports. Upon the commencement of this Lease and prior to the expiration of any of its required insurance policies, and at interim dates upon Landlord’s reasonable request,
Tenant shall furnish Landlord with a certificate or certificates of insurance confirming the existence and continuity of coverage. All policies maintained by Tenant in conformance with the requirements of this Lease shall provide at least thirty
(30) days’ advance written notice to Landlord of cancellation, material change or intent not to renew and ten (10) days’ notice to Landlord for non-payment. Should Tenant fail to carry such insurance and/or furnish Landlord with
a copy of all such certificates after a request to do so, Landlord shall have the right to obtain such insurance and collect the cost thereof from Tenant as Additional Rent or, at Landlord’s discretion, to evict Tenant and all its business
operations from the Premises, without liability to Landlord. 
 8.07 Landlord’s Responsibility. Except as provided in Paragraph 8.09, Landlord
shall assume the risk of, be responsible for, have the obligation to insure against and indemnify Tenant and hold it harmless from any and all liability for any loss, damage or injury to person or property occurring in, on or about the Common Areas,
regardless of cause, except for that caused by the negligence or malfeasance of Tenant and/or its employees, agents, customers and invitees. Landlord’s obligation to indemnify Tenant hereunder shall include the duty to defend against any claims
asserted by reason of such loss, damage or injury and to pay any judgments, settlements, costs, fees and expenses incurred in connection therewith. 

8.08 Landlord’s Insurance. Landlord shall be responsible for insuring and shall at all times during the Term carry, as an operating expense for
the Building, a policy of insurance which insures the Building, including the Premises, against loss or damage by fire or other casualty (namely, the perils against which insurance is afforded by the standard insurance policy and

  
 14 

 
extended coverage endorsement); provided, however, that Landlord shall not be responsible for and shall not be obligated to insure against any loss or damage to any trade fixtures or personal
property kept, placed or installed, or paid for, by Tenant on the Premises or any additional improvements which Tenant may construct on the Premises. 

8.09 Waiver of Subrogation. Landlord and Tenant hereby release each other and each other’s employees, agents, customers and invitees from any and
all liability for any loss or damage to property occurring in, on or about or to the Premises, the Building, improvements to the Building or personal property within the Building by reason of fire or other casualty which could be insured against
under a standard fire and extended coverage insurance policy, regardless of cause, including the negligence of Landlord or Tenant and their employees, agents, customers and invitees. Each party to this Lease shall obtain from its respective
insurance company a consent to this mutual waiver of subrogation/release, so as to prevent the invalidation of insurance coverage by reason of this mutual waiver of subrogation/release, and shall provide the other party a copy of any such consent.

 8.10 Refund of Prepaid Base Rent. Any provision of this Lease to the contrary notwithstanding, in the event that this Lease is terminated after a
fire or other casualty pursuant to the provisions of this Article VIII or otherwise due to a default by Landlord, then upon any such termination, Tenant shall be entitled to receive a pro-rata refund of any prepaid Base Rent paid to Landlord prior
thereto. 
 ARTICLE IX - EMINENT DOMAIN 

9.01 In the event the Building, or any portion thereof necessary, in the sole opinion of Landlord, to the continued efficient and/or economically
feasible use of the Building shall be taken or condemned in whole or in part for public purposes, or sold to a condemning authority to prevent taking, then the Term shall, at the option of Landlord, forthwith cease and terminate. All compensation
awarded for such taking or conveyance shall be the property of Landlord without any deduction therefrom for any present or future estate of Tenant, and Tenant hereby assigns to Landlord all its right, title and interest in and to any such award. All
compensation awarded is subject to the rights of Landlord’s mortgagee. However, Tenant shall have the right to recover from such authority, but not from Landlord, such compensation as may be awarded to Tenant on account of moving and relocation
expenses and depreciation to and removal of Tenant’s trade fixtures and personal property as long as such award does not diminish the award to Landlord, and if Landlord receives any such awards in favor of Tenant, Landlord shall promptly remit
the same to Tenant. Upon receipt of written notice of any such pending condemnation action, Landlord shall so notify Tenant. 
 ARTICLE X
- LIENS 
 10.01 Tenant will keep the Premises and Building free and clear of all mechanics’ and materialmen’s liens and other liens on
account of work done for Tenant or persons claiming under it. Should any such lien be filed against the Premises and/or the Building, Landlord may, without notice to Tenant, elect to obtain the release of each lien and any sums expended by Landlord
shall be immediately repaid to Landlord by Tenant together with interest at the rate of fifteen percent (15%) per annum. Should Tenant elect to dispute the amount required to release such lien or the

  
 15 

 
quality of service provided by the contractor who placed the lien, Landlord shall have the right to require Tenant to provide a bond or other security against such lien in form and content
acceptable to Landlord. 
 ARTICLE XI - RENTAL, PERSONAL PROPERTY AND OTHER TAXES 

11.01 Tenant shall pay before delinquency any and all taxes, assessments, fees or charges, including any sales, gross income, rental, business
occupation or other taxes, levied or imposed upon Tenant’s business operations in the Premises and any personal property or similar taxes levied or imposed upon Tenant’s trade fixtures, leasehold improvements or personal property located
within the Premises. In the event any such taxes, assessments, fees or charges are charged to the account of, or levied or imposed upon the property of, Landlord, Tenant shall reimburse Landlord for the same as Additional Rent. Notwithstanding the
foregoing, Tenant shall have the right to contest in good faith any such item and to defer payment, if permitted by applicable law, until after Tenant’s liability therefore is finally determined. 

ARTICLE XII - ASSIGNMENT AND SUBLETTING 

12.01 Tenant may not assign or transfer this Lease or sublet the Premises or any part thereof unless it first has obtained Landlord’s prior
written consent in its discretion; provided, that Tenant may sublet the Premises to any wholly-owned subsidiary or to any affiliate controlled by or under common control with Tenant without Landlord’s consent. In the event of any such permitted
assignment or subletting, Tenant and any Guarantors of this Lease shall nevertheless at all times remain fully responsible and liable for the payment of rent and the performance and observance of all of Tenant’s other obligations under the
terms, conditions and covenants of this Lease. No assignment or subletting of the Premises or any part thereof shall be binding upon Landlord unless such assignee or subtenant shall deliver to Landlord an instrument (in recordable form, if
requested) containing an agreement of assumption of all of Tenant’s obligations under this Lease. Upon the occurrence of an event of default, if all or any part of the Premises are then assigned or sublet, Landlord, in addition to any other
remedies provided by this Lease or by law, may, at its option, collect directly from the assignee or subtenant all rent becoming due to Landlord by reason of the assignment or subletting. Any collection by Landlord from the assignee or subtenant
shall not be construed to constitute a novation or release of Tenant from the further performance of its obligations under this Lease. In the event Landlord consents to Tenant assigning or subletting all or a portion of the Premises for which
Landlord’s consent is required, then any rent accruing to Tenant as the result of such subletting, which rent is in excess of the rent then being paid by Tenant, and any other economic consideration received by or to be received by Tenant in
connection with any subletting or assignment shall be paid to Landlord as Additional Rent. In the event Landlord consents to Tenant assigning or subletting all or a portion of the Premises, (i) both Tenant and the subtenant shall be held
responsible under all the terms and conditions of this Lease including but not limited to the Rules and Regulations, and (ii) any right to extend or any other option under this Lease shall terminate unless, however, the assignee or subtenant is
an affiliate or subsidiary of Tenant. 

  
 16 

 ARTICLE XIII - SUBORDINATION 

13.01 Landlord shall have the right to subordinate this Lease to any mortgage or deed of trust presently existing or hereafter placed upon the
Building, and the recording of any such mortgage or deed of trust shall make it prior and superior to this Lease regardless of the date of execution or recording of either document. Tenant shall, at Landlord’s request, execute and deliver to
Landlord, without cost, any instrument which may be deemed necessary or desirable by Landlord’s lender to confirm the subordination of this Lease; and, if Tenant fails or refuses to do so, Landlord may execute such instrument in the name and as
the act of Tenant. Notwithstanding the foregoing, no default by Landlord under any such mortgage or deed of trust shall affect Tenant’s rights hereunder so long as Tenant is not in default under this Lease. Tenant shall, in the event any
proceedings are brought forth for foreclosure of any such mortgage or deed of trust, attorn to the purchaser upon any such foreclosure and recognize such purchaser as Landlord under this Lease. 

13.02 Tenant agrees that in the event of a foreclosure of any mortgage or deed of trust affecting the Premises, that in addition of Tenant’s
attornment as set forth above in Paragraph 13.01, Tenant shall not hold any mortgagee or beneficiary of any purchaser at a foreclosure sale responsible for any defaults of any prior Landlord (including the original Landlord), or for the return of
any security deposit required hereby. 
 ARTICLE XIV - ABANDONMENT 

14.01 Tenant shall not vacate or abandon the Premises at any time during the Term; and if Tenant shall abandon, vacate or surrender said Premises, or
be dispossessed by process of law, or otherwise, any personal property belonging to Tenant and left on the Premises shall be deemed to be abandoned, at the option of Landlord, except such property as may be mortgaged by Tenant. Failure of Tenant to
occupy or use the Premises for a period of thirty (30) days or longer shall constitute abandonment by Tenant. 
 ARTICLE XV -
DEFAULTS AND REMEDIES 
 15.01 Defaults by Tenant. The occurrence of any one or more of the following events shall be a default and breach of
this Lease by Tenant: 
 A. Tenant shall fail to pay any payment of Base Rent within ten (10) days after the same shall be due and
payable, or any Additional Rent within thirty (30) days after the same shall be due and payable. No notice shall be required for default in payment. 

B. Tenant shall fail to perform or observe any term, condition, covenant or obligation, other than the payment of rent, required to be
performed or observed by it under this Lease for a period of thirty (30) days after notice thereof from Landlord; provided, however, that if the term, condition, covenant or obligations to be performed by Tenant is of such nature that the same
cannot reasonably be performed within such thirty-day period, such default shall be deemed to have been cured if Tenant commences such performance within said thirty-day period, thereafter diligently undertakes to complete the same, informs
Landlord, in writing, of Tenant’s progress in completing same on a weekly basis, and completes such cure within no later than 60 days after notice from Landlord. 

  
 17 

 C. A trustee or receiver shall be appointed to take possession of substantially all of
Tenant’s assets in, on or about the Premises or of Tenant’s interest in this Lease (and Tenant does not regain possession within thirty (30) days after such appointment); Tenant makes an assignment for the benefit of creditors;
substantially all of Tenant’s assets in, on or about the Premises or Tenant’s interest in this Lease are attached or levied upon under execution (and Tenant does not discharge the same within thirty (30) days thereafter); or, a
petition in bankruptcy, insolvency, or for reorganization or arrangement is filed by or against Tenant pursuant to any federal or state statute (and, with respect to any such petition filed against it, Tenant fails to secure a stay or discharge
thereof within thirty (30) days after the filing of the same). 
 D. Tenant abandons or vacates Premises. 

15.02 Remedies of Landlord. Upon the occurrence of any event of default set forth in Paragraph 15.01, Landlord shall have the following rights and
remedies, in addition to those allowed by law or equity, any one or more of which may be exercised without further notice to or demand upon Tenant: 

A. Landlord may apply the security deposit and/or re-enter the Premises and cure any default of Tenant, in which event Tenant shall, upon
demand, reimburse Landlord as Additional Rent for any reasonable costs and expenses which Landlord may incur to cure such default; and Landlord shall not be liable to Tenant for any loss or damage which Tenant may sustain by reason of
Landlord’s action. In the event Landlord should consult with or employ the services of legal counsel or bring suit against Tenant for any default or enforcement of any terms of this Lease, Tenant shall be liable for all such reasonable
attorney’s fees and litigation costs incurred by Landlord and the same shall be recoverable against Tenant in addition to all other amounts that Landlord may recover. 

B. Landlord may terminate this Lease as of the date of such default. Upon termination, Tenant or any party leasing the Premises through
Tenant, shall immediately surrender the Premises to Landlord. Landlord may re-enter the Premises and dispossess Tenant or any other occupants of the Premises by force, summary proceedings, ejectment or otherwise, and may remove their effects,
without prejudice to any other remedy which Landlord may have for possession or arrearage in rent. In addition, Landlord may accelerate and declare all past, present and future rent payments under this Lease to be immediately due and payable.
Landlord may re-let all or part of the Premises to another party on terms and conditions which may vary from the terms of this Lease. Tenant shall be obligated to pay to Landlord the difference between the rent provided for in any such subsequent
lease and the rent provided for in this Lease. No matter which remedy Landlord chooses, in its sole discretion, Tenant shall be liable for all costs and expenses caused by Tenant’s default and Landlord’s re-entry and re-letting, including
but not limited to, all repairs, improvements, broker’s fees and court costs and reasonable attorney’s fees. 
 15.03 Non-Waiver of
Defaults. The failure or delay by either party hereto to enforce or exercise at any time any of the rights or remedies or other provisions of this Lease shall not be construed to be a waiver thereof, nor affect the validity of any part of this
Lease or the right of either party thereafter to enforce each and every such right or remedy or other provision. No waiver of any default and breach of this Lease shall be held to be a waiver of any other default and breach. The receipt by Landlord
of less than the full rent due shall not be construed to be other than a payment 

  
 18 

 
on account of rent then due, nor shall any statement on Tenant’s check or any letter accompanying Tenant’s check be deemed an accord and satisfaction, and Landlord may accept such
payment without prejudice to Landlord’s right to recover the balance of the rent due or to pursue any other remedies provided in this Lease. No act or omission by Landlord or its employees or agents during the Term shall be deemed an acceptance
of a surrender of the Premises, and no agreement to accept such a surrender shall be valid unless in writing and signed by Landlord. 
 15.04 Default by
Landlord. In the event that Landlord shall fail to perform or observe any term, condition, covenant or obligation required to be performed or observed by it under this Lease for a period of thirty (30) days after notice thereof from Tenant,
the same shall be a default and breach of this Lease by Landlord; provided, however, that if the term, condition, covenant or obligations to be performed by Landlord is of such nature that the same cannot reasonably be performed within such
thirty-day period, such default shall be deemed to have been cured if Landlord commences such performance within said thirty-day period, thereafter diligently undertakes to complete the same, and completes such cure within no later than 60 days
after notice from Tenant. Upon the occurrence of any such event of default by Landlord, Tenant may terminate this Lease in writing as of the date of such default, shall be entitled to a prorata refund of any unearned prepaid Base Rent and shall have
such other remedies as may be available at law or in equity as a consequence of such default, excluding any claim for consequential or punitive damages. Any recovery by Tenant shall be limited to I Landlord’s interest in and to the Building.

 ARTICLE XVI - LANDLORD’S RIGHT TO RELOCATE TENANT 

16.01 [Intentionally omitted]. 

ARTICLE XVII - HAZARDOUS MATERIAL, GOVERNMENTAL, INSURANCE AND ADA REQUIREMENTS 

17.01 Hazardous Material. Tenant warrants and represents to Landlord that Tenant will comply with all federal, state and local environmental laws,
rules, regulations and statutes applicable to Tenant’s use and occupancy of the Premises during the Term. 
 Tenant shall not cause or
permit any Hazardous Material (as hereinafter defined) to be brought upon, kept, or used in or about the Premises by Tenant, its agents, employees, contractors or invitees, except for such Hazardous Material as is necessary to Tenant’s business
provided that Tenant has notified Landlord that it will be bringing upon, keeping or using such Hazardous Material on or about the Premises. 

Any Hazardous Material permitted on the Premises as provided in this Article, and all containers therefore, shall be used, kept, stored, and
disposed of in a manner that complies with all federal, state and local laws or regulations applicable to this Hazardous Material. 
 Tenant
shall not discharge, leak, or emit, or permit to be discharged, leaked, or emitted, any material into the atmosphere, ground, sewer system, or any body of water, if that material (as is reasonably determined by Landlord, or any governmental
authority) does or may pollute or contaminate the same, or may adversely affect (a) the health, welfare, or safety of persons, whether located on the Premises or elsewhere, or (b) the condition, use, or enjoyment of the building or any
other real or personal property. 

  
 19 

 As used herein, the term “Hazardous Material” means (a) a “hazardous
waste” as defined by the Resource Conservation and Recovery Act of 1976, as amended from time to time, and regulations promulgated thereunder; (b) any “hazardous substance” as defined by the Comprehensive Environmental Response,
Compensation and Liability Act of 1980, as amended from time to time, and regulations promulgated thereunder; (c) any oil, oil waste, petroleum products, and their by-products; and (d) any substance that is or becomes regulated by any
federal, state, or local governmental authority. 
 Tenant hereby agrees that it shall be fully liable for all costs and expenses related to
the use, storage, and disposal of Hazardous Material kept on the Premises by Tenant, and Tenant shall give immediate notice to Landlord of any violation or potential violation of the provisions of this Paragraph 17.01. Tenant shall defend, indemnify
and hold harmless Landlord and its officers, managers, members, partners, employees and agents, as applicable, from and against any claims, demands, penalties, fines, liabilities, settlements, damages, costs, or expenses (including, without
limitation, reasonable attorneys’ as well as all consultants’ fees, court costs, and litigation expenses) of whatever kind or nature, known or unknown, contingent or otherwise, arising out of or in any way related to (a) the presence,
disposal, release, or threatened release of any such Hazardous Material that is on, from, or affecting the soil, water, vegetation, building, personal property, persons, animals, or otherwise; (b) any personal injury (including wrongful death)
or property damage (real or personal) arising out of or related to that Hazardous Material; (c) any lawsuit brought or threatened, settlement reached, or government order relating to that Hazardous Material; or (d) any violation of any
laws applicable thereto. The provisions of this Article shall be in addition to any other obligations and liabilities Tenant may have to Landlord at law or equity and shall survive the transactions contemplated herein and shall survive termination
of this Lease. 
 Landlord is given the right, but not the obligation, to inspect and monitor the Premises and Tenant’s use of the
Premises in order to confirm Tenant’s compliance with the terms of this Paragraph 17.01. Landlord may require that Tenant deliver to Landlord concurrent with Tenant’s vacating the Premises upon the expiration of this Lease, or any earlier
vacation of the Premises by Tenant, at Tenant’s expense, a certified statement by licensed engineers satisfactory to Landlord, in form and substance satisfactory to Landlord, stating that Tenant, Tenant’s Work and any alterations thereto
and Tenant’s use of the Premises complied and conformed to all environmental laws. 
 17.02 Governmental and Insurance Requirements. Tenant
shall, at its sole cost and expense, comply with all of the requirements of any insurance carrier for the Building and of all county, municipal, state, federal and other applicable governmental authorities, now in force or which may hereafter be in
force. 
 17.03 Americans with Disabilities Act. Any costs for alterations, additions or improvements required to modify the Common Areas of the
Building in conjunction with the Americans with Disabilities Act (“ADA”) shall be paid by Landlord, and the cost thereof (excluding the amount of any fines or penalties assessed against Landlord for knowing and intentional non-compliance
with the ADA), shall be an Operating Expense of the Building. Such alternations, additions or improvements shall be made In the sole discretion of Landlord. Any alterations, additions or improvements required to modify the Premises in conjunction
with the ADA shall be approved by Landlord and paid by Tenant. Within ten (10) days after receipt, Tenant shall advise Landlord in 

  
 20 

 
writing of any notices alleging violation of ADA relating to any portion of the Building or the Premises. 

ARTICLE XVIII - NOTICE AND PLACE OF PAYMENT 

18.01 Notices. Any notice by Tenant to Landlord must be served by overnight delivery service (with confirmation of delivery), U.S. certified mail,
postage prepaid, return receipt requested, addressed to Landlord at the place designated in Paragraph 1.01H, or at such other address as Landlord may designate from time to time by written notice. Any notice by Landlord (which may be given by
Landlord or Landlord’s attorney or management company) to Tenant must be served by overnight delivery service (with confirmation of delivery), U.S. certified mail, postage prepaid, return receipt requested, addressed to Tenant at the place
designated in Paragraph 1.01H, or at such other address as Tenant may designate from time to time by written notice to Landlord. All notices shall be effective upon delivery or attempted delivery, and shall be deemed delivered three
(3) business days after deposit in the U.S. mail, in accordance with this Paragraph 18.01. 
 18.02 Place of Payment. All rent and other
payments required to be made by Tenant to Landlord shall be delivered or mailed to Landlord’s management agent at the address specified in Paragraph 1.01H or any other address Landlord may specify from time to time by written notice given to
Tenant. 
 ARTICLE XIX - MISCELLANEOUS GENERAL PROVISIONS 

19.01 Roof Rights. Except as otherwise provided in this Lease, Landlord shall have the exclusive right to use all or any portion of the roof of the
Building for any purpose. This Lease does not grant any rights to light, view and/or air over the Premises or Building. 
 19.02 Estoppel
Certificate. Tenant agrees, at any time, and from time to time, upon not less than 20 days’ prior notice by Landlord (and which 20-day period is not subject to any notice and cure periods otherwise provided under this Lease), to execute,
acknowledge and deliver to Landlord, a statement in writing addressed to Landlord or other party designated by Landlord certifying that this Lease is in full force and effect (or, if there have been modifications, that the same is in full force and
effect as modified and stating the modifications), stating the actual commencement and expiration dates of the Lease, stating the dates to which rent and other charges, if any, have been paid, that the Premises have been completed on or before the
date of such certificate and that all conditions precedent to the Lease taking effect have been carried out, that Tenant has accepted possession, that the Term has commenced, Tenant is occupying the Premises and is open for business, stating whether
or not there exists any default by either party in the performance of any covenant, agreement, term, provision or condition contained in this Lease, and if so, specifying each such default of which the signer may have knowledge and the claims or
offsets, if any, claimed by Tenant, and such other matters reasonably required by Landlord or any prospective purchaser, mortgagee or beneficiary of the Building; it being intended that any such statement delivered pursuant hereto may be relied upon
by Landlord or a purchaser of Landlord’s interest and by any mortgagee or beneficiary or prospective mortgagee or beneficiary of any mortgage or deed of trust affecting the Premises or the Building. If Tenant does not deliver such statement to
Landlord within such ten (10) day period, Landlord, and any prospective purchaser or encumbrancer, may conclusively presume and rely upon the following facts: (i) that the terms and 

  
 21 

 
provisions of this Lease have not been changed except as otherwise represented by Landlord; (ii) that this Lease has not been canceled or terminated except as otherwise represented by
Landlord; (iii) that not more than one month’s Base Rent or other charges have been paid in advance; and (iv) that Landlord is not in default under the Lease. In such event, Tenant shall be estopped from denying the truth of such
facts. Tenant shall also, on 20 days’ written notice, provide an agreement in favor of and in the form customarily used by such encumbrance holder, by the terms of which Tenant will agree to give prompt written notice to any such encumbrance
holder in the event of any casualty damage to the Premises or in the event of any default on the part of Landlord under this Lease, and will agree to allow such encumbrance holder a reasonable length of time after notice to cure or cause the curing
of such default before exercising Tenant’s right of self-help under this Lease, if any, or terminating or declaring a default under this Lease, In the event Tenant fails to timely deliver any document under this Paragraph 19.02, Landlord may
charge Tenant a penalty of Fifty Dollars ($50) for each day such delivery is delinquent. 
 19.03 Recording of Memorandum of Lease. This Lease or a
certificate or memorandum thereof prepared by Landlord may at the option of Landlord be recorded. Tenant shall execute any such certificate, short form lease or memorandum upon demand by Landlord. 

19.04 Real Estate Broker. Except as set forth in Paragraph 1.011, Tenant represents and warrants to Landlord that it has not engaged any broker, finder
or other person who will be entitled to any commission or fee with respect to the negotiation, execution or delivery of this Lease or any assignment, sublease or renewal thereof and shall indemnify Landlord against any loss, cost, liability or
expenses (including, without limitation, court costs and reasonable attorney’s fees) legally imposed by Landlord as a result of any claim asserted by any such broker, finder or other person on the basis of any arrangements or agreements made or
alleged to have been made by or on behalf of Tenant. 
 19.05 Force Majeure. In any case where either party hereto is required to do any act, delays
caused by or resulting from acts of God, war, civil commotion, fire, flood or other casualty, labor difficulties, shortages of labor, materials or equipment, government regulations, unusually severe weather or other causes beyond such party’s
reasonable control shall not be counted in determining the time during which work shall be completed, whether such time be designated by a fixed date, a fixed time or a “reasonable time,” and such time shall be deemed to be extended by the
period of such delay. The provisions of this Paragraph 19.05 shall not operate to excuse Tenant from the prompt payment of Base Rent, Additional Rent or any other payments required by the terms of this Lease. 

19.06 Applicable Law; Venue. This Lease and the rights and obligations of the parties arising hereunder shall be construed in accordance with the laws
of the Commonwealth of Kentucky. Any legal action under this Lease shall be brought in the county where the Premises are located. 
 19.07 Entire
Agreement; Preliminary Negotiations. The Lease, the exhibits and addendum, if any, set forth all the covenants, promises, agreements, conditions and understandings between Landlord and Tenant concerning the Premises and there are no covenants,
promises, agreements, conditions or understandings, either oral or written, between them other than as herein set forth. All prior communications, negotiations, arrangements, representations, agreements and understandings, whether oral, written or
both, between the parties hereto and their representatives, 

  
 22 

 
are merged herein and extinguished, this Lease superseding and canceling the same. Except as herein otherwise provided, no subsequent alteration, amendment, change or addition to this Lease shall
be binding upon Landlord or Tenant unless reduced to writing and executed by the party against which such subsequent alteration, amendment, change or modification is to be enforced. Tenant hereby acknowledges that (a) this Lease contains no
restrictive covenants or exclusives in favor of Tenant; (b) this Lease shall not be deemed or interpreted to contain, by implication or otherwise, any warranty, representation or agreement on the part of Landlord that any particular tenant
shall open for business or occupy or continue to occupy any space in or adjoining the Building during the Term of this Lease or any part thereof, and Tenant hereby expressly waives all claims with respect thereto and acknowledges that Tenant is not
relying on any such warranty, representation or agreement by Landlord either as a matter of inducement in entering into this Lease or as a condition of this Lease or as a covenant by Landlord; (c) Landlord and/or its real estate agent, has not
made, and does not now make, any representations as to the past, present or future condition, income, expenses, operation or any other matter or thing affecting or relating to the Premises except as may be herein expressly set forth, and no such
terms, agreements, covenants and conditions were made by and between the parties hereto; (d) Tenant has satisfied itself that the property described herein is properly zoned and usable for the purpose for which Tenant is leasing same; and
(e) Tenant has obtained or satisfied itself that it can obtain a Certificate of Occupancy and/or any other required permit(s) from any authority having jurisdiction over the Premises confirming that Tenant may occupy the Premises for the
purposes set forth in Paragraph 5.01. 
 19.08 Successors and Assigns. This Lease and the respective rights and obligations of the parties hereto
shall inure to the benefit of and be binding upon the successors and assigns of the parties hereto as well as the parties themselves; provided, however, that Landlord, its successors and assigns shall be liable for and obligated to perform
Landlord’s covenants under this Lease only during and in respect of their successive periods of ownership during the Term. 
 19.09 Severability of
Invalid Provisions. If any provision of this Lease shall be held to be invalid, void or unenforceable, the remaining provisions hereof shall not be affected or impaired, and such remaining provisions shall remain in full force and effect. 

19.10 Definition of the Relationship between the Parties. Landlord shall not, by virtue of the execution of this Lease or the leasing of the Premises
to Tenant, become or be deemed a partner of or joint venturer with Tenant in the conduct of Tenant’s business on the Premises or otherwise. 
 19.11
Certain Words, Gender and Headings. As used in this Lease, the word “person” shall mean and include, where appropriate an individual, corporation, partnership or other entity; the plural shall be substituted for the singular and the
singular for the plural, where appropriate; and words of any gender shall include any other gender. The topical headings of the several paragraphs of this Lease are inserted only as a matter of convenience and reference and do not affect, define,
limit or describe the scope or intent of this Lease. 
 19.12 Name of Building. Landlord shall have the right to change the name of the Building
during the Term or any extension thereof and shall have no obligation for any loss or damage to Tenant by reason thereof. 

  
 23 

 19.13 Common Areas. Tenant shall have the nonexclusive right, in common with others, to the use of common
entrances, lobbies, elevators, ramps, drives, stairs and similar access and service ways and other Common Areas in the Building, subject to the Rules and Regulations. 

19.14 Parking. Subject to limitations and conditions established from time to time by Landlord, Tenant and its employees and visitors shall have the
non-exclusive use, without charge, of any parking area made available and designated for parking generally for tenants and their employees and visitors at the Building. Upon Landlord’s request, Tenant shall indicate which cars are designated to
park in any one of the parking areas, and Landlord shall have the right to require that a parking sticker or decal be affixed to those cars so designated. Landlord may assign specific spaces and may reserve space for visitors, small cars,
handicapped individuals, and Tenant and its employees and visitors shall not park in any such assigned and/or reserved spaces. Landlord reserves the right to close all or a portion of the parking areas in order to make repairs or perform
maintenance, without claim of setoff or abatement by Tenant. 
 19.15 Entity Authority. If Tenant executes this Lease as a corporation, partnership
or limited liability company, each of the persons executing this Lease on behalf of Tenant does hereby personally covenant and warrant that Tenant is a duly authorized and existing legal entity, that Tenant has and is qualified to do business in
Kentucky, that the entity has full right and authority to enter into this Lease and that each person signing on behalf of the entity was authorized to do so. 

19.16 Examination of Lease. The submission of this lease form by Landlord for examination does not constitute an offer to lease or a reservation of an
option to lease. In addition, Landlord and Tenant acknowledge that neither of them shall be bound by the representations, promises or preliminary negotiations with respect to the Premises made by their respective employees or agents. It is their
intention that neither party be legally bound in any way until this Lease has been fully executed by both Tenant and Landlord. 
 19.17 Financial
Statements. The persons signing this Lease on behalf of Tenant hereby personally represent and warrant to Landlord that the financial statements delivered to Landlord prior to the execution of this Lease properly reflect the true and correct
value of all the assets and liabilities of Tenant and any Guarantors. Tenant acknowledges that in entering into this Lease, Landlord is relying upon such statements and Tenant shall supply Landlord updated financial statements of Tenant and any
Guarantors and from time to time as requested by Landlord. 
 19.18 Guarantors. This Lease shall not be effective unless the persons, if any, listed
in Paragraph 1.01F hereof shall execute the Guaranty of this Lease attached as Exhibit F. 
 19.19 Consents and Approvals. Whenever Landlord’s
consent or approval is required herein or when Tenant requests any processing or documentation of any assignment, subletting, license, concession, creating of a security interest, granting of a collateral assignment, change of ownership or other
transfer, such consent or approval shall not be deemed given until Landlord has provided such consent or approval in writing in its sole discretion. Tenant shall pay to Landlord the amount of five hundred dollars ($500.00) as an administrative fee
in addition to Landlord’s reasonable attorneys’ fees incurred in connection with Tenant’s request for Landlord’s consent, approval or other action. Such administrative fee shall be paid to Landlord within five (5) business
days of Landlord’s consent, approval or other action else such consent, approval or other action 

  
 24 

 
shall be null and void. Where the consent or approval of Landlord shall be required, such consent or approval shall be granted in Landlord’s sole discretion. With respect to any provision of
this Lease which either expressly provides or is held to provide that Landlord shall not unreasonably withhold or unreasonably delay any consent or approval, Tenant shall not be entitled to make claim for, and Tenant expressly waives claim for,
damages incurred by Tenant by reason of Landlord’s failure to comply, it being understood and agreed that Tenant’s sole remedy shall be an action for specific performance. 

19.20 Jury Trial; Claims; Survival. To the extent permitted by applicable law, and acknowledging that the consequences of said waiver are fully
understood, Tenant hereby expressly waives the right to trial by jury in any action taken with respect to this Lease and waives the right to interpose any set-off or counterclaim of any nature or description in any action or proceeding instituted
against Tenant pursuant to this Lease. Notwithstanding anything in this Lease to the contrary, the representations and undertakings of Tenant under this Lease shall survive the expiration or termination of this Lease regardless of the means of
such expiration or termination. 
 19.21 Arbitration. With respect to any dispute arising under this Lease, Landlord and Tenant shall first
use good efforts to resolve such dispute or matter between themselves. If the parties have not been able to resolve such dispute or matter after thirty (30) days from the date of the parties became aware of such dispute or matter, either party
may submit the same for settlement by arbitration in Metro Louisville, KY, in accordance with the procedural rules then governing the American Arbitration Association or any successor thereto. The decision of the arbitrator shall be final,
conclusive and binding upon the parties, and a judgment may be obtained thereon in any court having jurisdiction. Landlord and Tenant shall each pay one-half (1/2) of the cost and expense of such arbitration, and each shall separately pay for
its own attorneys’ fees and expenses. 
 19.22 Additional Provisions. Additional provisions of this Lease, if any, are set forth in the Addendum
to Lease attached hereto and made a part hereof. 
 IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the day and year
first written above. 
  

							
		 	TENANT:	 	APELLIS PHARMACEUTICALS INC., a Delaware corporation
				
		 		 	By:	 	 /s/ Pascal Deschatelets

		 		 	Title:	 	Chief Operating Officer
			
		 	LANDLORD:	 	 DHB PROPERTIES. LLC,

a Kentucky professional service corporation

				
		 		 	By:	 	 /s/ John A. Distler

		 		 	Title:	 	Partner

  
 25 

 EXHIBIT A - LEGAL DESCRIPTION 

BEING a consolidation of Lot 17 and Lot 17A of Arbor Ridge Subdivision, Section 5, a plat of which is of record in Plat Book 6, Page 77, in the
Office of the Clerk of Oldham County, Kentucky. 
 BEING a portion of the same property conveyed to Grantor by Deed dated November 25, 1998 of
record in Deed Book 591, Page 56, and the same property conveyed to Grantor by Deed dated August 24, 2007 of record in Deed Book 905, Page 266, both in the Office of the Clerk of Oldham County, Kentucky. 

  
 26 

 EXHIBIT B - THE PREMISES FLOOR PLAN 

 
 

 

  
 27 

 EXHIBIT C - EXAMPLE OF THE ACCEPTANCE OF PREMISES AMENDMENT 

As per Paragraphs 2.01 and 2.02, below is the form to be executed by Landlord and Tenant prior to delivery of possession of the Premises to
Tenant. 
  

							
	 ACCEPTANCE OF PREMISES AMENDMENT

 
 (Date)

 
 THIS ACCEPTANCE OF PREMISES AMENDMENT to the Lease by and between
                                , LLC, (“Landlord”), and
                                , (“Tenant”), is intended to amend the terms of
the Lease between Landlord and Tenant for certain office space located in
                                , Louisville, Kentucky, known as Suite
                    .
  

LANDLORD and TENANT hereby AGREE as follows:
  

1.      Except for those items shown on the attached “punch list”, which
Landlord will remedy within      days hereof, Landlord has fully completed the construction work required under the terms of the Lease.
  

2.      The Premises is tenantable. The Landlord has no further obligation for
construction (except as specified above) and Tenant acknowledges that both the Building and the Premises are satisfactory in all respects.
  

3.      The Commencement Date of the Lease (Paragraph 1.01C) is hereby agreed to be
                    .
  

4.      The Expiration Date of the Lease (Paragraph 1.01C) is hereby agreed to be
                    .
  

Except as modified herein, all terms and conditions of the Lease and any addenda are hereby ratified and acknowledged to be unchanged and shall remain in full
force and effect. In the event of any conflict between the terms and conditions of the Lease and the terms and conditions of this Acceptance of Premises Amendment, this Acceptance of Premises Amendment shall govern and control.

 

		 	TENANT:	 	APELLIS PHARMACEUTICALS INC., a Delaware corporation
				
		 		 	By:	 	  

		 		 	Title:	 	  

			
		 	LANDLORD:	 	DHB PROPERTIES, LLC,
		 		 	a Kentucky professional service corporation
				
		 		 	By:	 	 /s/

		 		 	 Title:
  
	 	 Partner
  

  
 28 

 EXHIBIT D - LANDLORD’S WORK 

 
 

 

  
 29 

 

 

  
 30 

 EXHIBIT D-2 - THE PLAN 
 

 

  
 31 

 EXHIBIT E - RULES AND REGULATIONS 

1. Standard hours of operation shall be between the hours of 7:30 a.m. and 6:00 p.m. on Monday through Friday of each week except on Legal
Holidays as provided below. 
 2. Legal Holidays: New Year’s Day, January 1; Memorial Day, observed; July 4; Labor Day,
observed; Thanksgiving Day, observed; Christmas, December 25; and business days before or after such days if businesses are generally closed on such business days. 

3. Services to be paid for by Landlord and included as part of Building Operating Expenses without limitation: Heating, ventilation and
air-conditioning; Electricity for lighting the Building lobbies, all Common Areas and Tenant’s Premises that are not separately metered; Water for lavatory and drinking purposes; Washing of windows at intervals established by Landlord; Cleaning
and maintenance for all Common Areas. 
 4. After hours electrical, lighting or HVAC controls selected either through the use of installed
override switches or provided at the special request by Tenant shall be billed to Tenant at rates reasonably established by Landlord. 
 5.
The sidewalks, halls, passages, exits, entrances, retail areas, elevators, escalators and stairways of the Building will not be obstructed by Tenant or used by Tenant for any purpose other than for ingress to and egress from the Premises. The halls,
passages, exits, entrances, elevators, escalators and stairwells are not for the general public, and Landlord will in all cases retain the right to control and prevent access to them by all persons whose presence, in the judgment of Landlord, would
be prejudicial to the safety, character, reputation, and interests of the Building and its tenants; however, such access will be permitted to persons with whom Tenant normally deals in the ordinary course of its business, unless such persons are
engaged in illegal activities. Tenant and its employees and invitees shall not go upon the roof of the Building. 
 6. No sign, placard,
picture, name, advertisement or notice visible from the exterior of Tenant’s Premises will be inscribed, painted, affixed or otherwise displayed by Tenant on any part of the Building or the Premises without the prior written consent of
Landlord. Landlord will adopt and furnish to Tenant guidelines relating to signs inside the Building on the office floors. Tenant agrees to conform to such guidelines. All approved signs or lettering on doors will be printed, painted, affixed or
inscribed at the expense of Tenant by a person approved by Landlord. Material visible from outside the Building will not be permitted. Landlord may remove such materials without any liability, and may charge the expense incurred by such removal to
Tenant. 
 7. No curtains, draperies, blinds, shutters, shades, screens or other coverings, hangings or decorations will be attached to,
hung, or placed in, or used in connection with any window of the Building or the Premises unless approved in writing by Landlord. 
 8. The
sashes, sash doors, skylights, windows, heating, ventilating, and air conditioning vents and doors that reflect or admit light and air into the halls, passageways or other public places in the Building will not be covered or obstructed by Tenant.

  
 32 

 9. No showcases or other articles will be put in front of or affixed to any part of the exterior
of the Building, nor placed in the public hails, corridors or vestibules without the prior written consent of Landlord. 
 10. Landlord
reserves the right to exclude or expel from the Building any person who, in the judgment of Landlord, is under the influence of liquor or drugs, or who shall in any manner do any act of violence or violate any of the Rules and Regulations of the
Building. 
 11. Tenant will not occupy or permit any portion of the Premises to be occupied as an office for a public stenographer or
typist, or for the possession, storage, manufacture, or sale of liquor, narcotics, dope, tobacco (except vending machine sale of tobacco for the convenience of Tenant’s employees) in any form, or as a barber or manicure shop, or as a public
employment bureau or agency, or for a public finance (personal loan) business. Tenant will not permit the Premises to be used for lodging or sleeping or for any immoral or illegal purpose. Tenant will not use or permit the use of the Premises in any
manner which involves the unusual risk of injury to any person. No cooking will be done or permitted by Tenant on the Premises, except in area of the Premises which are specially constructed for cooking, and except that use by Tenant of
Underwriters’ Laboratory - approved microwave equipment or equipment for brewing coffee, tea, hot chocolate and similar beverages will be permitted so long as such use is in accordance with all applicable federal, state and city laws, codes,
ordinances, rules and regulations. 
 12. Tenant will not employ any person or persons other than the cleaning service of Landlord for the
purpose of cleaning the Premises, unless otherwise agreed by Landlord in writing. Except with the written consent of Landlord, no person or persons other than those approved by Landlord will be permitted to enter the Building for the purpose of
cleaning it. Tenant will not cause any unnecessary labor by reason of Tenant’s carelessness or indifference in the preservation of good order and cleanliness. If Tenant’s actions result in any increased expense for any required cleaning,
Landlord reserves the right to assess Tenant for such expenses. Janitorial service will not be furnished on nights to offices which are occupied after business hours on those nights unless, by prior written agreement of Landlord, service is extended
to a later hour for specifically designated offices. 
 13. The toilet rooms, toilets, urinals, wash bowls and other plumbing fixtures will
not be used for any purposes other than those for which they were constructed, and no sweepings, rubbish, rags or other foreign substances will be thrown in them. All damages resulting from any misuse of the fixtures will be borne by Tenant who, or
whose servants, employees, agents, visitors or licensees have caused the damage. 
 14. Tenant will not deface any part of the Premises or
the Building of which they form a part. Without the prior written consent of Landlord, Tenant will not lay linoleum or other similar floor covering. If such floor covering is to be used, an interlining of builder’s deadening felt will be first
affixed to the floor, by a paste of other material soluble in water. The use of cement or other similar adhesive material is expressly prohibited. In those portions of the Premises in which carpet has been provided directly or indirectly by
Landlord, Tenant will at its own expense install and maintain pads to protect the carpet under all furniture having casters other than carpet casters, 

  
 33 

 15. The Building is open to the public during the standard hours of operations established by
Landlord and outlined herein under Paragraph 1. Landlord will furnish Tenant with four (4) keys to each door lock of the Premises, and four (4) building keys for entry to the Building after hours. Landlord will have the right to collect a
reasonable charge for additional keys requested by Tenant. Tenant, upon termination of its tenancy, will deliver to Landlord all keys which were furnished by Landlord for the Premises and Building or any other area of the Building (e.g., conference
room, exercise room, vending room). 
 16. Tenant will not alter, change, replace, or re-key and lock or install new lock or a knocker on
any door of the Premises. Landlord, its agents or employees, will retain a master key to all door locks on the Premises. Any new door locks required by Tenant or any change of keying of existing locks will be installed or changed by Landlord
following Tenant’s written request to Landlord and will be at Tenant’s expense. All new locks and re-keyed locks will remain operable by Landlord’s master key. 

17. Tenant will see that the doors of the Premises are closed and locked and that all water faucets, water apparatus and utilities are shut
off before Tenant or Tenant’s employees leave the Premises, so as to prevent waste or damage, and for any default or carelessness in this regard Tenant will make good all injuries sustained by other tenants or occupants of the Building or
Landlord. On multiple-tenancy floors, all tenants will keep the doors to the Building corridors closed at all times except for ingress and egress. 

18. Tenant agrees that Landlord shall not be responsible for lost or stolen personal property, money or jewelry from the Premises or Building
regardless of whether such loss occurs when the area is locked against entry or not. 
 19. Smoking is not permitted in Building including,
but not limited to, lobbies, common hallways, restrooms, vending areas, conference rooms and exercise facilities. 
 20. Tenant, its
employees, agents, customers and invitees shall not loiter or solicit in the Common Areas, nor shall Tenant distribute any handbills or other advertising at the Building. 

21. Upon Tenant’s taking possession of the Premises, Tenant shall supply to Landlord the name, address and phone number of an emergency
contact. Tenant authorizes Landlord to relinquish said information to the Police Department and Fire Department in case of an emergency. 

22. Landlord may from time to time adopt appropriate systems and procedures for the security or safety of the Building, any persons occupying,
using, or entering the Building, or any equipment, finishings or contents of the Building, and Tenant will comply with such systems and procedures. 

23. All persons entering or leaving the Building after standard hours of operation including Saturday, Sunday, and holidays will comply with
such off-hours regulations as Landlord may establish and modify from time to time. Landlord reserves the right to limit or restrict access to the Building during such time periods. 

  
 34 

 24. The elevator designated by Landlord will be available for use by all tenants in the Building
during the hours and pursuant to such procedures as Landlord may determine from time to time. The persons employed to move Tenant’s equipment, material, furniture or other property in or out of the Building must be accepted by Landlord. The
moving company must be a locally recognized professional mover, whose primary business is the performing of relocation services, and must be bonded and fully insured. A certificate or other verification of such insurance must be received and
approved by Landlord prior to the start of any moving operations. Insurance must be sufficient, in Landlord’s sole opinion, to cover all personal liability, theft or damage to the Building, including without limitation, floor coverings, doors,
walls, elevators, stairs, foliage and landscaping. Special care must be taken to prevent damage to foliage and landscaping during adverse weather. All moving operations will be conducted at such times and in such a manner as Landlord may direct, and
all moving will take place during non-business hours unless Landlord agrees in writing otherwise. Tenant will be responsible for the provision of Building security during all moving operations, and will be liable for all losses and damages sustained
by any party as a result of the failure to supply adequate security. Landlord will have the right to prescribe the weight, size and position of all equipment, materials, furniture or other property brought into the Building. Heavy objects will, if
considered necessary by Landlord, stand on wood strips of such thickness as is necessary to distribute the weight properly. Landlord will not be responsible for loss of or damage to any such property from any cause, and all damage done to the
Building by moving or maintaining such property will be repaired at the expense of Tenant. Landlord reserves the right to inspect all such property to be brought into the Building and to exclude from the Building all such property which violates any
of these Rules and Regulations. Supplies, goods, materials, packages, furniture and all other items of every kind delivered to or taken from the Premises will be delivered or removed through the entrance and route designated by Landlord. Landlord
will not be responsible for the loss or damage of any such property, even if such loss or damage may occur through the carelessness or negligence of Landlord, its agents or employees. 

25. Tenant will not use or keep in the Premises or the Building any kerosene, gasoline, or flammable or combustible or explosive fluid or
material or chemical substance other than limited quantities reasonably necessary for the operation or maintenance of office equipment or limited quantities of cleaning fluids and solvents required in normal operation of the Premises. Without
Landlord’s prior written approval, Tenant will not use any method of heating or air conditioning other than that supplied by Landlord. Tenant will not use or keep or permit to be used or kept, any foul or noxious gas or substance in the
Premises, or permit or suffer the Premises to be occupied or used in a manner offensive or objectionable to Landlord or other occupants of the Building by reason of noise, odors or vibrations, or interference in any way with other tenants or those
having business in the Building. Tenant will not place or install any object (including, without limitation, radio and television antenna, loudspeakers, sound amplifiers, microwave dishes, solar devices or similar devices) on the exterior of the
Building or on the roof of the Building. 
 26. Landlord may without notice and without liability to Tenant, change the name and street
address of the Building. 
 27. Landlord will have the right to prohibit any advertising by Tenant (mentioning the Building) which, in
Landlord’s reasonable opinion, tends to impair the reputation of the Building 

  
 35 

 
or its desirability as a building for offices, and upon written notice from Landlord, Tenant will discontinue such advertising. 

28. Tenant will not bring any animals or birds into the Building, and will not permit bicycles or other vehicles inside or on the sidewalks
outside the Building except in areas designated from time to time by Landlord for such purposes. 
 29. Tenant will store all of its trash
and garbage within the Premises. No material will be placed in the trash boxes or receptacles if such material is of such nature that it may not be disposed of in the ordinary and customary manner of removing and disposing of trash and garbage
without being in violation of any law or ordinance governing such disposal. All garbage and refuse disposal will be made only through entryway and elevators provided for such purposes and at such times as Landlord may designate. Removal of any
furniture or furnishings, large equipment, packing crates, packing materials and boxes will be the responsibility of Tenant, and such items may not be disposed of in the Building trash receptacles, nor will they be removed by the Building’s
janitorial service, except at Landlord’s sole option and at Tenant’s expense. No furniture, appliances, equipment or flammable products of any type may be disposed of in the Building trash receptacles. 

30. Canvassing, peddling, soliciting and distribution of handbills or any other written materials in the Building are prohibited, and Tenant
will cooperate to prevent same. 
 31. The requirements of tenants will be attended to only upon application by written, personal or
telephone notice at the office of the Building. Employees of Landlord will not perform any work or do anything outside of their regular duties unless under special instruction from Landlord. 

32. A directory of the Building will be provided for the display of the name and location of Tenant but Landlord will not in any event be
obligated to furnish more than one (1) directory strip for the Premises. Any additional names which Tenant will desire to place in such directory must first be approved by Landlord, and if so approved, a charge will be made for them. 

33. Whenever Tenant submits to Landlord any plan, agreement or other document for Landlord’s consent or approval, Tenant agrees to pay
Landlord as additional rent, on demand, a processing fee in the sum equal to the reasonable fee of the architect, engineer or attorney employed by Landlord to review the plan, agreement or document. 

34. Tenant will not conduct itself in any manner which is inconsistent with the character of the Building as a first quality building or which
will impair the comfort and convenience of other tenants in the Building. 
 35. No act or thing done or omitted to be done by Landlord or
Landlord’s agent during the term of the lease in connection with the enforcement of these Rules and Regulations will constitute an eviction by Landlord of Tenant nor will it be deemed an acceptance of surrender of the Premises by Tenant. No
agreement to accept such termination or surrender will be valid unless in a writing signed by Landlord. The delivery of keys to any employee or agent of Landlord will not operate as a termination of the lease or a surrender of the Premises unless
such delivery of keys 

  
 36 

 
is done in connection with a written instrument executed by Landlord approving the termination or surrender. 

36. Tenant agrees that it shall not willfully do or omit to do any act or thing which shall discriminate or segregate upon the basis of race,
color, sex, creed or national origin in the use and occupancy or in any subleasing or subletting in the Premises. 
 37. Tenant shall be
deemed to have read these Rules and Regulations and to have agreed to abide by them as a condition of its occupancy of the Premises. 

  
 37 

 Apellis Pharmaceuticals, Inc., Tenant 

THIS ADDENDUM TO LEASE is entered into by and between DHB Properties. LLC, a Kentucky professional services corporation
(“Landlord”), and Apellis Pharmaceuticals, Inc., a Delaware corporation (“Tenant”) to amend the terms of the Lease (“Lease”) between Tenant and Landlord for certain office space located The Bluegrass Eye Building, 8400
Westwind Way, Crestwood, Kentucky, designated as Suite A. 
 Now, therefore, Landlord and Tenant mutually agree to the following: 

 

	1.	Prepaid Base Rent of $60,000 shall be paid in two stages as outlined herein. On or about December 1, 2010 Landlord shall provide to Tenant an invoice from G&M Maintenance (“Genera Contractor”) which
Invoice shall be for one half the coat of the Landlord’s work e$ outlined on Exhibit D, which Tenant shall directly reimburse General Contractor for, not to exceed $50,000. Upon completion of Landlord’s work and acceptance of the
improvements as completed in accordance with the plans by Tenant, Landlord shall provide to Tenant the final invoice from General Contractor and Tenant shall pay the balance of Prepaid Base Rent, not to exceed $60,000 directly to General Contractor.
Landlord shall be responsible for the balance and remaining cost of Landlord’s work as outlined on Exhibit D. 

  

	2.	In the event that Landlord is unable to deliver possession of the Premises to Tenant by April 30, 2011 then Tenant shall have the right to terminate the Lease upon written notice to Landlord and within five
(5) business days or receipt of Tenant’s notice, Landlord shall reimburse Tenant for all Prepaid Base Rent. 

Except as modified herein, all terms and conditions of the Lease and any addenda are hereby ratified and acknowledged to be unchanged and
shall remain in full force and effect. In the event of any conflict between the terms and conditions of the Lease and the terms and conditions of this Addendum, this Addendum shall govern and control. 

 

											
		 	TENANT:	 		 	Apellis Pharmaceuticals, Inc. a Delaware corporation	 	
						
		 		 		 	By:	 	 /s/ Pascal Deschatelets
	 	
		 		 		 	Title:	 	Chief Operating Officer	 	
					
		 	LANDLORD:	 		 	DHB Properties, LLC	 	
		 		 		 	a Kentucky professional services corporation	 	
						
		 		 		 	By:	 	 /s/ Anne C. Huntington
	 	
		 		 		 	Title:	 	Partner	 	

 ACCEPTANCE OF PREMISES AMENDMENT 

February 25, 2011 
 (Date)

 THIS ACCEPTANCE OF PREMISES AMENDMENT to the Lease by and between DHB Properties, LLC, (“Landlord”), and Apellis
Pharmaceuticals, Inc., (“Tenant”), is intended to amend the terms of the Lease between Landlord and Tenant for certain office space located in The Bluegrass Eye Building, 6400 Westwind Way, Crestwood, Kentucky, 40014 known as
Suite                     . 
 LANDLORD
and TENANT hereby AGREE as follows: 
  

	1.	Except for those items shown on the attached “punch list”, which Landlord will remedy within     days hereof, Landlord has fully completed the construction work required under the terms of
the Lease. 

  

	2.	The Premises is tenantable. The Landlord has no further obligation for construction (except as specified above) and Tenant acknowledges that both the Building and the Premises are satisfactory in all respects.

  

	3.	The Commencement Date of the Lease (Paragraph 1.01 C) is hereby agreed to be February 28, 2011. 

  

	4.	The Expiration Date of the Lease (Paragraph 1.01 C) is hereby agreed to be February 29, 2016. 

 Except as
modified herein, all terms and conditions of the Lease and any addenda are hereby ratified and acknowledged to be unchanged and shall remain in full force and effect. In the event of any conflict between the terms and conditions of the Lease and the
terms and conditions of this Acceptance of Premises Amendment, this Acceptance of Premises Amendment shall govern and control. 
  

											
		 	TENANT:	 		 	Apellis Pharmaceuticals, Inc.	 	
		 		 		 	a Delaware corporation	 	
						
		 		 		 	By:	 	 /s/ Pascal Deschatelets
	 	
		 		 		 	Title:	 	COO	 	
					
		 	LANDLORD:	 		 	DHB Properties, LLC	 	
		 		 		 	a Kentucky professional services corporation	 	
						
		 		 		 	By:	 	 /s/ Matt Blair
	 	
		 		 		 	Title:	 	  
	 	, Partner

 THIRD ADDENDUM TO OFFICE LEASE AGREEMENT 

THIS THIRD ADDENDUM TO OFFICE LEASE AGREEMENT (“Third Addendum”) is made and entered into as of April 27th, 2015 (the “Effective Date”), by and between (I) DHB PROPERTIES, LLC, a Kentucky limited liability company (“Landlord”), and (II)
APELLIS PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). 

WITNESSETH: 

WHEREAS, Landlord and Tenant entered into that certain Office Lease Agreement dated
October 21, 2010, which was subsequently amended by an Addendum to Lease dated October 27, 2010, and Second Addendum dated May 20, 2014, executed prior to this Third Addendum (as previously amended, the “Lease”), and
capitalized terms used and not otherwise defined in this Third Addendum will have the respective meanings given to such terms in the Lease; and 

WHEREAS, Landlord and Tenant desire to further amend the Lease as hereinafter set forth;

 NOW, THEREFORE, in consideration of the foregoing premises, which are incorporated within this Third
Addendum, and for other good and valuable consideration, the mutuality, receipt and sufficiency of which are hereby acknowledged and agreed, the parties hereto hereby agree as follows: 

 

	1.	Second Expansion Space: The area of the Premises leased to Tenant under the Lease is expanded as of the Effective Date by an additional 3,325+/- square feet, the location of such additional area being depicted
and labeled as the “Second Expansion Space” on the Exhibit A attached hereto and made a part hereof (the “Second Expansion Space”). As of the Effective Date the Second Expansion Space shall be encompassed and
included within the definition of the Premises leased to Tenant under the Lease, and the area of the Premises is agreed to be 7,125 square feet. 

  

	2.	Second Expansion Space Delivery Date: The delivery date of the Second Expansion Space is estimated to be July 15, 2015. Delivery shall be deemed satisfied upon issuance of a certificate of occupancy
on the Second Expansion Space and Landlord and Tenant agree to execute an Acceptance of Premises Amendment that shall establish actual delivery of the Second Expansion Space. 

 

	3.	Term Extension: The Term is hereby extended through, and the Expiration Date of the Term shall now be the date that is three (3) years from the Delivery Date, estimated to be July 14,
2018. 

  

	4.	Base Rent: The Base Rent for the Premises shall be calculated as follows: Original Premises: 

  

	 	(a)	The monthly installments of Base Rent for the area of the Premises originally leased to Tenant under the Lease (the “Original Premises”) shall continue to be $2,984.92 (based on an annual rental amount
of $17.00 per square foot), and shall continue to be due and payable on the first (1st) day of each month through February 2016. 

					
		  	(b)	  	The monthly installments of Base Rent due and payable to Landlord for the Original Premises shall increase as of March 1, 2016 (based on an annual rental amount of $18.00 per square foot), and will be due and payable to
Landlord by Tenant in monthly amounts of $3,160.50 commencing on March 1, 2016, and continuing on the first (1sl) day of each month thereafter through the remaining Term as extended by
this Third Addendum.
		
		  	First Expansion Premises:
			
		  	 (a)
	  	Base Rent for the area of the Premises which comprises the First Expansion Space shall commence on October 7, 2014, and shall be due and payable to Landlord by Tenant in monthly installments of $2,398.42 (based on an annual
rental amount of $17.00 per square foot) on October 7, 2014, and continuing on the first (1st) day of each month thereafter through February 2016.
			
		  	(b)	  	The monthly installments of Base Rent due and payable to Landlord for the area of the Premises which comprises the First Expansion Space shall increase as of March 1, 2016 (based on an annual rental amount of $18.00 per square
foot), and will be due and payable to Landlord by Tenant in monthly amounts of $2,539.50 commencing on March 1, 2016, and continuing on the first (1st) day of each month thereafter
through the remaining Term as extended by the Third Addendum.
		
		  	Second Expansion Premise
			
	5.	  	(a)	  	Base Rent for the area of the Premises which comprises the Second Expansion Space shall commence on delivery estimated to be July 15, 2015 and shall be due and payable to Landlord by Tenant in monthly installments of $4,710.42
(based on an annual rental amount of $17.00 per square foot) and continuing on the first (1sl) day of each month thereafter through February 2016.
			
		  	(b)	  	The monthly Installments of Base Rent due and payable to Landlord for the area of the Premises which comprises the Second Expansion Space shall increase as of March 1, 2016 (based on an annual rental amount of $18.00 per square
foot), and will be due and payable to Landlord by Tenant In monthly amounts of $4,987.50 commencing on March 1, 2016, and continuing on the first (1st) day of each month thereafter
through the remaining Term as extended by the Third Addendum,
		
	6.	  	Tenant Finish: The Landlord’s Work with regard to the Second Expansion Space is out depicted and described on Exhibit B attached hereto and made a part hereof (the “Tenant
Finish”), and Tenant shall be responsible for and shall pay the cost of the Tenant Finish, up to an agreed aggregate maximum amount of $207,788.00 (the “Tenant Contribution”), in two stages as follows:
			
		  	(a)	  	On or about                                 , Landlord shall provide to
Tenant a copy of an invoice from the general contractor (the “General Contractor”) for one-half (1/2) of the cost of the Tenant Finish, which invoice amount Tenant shall directly pay to the General Contractor up to a maximum amount of
$89,644.

	 	(b)	Upon completion of the Tenant Finish, Landlord shall provide to Tenant a copy of the final invoice from the General Contractor for the cost thereof, and Tenant shall pay directly to the General Contractor the balance of
the amount due for the Tenant Finish, not to exceed a maximum amount from Tenant $89,644. 

  

	 	(c)	Landlord shall be responsible for the HVAC cost for the Second Expansion Space and shall pay the General Contractor directly for the cost estimated to be $28,500. 

Landlord shall be responsible for any amounts due to the General Contractor for the Tenant Finish In excess of the Tenant Contribution. 

 

	7.	Expansion Space Delivery: Landlord shall deliver the Expansion Space to Tenant, with the Tenant Finish complete, on or before July 15, 2015, subject to extension for delays resulting from Acts of God,
unusual Inclement weather and occurrences of force majeure. 

  

	8.	Expansion Space Rent Credit: Notwithstanding the terms of Section 4 above, Tenant shall be entitled to credit the amount of the Tenant Contribution actually paid by Tenant against the amount of Base Rent due
with respect to the Second Expansion Space, to be taken by Tenant as a credit against each such Installment of Base Rent until such credit amount has been exhausted. 

 

	9.	Utilities. Tenant shall be responsible for heating and cooling costs for the Second Expansion Space. 

  

	10.	Miscellaneous. Except as expressly modified herein, all terms and conditions of the Lease fire hereby ratified and acknowledged to be unchanged and shall remain in full force and effect. Nothing herein modifies
the terms of Section 6 of the Second Amendment. In the event of any conflict between the terms and conditions of the Lease and the terms and conditions of this Addendum, this Addendum shall govern and control. 

WITNESS the signatures of the undersigned as of the Effective Date. 

 

											
		 	TENANT:	 		 	Apellis Pharmaceuticals, Inc. a Delaware corporation	 	
						
		 		 		 	By:	 	 /s/ Pascal Deschatelets
	 	
		 		 		 	Title:	 	COO	 	
					
		 	LANDLORD:	 		 	DHB Properties, LLC a Kentucky limited liability company	 	
						
		 		 		 	By:	 	 /s/ Bryan Matthew Blair
	 	
		 		 		 	Title:	 	VP

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]